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Abstract
Tran, Nhu Quynh T. Ph.D. The University of Memphis. December 2011. EGFR
Regulation of Epidermal Barrier Function. Major Professor: Thomas R. Sutter, Ph.D.
Keratinocyte terminal differentiation is the process that ultimately forms the
epidermal barrier that is essential for mammals to survive in the ex utero environment.
This process is tightly controlled by the expression of many well-characterized genes.
Although a few of these genes are known to be regulated by the epidermal growth factor
receptor (EGFR), an important regulator of multiple epidermal functions, neither the
genome-wide scale of EGFR-mediated regulation nor the mechanisms by which EGFR
signaling controls keratinocyte differentiation are well understood. Using microarray
analysis we identified 2,676 genes that are regulated by EGF, a ligand of the EGFR. We
further discovered, and separately confirmed by functional assays, that EGFR activation
abrogates all essential metabolic processes of keratinocyte differentiation by (1)
decreasing the expression of lipid matrix biosynthetic enzymes, (2) regulating numerous
genes forming the cornified envelope, and (3) suppressing the expression of tight junction
proteins. In organotypic cultures of skin, the collective effect of EGF impaired epidermal
barrier integrity, evidenced by increased transepidermal water loss. As defective
epidermal differentiation and disruption of the epidermal barrier are primary features of
many human skin diseases, we used bioinformatics analysis to identify genes that are
known to be associated with human skin diseases. In comparison to non-EGF-regulated
genes, the EGF-regulated gene list was significantly enriched for disease genes. Further
validation of the expression profiles of many of the 114 identified skin disease genes
included the transcription factors GATA binding protein 3 (GATA3) and Kruppel-like
factor 4 (KLF4), both required for establishing the barrier function of the skin in
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developing mice. These results provide a new systems level understanding of the actions
of EGFR signaling to inhibit keratinocyte differentiation. As the overall effect of this
inhibition is to impair epidermal barrier integrity, this study clarifies how dysregulation
of the EGFR and its ligands may contribute to diseases of the skin.
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INTRODUCTION AND BACKGROUND
Origins of the Skin Epithelium
In mammals, the skin is the largest organ in the integumentary system, consisting of 3
different layers, the epidermis, dermis, and hypodermis (subcutaneous tissue) (Figure 1).
The epidermis originates from the outermost layer, or ectoderm, of a 3-layered embryo.
When cells in this layer respond to Wnt signaling, they are fated to develop into the
epidermis. Wnt signaling blocks the ability of ectoderm to respond to FGF signaling,
causing expression of bone morphogenetic proteins (BMPs) which signal the epidermis,
instead of the nervous systems to develop (Stern, 2005). The ectodermal cells produce
predominantly mucoproteins (in fish) or keratinaceous proteins in land dwelling animals
(Flaxman and Maderson, 1976). In higher vertebrates, there are two distinct categories
of keratinaceous proteins, the hair or alpha-type and the feather or beta-type (Baden and
Maderson, 1970). In the vertebrate epidermis, the alpha-keratin is mostly synthesized
(Flaxman, 1972).
The dermis is mesenchymal tissue that originates from the middle layer, or mesoderm
of the embryo (Flaxman and Maderson, 1976). The mesenchymal cells produce dermal
fibroblasts which secrete the precursors of self-assembling, extracellular collagen, elastin,
glycoproteins, and glucosaminoglycans (Flaxman and Maderson, 1976). These cells also
give rise to dermal blood vessels and fat cells. Mesenchymal cell fate is specified by Wnt
signaling (Atit et al., 2006). Interaction between the mesenchyme and ectoderm is
essential throughout the entire life of the organism. This interaction induces the
formation of hair placodes which respond to signals produced by FGFs and BMPinhibitory factors to determine their position and density (Fuchs, 2007). In parallel,
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epidermal cells are also directed by the ectodermal Wnt signals to grow downward to
form the hair bud or placode (Fuchs, 2007). The formation of the hair follicle may also
be controlled by epidermal growth factor receptor (EGFR) signaling. Studies in chicks
indicate that elevated levels of EGF increases the proliferation of interbud epidermal cells,
whereas inhibition of EGFR signaling increases the acquisition of a feather bud fate (Atit
et al., 2003). In mammalian skin, EGFR signaling is associated with enhanced epidermal
proliferation and hair loss (Blanpain and Fuchs, 2006).
At the end of embryonic development, the interfollicular epidermis reaches
maturity and is composed of multiple layers that form the outermost structure of the skin.
The epidermis undergoes a process called homeostasis in which dividing cells in the
innermost layer continually move outwards to replace terminally differentiated cells
being sloughed off from the skin surface. Structure and function of the epidermis are
discussed in the next sections.

Figure 1. Normal skin
Skin consists of 3 major layers: epidermis, dermis, and hypodermis. The epidermis is a
stratified epithelium (Figure 2). The dermis is connective tissue with hair follicle, blood
vessels, and sebaceous glands embedded in it. The hypodermis consists mostly of
adipocytes. Adapted from http://blog.celluliterxworks.com/blog/page/5/.
2

Structure and Function of the Epidermis
The epidermis is the outer layer of the skin. It consists of 4 principal layers, the
stratum corneum (SC), the stratum granulosum (SG), the stratum spinosum (SP), and the
stratum basale (SB) (Figure 2). Together, these layers form a barrier which is essential
for life. The barrier prevents the body from dehydration in a dry environment and
reduces hydration in a humid environment. It blocks the penetration of microorganisms
and destructive chemicals. It protects the body from harmful ultraviolet radiation. The
epidermis is capable of self-repair and has the mechanical strength to withstand damage.
These functions of the skin barrier are accomplished by epidermal cells, the keratinocytes.
The keratinocytes are the major cell population in the epidermis. They play a critical role
in providing the properties of the epidermal barrier.

Keratinocytes
The structure of the keratinocyte depends on its position within the epidermis and its
state of differentiation. In all keratinocytes the primary elements of the cytoskeleton are
the intermediate filaments. These intermediate filaments are made of keratin proteins,
which are bundled and span throughout the cytoplasm from the nuclear envelope to the
desmosomes (Leigh et al., 1994). Keratins are alpha-helical molecules and can be
divided into two subfamilies: Type I (acidic keratins; pI < 5.5) and Type II (basic keratins;
pI > 6) (Eichner et al., 1984). An acidic and a basic keratin are paired to form
heteropolymers, which are assembled into filaments (Coulombe and Fuchs, 1990). The
expression of keratins changes during epidermal differentiation. For example, early
differentiation markers such as KRT1 and KRT10 start to replace KRT5 and KRT14 as the
cells migrate to the stratum spinosum from the stratum basale.
3

Figure 2. The Four Principal Layers of the Epidermis
The epidermis is a stratified keratinized squamous epithelium consisting of four different layers: stratum basale, stratum spinosum,
stratum granulosum, and stratum corneum. The major cell type in the epidermis is the keratinocyte, which undergoes terminal
differentiation to form the corneocyte. Other cell types include melanocytes (UV protection), Langerhans cells (immunity), and
Merkel cells (touch). The locations of certain markers of keratinocytes differentiation such as KRT5, KRT14, KRT1, KRT10, IVL,
FLG, LOR, and TGM1 are shown. Adapted from (Candi et al., 2005; Garrett et al., 2002).
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Other cytoskeleton elements include microfilaments and microtubules, which
contribute to the movement of cells in culture and in tissue. These structures enhance the
communication within the cell and between the cell and its environment (Leigh et al.,
1994). It has been shown that there is a physical association between intermediate
filaments and microfilaments in mouse epidermal keratinocytes before and after raising
the Ca2+ level in culture media (Green et al., 1987). During mitosis and keratinocyte
differentiation, the pattern of organization of the intermediate filaments, microfilaments,
and microtubules cytoskeleton coordinately change (Lewis et al., 1987; Zamansky et al.,
1991).
A second feature common to keratinocytes of all layers, except the stratum
corneum (the outermost layer), are desmosomes and focal junctions between adjacent
keratinocytes. These structures attach keratin filaments within the cell and include
intracellular and extracellular components that function in cell-to-cell adhesion
(Steinberg et al., 1987). Keratinocytes adhere at desmosomes through interaction of
transmembrane glycoproteins tha belong to the cadherin families known as desmogleins
and desmocollins (Figure 3A). Desmosomes have mirror image plaques that sandwich a
membrane core region. The plaques are present beneath the plasma membrane of each
keratinocytes and associate with keratin filaments via plaque proteins such as plakoglobin
and desmoplakin (Figure 3A) (Green and Jones, 1996). The intermediate filament
anchorage of the plaques creates a transcellular network that is thought to resist forces of
mechanical stress (Green and Jones, 1996). Keratinocytes in cultures form focal contacts
with their substrate and form adherens and gap junctions with each other in cultures and
in tissue (Burridge et al., 1988).
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Figure 3. Desmosomes and Hemidesomsomes Structures of a Basal
Keratinocyte
(A) Desmosomes. Desmosomes are primary components that maintain the
integrity of epidermal cell cohesion. The intracellular desmosomal plaque
proteins include desmoplakin, plakoglobin, plakophilin, envoplakin, and
periplakin, which interact with intercellular plaques to connect transmembrane
adhesion molecules such as the desmogleins and desmocollins with keratins of
the cytoskeleton.
(B) Hemidesmosomes are components of the basement membrane.
Hemidesmosomes connect the basal keratinocytes to the basement membrane.
The intracellular hemidesmosomal proteins include BP230 and plectin that are
linked to keratins and interact with the cytoplasmic domains of BP180 and α6β4
integrin, which in turn interact with laminin 332 via their ectodomains (Hertl et
al., 2006).
6

Layers of the Epidermis
Stratum Basale
Cells in the stratum basale have a columnar shape and attach to the basement
membrane (Figure 2). The association between the basal cells and the basement
membrane is very important for the physical and mechanical integration of the epidermis
as well as the regulatory signal to restrain or differentiate (Watt et al., 1988). The
proliferation of keratinocytes is only found in the stratum basale. This basal layer
contains epidermal stem cells that continuously provide new cells to repopulate the
epidermis (Lavker et al., 1993). Besides stem cells, there are transit amplifying cells and
postmitotic cells that are ready to move into the suprabasal layers. Basal keratinocytes
also contain melanosomes, the pigment granules that provide tissues with color and
photoprotection. These melanosomes produce, store, and transport melanin pigments.
They are synthesized in melanocytes (Wasmeier et al., 2008) (Figure 2) and phagocytized
into vacuoles either in clusters (caucasian skin) or individually (black skin). Most of
these vacuoles or melanosome complexes are degraded within the spinous layer (Leigh et
al., 1994).
The mechanical strength of basal cells is provided by the structure, composition,
organization and stability of the keratin filament cytoskeleton even though keratin
comprises only 30% of the protein present in the basal cells (Leigh et al., 1994). The
cytoskeleton of the basal layer contains KRT5, KRT14, and small amounts of KRT15,
which anchor the epidermis firmly to its substratum (Porter and Lane, 2003). The keratin
intermediate filaments are grouped in bundles surrounding the nucleus, but do not attach
to it (Figure 3). Mutations in basal cells keratin polypeptides and abnormaltities in
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keratin filament assembly are seen in disorders such as epidermolysis bullosa simplex
(EBS) (Bonifas et al., 1991; Coulombe et al., 1991).
The interface between the basal keratinocyte and the dermis is a complex
structure. The basement membrane is joined with the plasma membrane of the basal cells
by hemidesmosomes (Figure 3B). The hemidesmosome and the desmosome exhibit
similar structural characteristics, but each also has unique morphologic and
compositional features (Green and Jones, 1996). Both junctions are composed of a
tripartite electron-dense plaque with cytoplasmic and membrane-related domains. The
proteins of the hemidesmosomal plaque are well characterized. The primary protein of
the hemidesmosomal plaque is the bullous pemphigoid (BP) antigen (BP230) (Tanaka et
al., 1991). BP230 proteins are found in the regions of hemidesmosome plaque to which
keratin intermediate filaments attach (Jones et al., 1994). BP230 has some structural and
amino acid homology with one of the desmosomal plaque proteins (Tanaka et al., 1991).
The membrane-bound molecules of hemidesmosomes include integrins, which are
heterodimeric matrix receptors. Besides linking the extracellular matrix and the
cytoskeleton of the cells, these receptors also act to transduce signals (Giancotti et al.,
1992). There are α and β subunits in each receptor. The α6 subunit can bind either the
β1 or β4, but binds preferentially with the β4 integrin subunit (Giancotti et al., 1992).
This β4 integrin is unique among the β integrins with its extended carboxy-terminal
cytoplasmic tail of 1000 amino acids (Hogervorst et al., 1990). This tail is physically
associated with one or more protein kinases. When the extracellular ligands interact with
the α6β4 receptors, β4 becomes phosphorylated on tyrosine (Mainiero et al., 1995). It
has been shown that a tyrosine phosphorylation site in the cytoplasmic domain of β4
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triggers binding of the signaling adaptor Shc (Src homologous collagen protein), which
upon phosphorylation recruits the adaptor Grb2 (growth factor receptor binding protein
2), linking the integrin to the Ras signaling pathway (Mainiero et al., 1995). Another
membrane molecule is the BP180 protein, also known as type XVII collagen (Giudice et
al., 1991; Hopkinson et al., 1992) (Figure 3B). This protein has been shown to be missing
from the skin of individuals carrying generalized atrophic benign epidermolysis bullosa
(Jonkman et al., 1995; McGrath et al., 1995). The lack of BP180 proteins in the skin
weakens the attachment of the epidermal cells to the basement membrane, leading to
blistering. In autoimmune diseases such as bullous pemphigoid and gestationis, BP180 is
a target for pathogenic antibodies (Giudice et al., 1993). The matrix molecules include
laminin 332 (previously known as laminin 5), which is composed of three subunits
termed α3, β3, and γ2 (Tryggvason, 1993). They are concentrated in the basement
membrane zone immediately underlying the hemidesmosome (Jones et al., 1994).
Laminin 332 can interact with several cell-surface receptors including α6β4, α3β1, EGFR
and syndecan 1 (Marinkovich, 2007). This protein has been shown to be deficient in the
skin of patients with a genetic disease called junctional epidermolysis bullosa (Kivirikko
et al., 1995; Pulkkinen et al., 1994).
In addition to structural proteins, there are other proteins with regulatory function
such as basonuclin (BNC1), a zinc-finger protein mainly expressed in basal keratinocytes
and the outer root sheath of hair follicles. Immunocytological experiments using Ki-67, a
common marker of proliferating cells, and bromodeoxyuridine (BrdU) incorporation into
DNA, have demonstrated that BNC1 is present in cells that are able to enter the growth
cycle, but disappears in terminally differentiated cells that have irreversibly withdrawn

9

from the cell cycle (Tseng and Green, 1994). The ability of BNC1 to associate with
ribosomal RNA genes on human keratinocyte mitotic chromosomes, as well as its own
gene promoter, has identified BNC1 as a transcription factor with the unsual ability to
interact with promoters of both RNA polymerases I and II (Tian et al., 2001; Tseng et al.,
1999). This notion is supported by a study in which mouse oocytes with Bnc1 knockdown exhibits a large perturbed number of RNA polymerase II transcripts (Ma et al.,
2006).
Stratum Spinosum
As cells leave the basal layer and move to the spinosum layer, their shape changes
from columnar to polygonal (Figure 2). Spinous cells are joined by ‘spines’ that extend
from the cell surface (Leigh et al., 1994). The spines are formed by bundles of keratin
filaments that insert into the desmosomal plaques of opposing cells. As keratinocytes
migrate to the stratum spinosum from the stratum basale, newly synthesized keratin
polypeptides are added, thus increasing the quantity and diversity of keratin species.
During this journey, many genes have been sequentially turned on and off to support the
differentiation of keratinocytes. For example, early differentiation markers such as KRT1
and KRT10 start to replace KRT5 and KRT14. Other important genes are also activated in
the stratum spinosum such as involucrin (IVL), an important component of the cornified
envelope, and transglutaminase-1 (TGM1), the enzyme that cross-links IVL and other
substrates during the synthesis of the cornified envelope (Holbrook and Wolff, 1987).
The first appearance of lamellar granules, also known as lamellar bodies, is seen
in the uppermost spinous cells. These structures have been observed by electron
microscopy as round and oblong membrane-bound organelles containing disk-like lipid
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bilayers (Odland and Holbrook, 1981). They contain glucosylceramides, and other lipids,
various hydrolytic enzymes (Madison et al., 1998), and other proteins including
corneodesmosin (CDSN) (Serre et al., 1991). Previously, lamellar granules were thought
of as discrete granules produced from the Golgi apparatus, which then migrated to the
cell surface, and fused with the plasma membrane. However, this view was recently
challenged by Norlen (Norlen, 2001). Norlen proposed the “membrane folding” model in
which the trans-Golgi network and lamellar bodies of the uppermost SG cells, as well as
the multilamellar lipid matrix of the intercellular space at the border zone between the SG
and SC, are part of one continuous membrane structure (Norlen, 2001). In 2003, Norlen
and his colleagues used a cryotransmission electron microscopy technique and provided
evidence to support this hypothesis (Norlen et al., 2003). The activities of the lamellar
granules are very important for the permeability barrier formation and will be discussed
in more detail in the section describing the granular cell layer.
Stratum Granulosum
The stratum granulosum is typically comprised of two to three layers of granular
keratinocytes (Figure 2). In the palm and sole, there are more granular layers. Hallmarks
of this layer are keratohyalin granules (KHG), which are composed of the intermediate
filament-associated protein, profilaggin (proFLG). ProFLG is synthesized in the granular
cells and deposited to the intersections of keratin filament bundles (Leigh et al., 1994).
KHG become larger as the cells move upward. In some of the uppermost granular cells,
the filaggrin subunits of proFLG may start to assist the aggregation and alignment of the
keratin filaments (Leigh et al., 1994). The quantity and composition of the keratins in the
granular cells determine the structure of the KHG. Reduction in KRT1 and KRT10
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expression is observed in disorders of keratinization where KHG are often globular in
shape and may have different substructures (Holbrook and Wolff, 1987). In a group of
ichthyosis vulgaris patients, KHG and proFLG are reduced or absent (Sybert et al.,
1985).
Another characteristic feature of the SG is the presence of the lamellar
granules (LG). LG are branched tubular structures continuous with the trans-Golgi
network (Norlen et al., 2003). LG contain many cargoes including glucosylceramides
(GlcCer), sphingomyelin (SM) and other lipids (Madison et al., 1998), various hydrolytic
enzymes, such as proteases, acid phosphatases, glucocidase, and lipases, and other
proteins including cathepsin D (CTSD), CDSN, kallikerin (KLK)7, and KLK8 (IshidaYamamoto et al., 2004). These cargoes are synthesized at different times during
keratinocyte differentiation and are transported independently through the trans-Golgi
network and LG (Ishida-Yamamoto et al., 2004). KLK7, KLK8, CDSN, and GlcCer are
individually transported as aggregates and directly form bulbous protrusions of the transGolgi network. CTSD proteins are packed into small vesicles, some of which may join
with LG from the trans-Golgi network. As the LG move toward the apical surface, they
fuse with the plasma membrane of the uppermost granular cells and extrude their
contents into the intercellular space (Ishida-Yamamoto et al., 2004). The major lipid
components of the intercellular lipid matrix are ceramides (Cer), cholesterol (CHOL),
and free fatty acid (FFA). The lower pH at the SG/SC interface activates hydrolytic
enzymes such as β-glucocerebrosidase (GBA) and acid sphingomyelinase to cleave
glucose and choline phosphate from GlcCer and SM in order to form Cers. Sterol
sulfatase and phospholipase(s) are activated to help form CHOL and FFA from
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cholesterol sulfate and glycerophospholipids, respectively. GlcCer and SM are modified
forms of ceramide products synthesized from de novo and salvage pathways, which occur
as a series of steps catalyzed by enzymes located in the endoplasmic reticulum (ER)
(Uchida and Holleran, 2008). The initial condensation step, catalyzed by serine
palmitoyltransferase (SPTLC), is the rate limiting step of the de novo synthesis, forming
3-ketodihydro-sphingosine (Hornemann et al., 2009). This product is reduced to
sphinganine, which is then acylated by ceramide synthases (LASS) to form
dihydroceramide. In the epidermis, LASS3 is the most relevant isozyme, due to its fatty
acyl-CoA chain length specificity (Stiban et al., 2010). Dihydroceramide is then
desaturated by DEGS1/2 or hydroxylated by DEGS2 to form Cer and phytoceramide,
respectively. In addition to de novo synthesis, salvage synthesis also occurs to form Cer5
(AS) and Cer2 (NS) via acylation of sphingosine by LASS. Ceramides can also be
synthesized from FFA that are acylated to sphingoid bases. FFA synthesis is first
catalyzed by fatty acid synthase (FASN) in the cytosol. Fatty acid chain elongation
occurs in the ER using metabolically-linked enzymes ELOVL 1-7 (condensation),
hydroxysteroid (17-beta) dehydrogenase (HSD17B, reduction), protein tyrosine
phosphatase-like, member B (PTPLB, dehydration), trans-2,3-enoyl-CoA reductase
(TECR, reduction) (Jakobsson et al., 2006). The initial step of elongation is the ratelimiting step (Jump, 2009). Among the ELOVL family of enzymes, ELOVL3 and
ELOVL6 catalyze the majority of the fatty acids present in the epidermal barrier.
ELOVL1 and ELOVL 4 catalyze the elongation of the VLCFA present in the ceramides
of the epidermal barrier (Ohno et al., 2010). In addition, FFA are hydroxylated to form
2-OH FFA by FA2H. Ceramides containing 2-OH FFA include Cer7 (AH), Cer6 (AP)
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and Cer5 (AS), and are critical for proper formation of the epidermal barrier (Uchida et
al., 2007).
Cells in the granular layer are interconnected by a junctional complex including
tight junctions (TJ), desmosomes, adheren, and gap junctions. TJ are the most apical
components in the junctional complex. They seal neighbouring cells together to prevent
diffusion of solutes through the intercellular spaces. Components of TJ, e.g. claudin
(CLDN)1, CLDN4, occludin (OCLN), and tight junction protein 1 (TJP1) are expressed
throughout the epidermis. However, the formation of TJ is only found in the apical-most
layer of the SG (Furuse et al., 2002). Defects in TJ are observed in patients with AD (De
Benedetto et al.). Mice lacking Clnd1 die within 1 day of birth due to tremendous TEWL
(Furuse et al., 2002), marking CLDN1 a key TJ protein. A mutation and reduction in
human CLDN1 has been reported in patients suffered from neonatal ichthyosis-sclerosing
cholangitis and from AD, respectively (De Benedetto et al.; Hadj-Rabia et al., 2004).
These studies indicate that tight junctions play a critical role in the permeability barrier
function of mammalian skin.
Stratum Corneum
The stratum corneum is the outermost layer of the epidermis (Figure 2), which has
been described as the series of bricks (corneocytes) glued by mortar (lipids). Corneocytes
are terminally differentiated, cornified, flattened, hexagonal-shaped cells that undergo a
specialized type of cell death leading to loss of the cell nucleus. They are filled with
water-retaining keratin proteins surrounded by cornified envelope (CE) and lipids. The
insoluble CE structures are formed beneath the plasma membrane of the corneocytes and
covalently bound to ceramide lipids in order to provide an effective physical and water
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barrier function in the skin. CE formation requires deposition of filaggrin (FLG), which
aggregates the keratin filaments into tight bundles, causing the flattened shape of
corneocytes. This formation creates a template or scaffold for the subsequent maturation
steps of CE assembly. Besides FLG, a series of other structural proteins including IVL,
LOR, trichohyalin (THH), and small proline-rich proteins (SPRR) are synthesized and
then catalytically cross-linked by several TGMs (Candi et al., 2005). Corneocytes are
linked one to another by corneodesmosomes, modified desmosomal structures that are
composed mainly of desmoglein-1 (DSG1), desmocolin-1 (DSC1), and CDSN (Candi et
al., 2005). In normal epidermis, the corneocytes are continually shed by the
physiological process called desquamation to balance the proliferation rate in the basal
layer, thereby maintaining epidermal homeostasis. Desquamation requires
corneodesmosome degradation by several proteolytic enzymes such as SC chymotryptic
enzyme (SCCE) and the SC tryptic enzyme (SCTE) (Brattsand and Egelrud, 1999;
Ekholm et al., 2000).
Corneocytes have the biggest dimensions of all the keratinocytes. One
corneocyte is equivalent in area to approximately 25 basal cells (Leigh et al., 1994). Cell
size and the number of corneocyte layers vary, depending on the region of the skin, sex,
and age of the individual (Plewig and Marples, 1970). For example, there are hundreds
more of cell layers in the palms and soles than in other skin parts of the body (Leigh et
al., 1994). The SC functions as a barrier that protects our body from excessive water
loss. The water impermeability of this layer is 1000 times higher than that of other
membranes of living organisms (Potts and Francoeur, 1991).
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Nonkeratinocyte Cells of the Epidermis
In addition to keratinocytes, there are melanocytes, Langerhans, and Merkel cells
(Figure 2). Melanocytes migrate into the epidermis from the neural crest early in the
embryonic development (Holbrook, 1989; Rawles, 1947). Langerhans cells originate
from the bone marrow (Stingl et al., 1980). The origin of the Merkel cells has been
controversial. It has been thought that these cells arise from either the skin or neural crest
lineages, but no definite proof was given. Recently, Morrisson and colleagues have
shown that Merkel cells originate from an epidermal lineage, based on mice with a
conditional knockout of Atoh1 (atonal homolog 1), a transcription factor essential for the
production of Merkel cells (Maricich et al., 2009; Morrison et al., 2009). Knocking out
Atoh1 in the neural crest did not affect the Merkel cell population, whereas loss of Atoh1
expression in the skin deleted all Merkel cells (Morrison et al., 2009).
Melanocytes and Merkel cells are found in the stratum basale, while Langerhans
cells often appear in the suprabasal layer (Figure 2). Melanocytes are uniformly
distributed within the basal layer in a ratio of 1 melanocyte to approximately 10
keratinocytes. However, each melanocyte, via its dendrites, supplies melanin to about 36
nearby keratinocytes (Jimbow et al., 1976). Human skin and hair color is determined by
the amount of melanin (eumelanin and pheomelanin, respectively) produced by the
melanosome, a unique intracytoplasmic organelles of melanocytes (Boissy and Nordlund,
1996).
Langerhans cells are dendritic cells and are typically found in the spinous layer of
the epidermis. They have dark nuclei and pale or clear cytoplasm. They contain large
granules called Birbeck granules, which make them distinguishable from other cell types
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(Birbeck, 1962). Langerhans cells are considered to be the primary antigen-presenting
cell of the skin. They contain antigen markers, human leukocyte antigen (HLA)-D, T4
antigen, and some of the CD1 antigens that are not expressed by other epidermal cells
(Ray and Schmitt, 1988). Compared to keratinocytes, Langerhans cells have been shown
to be sensitive to the effect of ultraviolet A and B radiation. A single doses of 60 mJ/cm2
of UVB spectrum almost completely eliminated all Langerhans cell membrane markers
(Aberer et al., 1981). Langerhan cells play an important role in immunogenic and
tolerogenic aspects of epidermal cells.
Merkel cells are neuroendocrine cells that are intimately associated with a nerve
terminal. They contain small membrane-bound dense-core granules that resemble
neuroendocrine cells. The number of Merkel cells in the skin is lower than melanocytes
and Langerhans cells. Merkel cells are present at higher density in regions of high touch
sensitivity such as the palm, buccal mucosa and lips, face and foot (Lacour et al., 1991;
Moll et al., 1990).
Factors that Regulate Keratinocyte Growth and Differentiation
Calcium Ions (Ca2+)
In vitro, the addition of extracellular Ca2+ mimics the gradient existing in vivo where
calcium is low in basal and significantly increased in the mid to upper granular toward
cornified layers (Forslind et al., 1997; Menon et al., 1992). With concentrations of
extracellular Ca2+ between 1.2 mM to 2 mM, primary human keratinocytes can establish
close intercellular contacts, stratify, cornify, and express biochemical markers of
differentiation such as KRT1, KRT10, IVL, LOR, FLG, and TGM1, resembling those that
occur in vivo (Dotto, 1999). After 24 hours in high calcium, more than 95% of
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keratinocytes are found to be arrested in G1 phase of the cell cycle (Missero et al., 1996),
whereas more than 50% of the attached cells are reversibly arrested when switched back
to low calcium containing medium (Topley et al., 1999). Thus, increased extracellular
calcium may serve as a primary trigger for keratinocyte differentiation both in vitro and
in vivo.
Increasing extracellular calcium to the same level that leads to increased
differentiation has been shown to increase intracellular calcium (Hennings et al., 1989;
Yuspa et al., 1989). This increase in intracellular Ca2+ is thought to happen in two ways.
Firstly, exogeneous calcium binds the calcium receptor and stimulates non-receptor
tyrosine kinases, fyn and src, which activates phosphatidylinositol-3-kinase (PI3K) via
phosphorylation of the PI3K regulatory subunit, p85α, leading to phosphotidylinositol
3,4,5-triphosphate (PIP3) formation. PIP3 then binds to and activate phospholipases C
(PLC)γ1 (Xie et al., 2005), which increases diacylglycerol (DAG), an endogenous protein
kinase C (PKC) activator (Jaken and Yuspa, 1988), and inositol triphosphate (IP3)
production. IP3 then binds to IP3 receptors in the Golgi and endoplasmic reticulum (ER),
releasing intracellular Ca2+ and hence triggering keratinocyte differentiation (Bikle et al.,
1996; Xie et al., 2005). Secondly, the increase in extracellular calcium results in calcium
influx through calcium-gated chloride channels, causing Cl- to exit the cells, which
results in a depolarization of the plasma membrane. This depolarization leads to the
opening of voltage gated calcium channels, allowing influx of calcium from the external
environment (Reiss et al., 1991). A rising level of intracellular calcium causes genomic
and nongenomic effects, such as a redistribution of desmoplakin to the membrane (Watt
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et al., 1984), increases in IVL, LOR, and TGM1 protein within hours (Rice and Green,
1979), and increased cornification at 1-2 days (Pillai et al., 1990).
Confluent Cell Density
Confluent cell density of keratinocytes in culture has been shown to strongly induce
commitment to terminal differentiation (Lee et al., 1998; Poumay and Pittelkow, 1995).
In normal human epidermis, keratinocytes undergo constant renewal, during which stem
cells in the basal layer of the epidermis replace keratinocytes that are constantly lost or
shred off during terminal differentiation. The differentiation process is initiated when
stem cells are replaced by transit amplifying cells (Watt et al., 2006), which are in
equilibrium with cells that have withdrawn reversibly and irreversibly from the cell cycle
to commit to terminal differentiation (Okuyama et al., 2004). At cell confluence, a large
majority of proliferative keratinocytes rapidly undergo irreversible growth arrest, as
demonstrated by a dramatic loss of keratinocyte clonogenicity (Poumay and Pittelkow,
1995). Cell density induces expression of multiple keratinocyte differentiation markers
such as SPRR1, KRT1, IVL, LOR, FLG, and TGM1, independent of extracellular Ca2+
concentration of the medium (Lee et al., 1998; Poumay and Pittelkow, 1995). In NHEK
cultures, density-mediated keratinocyte differentiation is associated with activation of
PKCα, as demonstrated by its translocation to the particulate fraction, and the blockage of
keratinocyte differentiation markers by the inhibition of this PKC isoform activation (Lee
et al., 1998).
Kolly and colleagues have demonstrated that confluency plays an key role in
driving proliferating keratinocytes into terminal differentiation by studying the effect of
confluency at low (up to 0.9 mM) and high (1.2 and 1.8 mM) calcium (Kolly et al., 2005).
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When keratinocytes reach confluency, they are contact inhibited. As cells are contact
inhibited, Notch1 is activated by the binding of Delta1 or Jagged, Notch1 ligands
expressed on neighboring cells (Kolly et al., 2005; Mumm and Kopan, 2000). Notch1 is
a key determinant of keratinocyte growth arrest and differentiation. Activation of Notch1
causes growth suppression by inducing p21WAF1/Cip1 expression (Rangarajan et al., 2001),
one of the earliest cell cycle regulatory events essential for keratinocyte terminal
differentiation (Missero et al., 1996). At confluence, c-Myc is also inhibited (Kolly et al.,
2005). The protooncogene c-Myc plays a key role in promoting the exit of stem cells
into the transit amplifying compartment (Arnold and Watt, 2001). Low levels of c-Myc
expression are required for transit amplifying cells to commit to terminal differentiation
(Waikel et al., 1999). These results indicate that confluency, independent of calcium
concentration, is a key regulator of keratinocyte proliferation and terminal differentiation.
Cell-cell Adhesions
Control of cell-cell contact has been shown to play an inherent role in the regulation
of skin cell differentiation (Charest et al., 2009; Hines et al., 1999; Owens et al., 2000).
With the formation of cell-cell contacts, the cells begin to stratify to generate multiple
epidermal layers, with the basal-like cells remaining attached to the dermis while the
more differentiated cells forming the suprabasal layers (Hennings et al., 1989).
Differentiating keratinocytes develop cell-cell junctions through various transmembrane
proteins, such as E-cadherin and P-cadherin. In vivo, loss of E-cadherin in keratinocytes
leads to down-regulation of markers of differentiation (Young et al., 2003b). In vitro
human keratinocytes, blocking E-cadherin activity with antibodies leads to abnormal
stratification and delayed localization of junction proteins (Wheelock and Jensen, 1992).
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Blocking the function of both E-cadherin and P-cadherin with antibodies prevents the
induction of differentiation markers such as TGM1, LOR, and proFLG proteins in vitro;
however inhibition of only E-cadherin increases protein levels of LOR and proFLG
(Hines et al., 1999), indicating that cell-cell contact affects differentiation through
multiple junction proteins. Charest and colleagues demonstrated that cadherin-mediated
cell-cell contact regulates keratinocyte differentiation by using a micropatterned surfaces
in vitro cell model, which provides a controlled and simple strategy to inhibit or permit
cell-cell contact between isolated pairs of cells while controlling cell spreading, shape,
and density (Charest et al., 2009). Micropatterned surfaces are microcontact printing of
self-assembled monolayers of alkanethiolates on gold. These surfaces are printed with
bowtie patterns using a polydimethylsiloxane stamp. Each bowtie has 15 distinct fields,
each with several hundred replicates and is coated with the extracellular matrix protein
fibronectin (Charest et al., 2009).
Biology and Structure of EGF
EGF was first described by Cohen in the 1960s. The protein was isolated from
murine submaxillary glands and caused tooth eruption and premature eyelid opening in
new-born mice (Cohen, 1962). It was named epidermal growth factor after the
observation that its direct addition to organ cultures of chick embryonic skin led to a
significant increase in epidermal cell number and size (Cohen, 1965). It is a small
peptide (6045 Da) that produces a variety of biological responses, including promotion of
proliferation and differentiation of skin tissue (Cohen and Carpenter, 1975), corneal
epithelial tissue (Savage and Cohen, 1973), lung and tracheal epithelia (Catterton et al.,
1979); potentiation of 3-methylcholanthrene carcinogenesis (Reynolds et al., 1965);
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phosphorylation of nuclear proteins (Huff and Guroff, 1978); formation of fatty liver
(Heimberg et al., 1965); and inhibition of gastric acid secretion (Bower et al., 1975). In
humans, EGF has been found in many body fluids such as urine, saliva, breast milk,
amniotic fluids, and plasma (Carpenter, 1980b). It is a major growth-promoting agent in
human milk (Carpenter, 1980a). The human equivalent of mouse EGF is urogastrone, a
hormone that inhibits gastric acid secretion (Gregory, 1975). In cultured cells and
tissues, exogenous EGF has multiple functions. Some of the functions include activation
of glycolysis (Diamond et al., 1978; Schneider et al., 1978), phosphorylation of nuclear
protein (Huff and Guroff, 1978), stimulation of macromolecular (hyaluronic acid, RNA,
protein, DNA) synthesis (Cohen and Stastny, 1968; Hoober and Cohen, 1967; Lembach,
1976), enhanced cell proliferation (Gospodarowicz et al., 1977; Hollenberg, 1975), and
alteration of viral growth (Knox et al., 1978).
EGF consists of 53 amino acid residues. In humans, EGF is translated from a gene
that is located on chromosome 4. This gene contains 24 exons separated by large noncoding regions (Bell et al., 1986; Savage et al., 1972). The precursor of EGF has 1207
amino acids which are translated from a 4.8 kb mRNA. This mRNA is spliced from an
initial transcript of approximately 110 kb (Bell et al., 1986). The EGF precursor contains
a hydrophobic domain, assumed to be required for anchoring the protein to the membrane
(Rall et al., 1985), and 7 EGF-like domains (Gray et al., 1983) with unknown functions.
The tertiary structure of EGF is non-glycosylated and stabilized by three intramolecular
disulfide bonds that are the characteristic for EGF and EGF-like growth factors and also
required for its biological activity (Savage et al., 1973; Taylor et al., 1972).
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Structure and Function of the Human EGF Receptor
EGF exerts its function via EGF receptors (EGFRs). The EGFR (ErbB1 or Her1) is
a 170-kDa transmembrane glycoprotein. It belongs to the ErbB family, which contains
four related receptor tyrosine kinases: EGFR (ErbB1, Her1), ErbB2 (Her2), ErbB3 (Her3),
and ErbB4 (Her4). The EGFR and ErbB2 are the most closely related with 49% identity
(64% similarity) and EGFR/ErbB3 being the furthest from one another with 37% identity
(53% similarity) (Jorissen et al., 2003).
The extracellular domain (or ectodomain) of the EGFR contains the amino terminus
with 62 amino acid residues, two ligand binding (L1 and L2) and two cysteine-rich
domains (CR1 and CR2) (Figure 4) (Carpenter and Zendegui, 1986). EGF binds to the
L1 and L2 regions (Garrett et al., 2002; Ogiso et al., 2002). The hydrophobic domain of
the EGFR was originally identified by hydrophobicity analysis of the EGFR sequence.
This region contains 23 amino acid residues that span the membrane (Ullrich et al.,

Figure 4. Architecture of the Epidermal Growth Factor Receptor
The extracellular domain contains the two ligand binding (L1 and L2) and two
cysteine-rich domains (CR1 and CR2). The cytosolic domain contains juxtamembrane,
kinase, and actin binding domains. Adapted from (Carpenter and Zendegui, 1986;
Garrett et al., 2002).
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1984). However, nuclear magnetic resonance analysis of the EGFR transmembrane
peptide and the beginning of the cytoplasmic domain indicated that the transmembrane
domain is α- helical and expands to the juxtamembrane domain (Rigby et al., 1998). The
juxtamembrane region has multiple regulatory functions including downregulation and
internalization of ligand-receptor complexes (Kil and Carlin, 2000), basolateral sorting of
the EGFR in polarized cells (He et al., 2002), and direct binding with proteins such as
EGFR kinase substrate (EPS8) (Castagnino et al., 1995) and calmodulin (Li and
Villalobo, 2002; Martin-Nieto and Villalobo, 1998). Continuing into the cytosol is the
highly conserved tyrosine kinase domain of the EGFR. The three-dimensional structure
of the EGF kinase domain is similar to other tyrosine kinases. The ATP binding region is
located between the N-terminal region and the larger C-terminal region. The carboxy
terminus of the EGFR is composed of 542 amino acid residues. The C-terminal domain
contains tyrosine residues that can be phosphorylated by the receptor itself (Downward et
al., 1984). This autophosphorylation modulates EGFR-mediated signal transduction.
Phosphorylation at serine/threonine residues on the kinase domain has been suggested to
be important for the downregulation and endocytosis processes of the receptor (Zwang
and Yarden, 2006). The C-terminal domain also contains a binding site for actin (den
Hartigh et al., 1992) which is believed to play a role in the formation of higher order
receptor oligomers and/or receptor clustering after phosphorylation.
Signal Transduction
In the absence of ligand binding, EGFRs exist in monomeric and dimeric forms, but
both are inactive (Yu et al., 2002). When ligands such as EGF bind, there is a change in
the conformation of the receptor that reorients the intracellular domains to form a

24

structure having an active kinase (Moriki et al., 2001). This configuration allows the
tyrosine kinase domains of the two ligand-bound monomers to transphosphorylate each
other. Tyrosine phosphorylation serves as the first and crucial step in the EGFRmediated signal transduction.
Different ligands and combinations of homo- and heterodimerizations within the
EGFR family lead to a diverse set of signaling events. Some basic features of EGFR
signal transduction can be summarized as follows. Upon ligand binding, receptor
dimerization occurs, leading to autophosphorylation of distinct tyrosine residues. This
autophosphorylation creates docking sites for various cytoplasmic adaptor proteins and
enzymes with SH2 (Src homology 2) and PTB (phosphotyrosine binding) domains. The
SH2 domain binds specifically to the residues located downstream of the EGFR
phosphotyrosine (pY) while PTB binds to the residues located upstream of the pY.
Docking proteins are important to receptor tyrosine kinases as they recruit signaling
molecules to the receptors, regulating variety of cellular responses (Figure 5).
Activation of the Mitogen-activated Protein Kinase (MAPK) Cascade
The MAPK cascade includes four major groups of MAP kinases including
extracellular regulated kinases (ERKs) 1 and 2, jun N-terminal kinases (JNKs), p38, and
the extracellular signal regulated kinase-5 (ERK5) (Kyriakis and Avruch, 2001). These
serine/threonine kinases are evolutionarily conserved in all eukaryotes (Garrington and
Johnson, 1999). Signaling through ERK1/2 is the best characterized pathway among
other MAPK pathways. The first biochemical event in this cascade is the activation of
the proto-oncogene Ras. Ras is activated by a guanine nucleotide exchange factor, Sos.
In this cascading event, the adaptor protein Grb2 is a key component of EGFR signaling
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Figure 5. EGFR Signal Transduction
Activation of the EGFR leads to a number of serine/threonine cascades. This includes
the MAPK, PI3K, and PLCγ signaling pathways, producing diverse cellular responses
such as proliferation, differentiation, motility, and apoptosis. Adapted from (Davis,
2000; Garrington and Johnson, 1999; Johnson and Vaillancourt, 1994; Kyriakis and
Avruch, 2001; Prenzel et al., 2001). Arrow indicates activation. Flat head line
indicates inhibition. Chemicals known to inhibit PKC, PI3K, P38, and MEK1/2 are
Gö6983, wortmannin, SB203580, and U0126, respectively.

to Ras (Lowenstein et al., 1992). Grb2 forms a complex with Sos through its SH3
domain. The Grb2/Sos complex binds to the tyrosine phosphorylated EGFR via the SH2
domain in Grb2, thus recruiting Sos to the plasma membrane where it stimulates the
exchange of GDP for GTP for Ras. Ras-GTP binds to and activate the serine/threonine
kinase Raf-1 and subsequently the activation of the dual specificity kinase MEK1/2
(Hallberg et al., 1994). This in turn leads to the phosphorylation and activation of ERK1
and ERK2, allowing them to translocate to the nucleus where they catalyze the
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phosphorylation of nuclear transcription factors such as Elk1, cFos (Prenzel et al., 2001),
cJun, cMyc, and NFκB. Sos can also be recruited to the plasma membrane by binding of
Grb2/Sos to Shc, another adaptor protein with SH2 and PTB domains (Margolis, 1999).
These signaling cascades regulate diverse cellular responses such as proliferation,
differentiation, motility, and apoptosis (Davis, 2000; Johnson and Vaillancourt, 1994).
Signaling through the JNK and p38 stress-activated kinases is less well
understood than for ERK1/2. EGF activates JNK via the small GTP-binding proteins
Rac1 and Cdc42 (Coso et al., 1995; Minden et al., 1995). The adaptor Crk protein has
been shown to be critical for JNK activation following EGF treatment of Crk-transfected
COS7 cells (Dolfi et al., 1998). JNK activity is not detected in healthy human epidermis,
but is elevated in psoriasis (Takahashi et al., 2002). In cultures of keratinocytes, JNK
activation has been shown to be associated with epidermal proliferation (Zhang et al.,
2004), while inhibition of JNK promotes differentiation of epidermal keratinocytes
(Gazel et al., 2006). The activation of the p38 pathway is required for the migration of
cultured human keratinocytes on dermal collagen (Li et al., 2001), and for the
downregulation of EGFR, explaining its role in the regulation of EGF-stimulated
epithelial wound healing and proliferation (Frey et al., 2006).
Activation of Phosphotidylinositol-3-kinase (PI3K)
EGF activates the lipid kinase PI3K, which consists of a p85 regulatory domain and a
p110 catalytic domain. The activation of PI3K by EGF is relatively weak compared to
other receptor tyrosine kinases since EGFR does not have a binding sites for the SH2
domain of PI3K (Soltoff et al., 1994). The EGFR activates PI3K via the adaptor protein
Gab1. PI3K activation leads to membrane recruitment and activation of the
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serine/threonine kinase PDK1. Subsequently, protein kinase B (PKB/Akt) is
phosphorylated (Prenzel et al., 2001). These cascading events stimulate a variety of
cellular responses. It has been shown that activation of PKB leads to phosphorylation
and inactivation of BAD, preventing apoptotic cell death by inhibiting its formation with
the apoptotic proteins Bcl-2 and Bcl-xl (Datta et al., 1999). PKB can also inhibit
apoptosis by phosphorylating the transcription factor FKHR1, suppressing proapoptotic
gene expression (Brunet et al., 1999). PDK1 and PKB have been suggested to play a role
in the control of protein synthesis, gluconeogenesis and glycolysis in response to insulin
stimulation through phosphorylation of the S6 kinase, glycogen synthase kinase-3 (GSK3)
and phosphofructokinase (Toker and Newton, 2000). Activation of PI3K also results in
activation of mammalian target of rapamycin (mTOR) and the p70 S6 kinase (S6K). This
signaling cascade controls the expression of several genes that involved in cell growth
and survival (Heinonen et al., 2008).
Activation of Phospholipase C (PLC)
EGF activates the autophosphorylation of the EGFR, providing the docking site for
the SH2 domain of PLCγ (Jorissen et al., 2003). PLCγ is recruited to the plasma
membrane and is tyrosine phosphorylated and activated by the EGFR. Activated PLCγ
hydrolizes the phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)IP2) substrate to form
two second messengers, 1,2-diacylglycerol (DAG) and inositol 1,3,5-trisphosphate (IP3).
IP3 mediates the release of Ca2+ from intracellular stores. Ca2+ binds to calmodulin,
activating a family of Ca2+/calmodulin-dependent protein kinases. Both Ca2+ and DAG
activate members of the serine/threonine kinase PKC. Activation of certain PKC
isoforms alters the growth and differentiation of human epidermal keratinocytes (Szegedi
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et al., 2009). Specifically, PKCα activation is required and sufficient to trigger
irreversible growth arrest during human keratinocyte differentiation (Jerome-Morais et al.,
2009).
EGFR and Keratinocyte Differentiation
Epidermal development is tightly regulated by cytokines and growth factors (Fuchs
and Raghavan, 2002). These molecules provide spatial and temporal signaling that
controls keratinocyte proliferation, differentiation, migration, and finally, terminal
differentiation and cornification. TGF-α and EGF are related growth factors that activate
EGFR to regulate growth and differentiation in epidermal keratinocytes (Schneider et al.,
2008). Dysregulation of EGFR signaling results in abnormal “wavy hair” and “curly
whiskers” phenotypes of spontaneous loss-of-function mutations in the mouse TGF-α
gene (named waved-1 or wa1) or in the EGFR (named wave-2 or wa2), repectively
(Mann et al., 1993; Threadgill et al., 1995). Depending on the genetic background of the
mice, complete loss of the EGFR can cause death at embryonic or mid-gestation stage, or
after a few weeks of postnatal life (Sibilia and Wagner, 1995; Threadgill et al., 1995).
Mice lacking ERBB2, ERBB3, or ERBB4 die during embryonic development (Gassmann
et al., 1995; Lee et al., 1995; Riethmacher et al., 1997). Abnormally high levels of EGFR
activities cause a hairless phenotype and skin cancers (Ferby et al., 2006).
In keratinocyte cultures, EGFR signaling is known to have an inhibitory effect on
multiple pro-differentiation signals and down-regulates the expression of both early and
late differentiation markers, as well as inhibits the formation of cornified envelope (CE)
(Sun and Green, 1976). In keratinocyte cultures containing growing colonies, the
percentage of cornified cells is reduced in the presence of EGF compared to that of
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untreated cells (Sun and Green, 1976). Keratinocytes undergoing differentiation first
enter reversible cell cycle withdrawal and then irreversible cell cycle withdrawal. During
this process, many differentiation-specific proteins are expressed (Poumay and Pittelkow,
1995). Early differentiation markers such as KRT1 and KRT10 are induced in cells that
undergo differentiation. The induction of these genes is suppressed by the addition of
EGF to the culture medium (Poumay and Pittelkow, 1995). A study has shown that the
suppression of KRT1 by EGF is due to the repression of Notch1 expression, an important
regulator of cell fate decisions in the epidermis (Kolev et al., 2008). EGF also
moderately reduces activity of TGM1 and inhibits late markers of differentiation such as
FLG (Marchese et al., 1990; Monzon et al., 1996). Organotypic cultures grown at 33ºC
in the presence of EGF exhibit no LOR expression and abnormal expression of SPRR2
and SPRR3 (Gibbs et al., 1998). Inhibition of the EGFR with neutralizing antibodies or
EGFR tyrosine kinase inhibitors diminishes the effects of EGF and promotes terminal
differentiation (Hashimoto, 2000; Jost et al., 2000; Peus et al., 1997; Sutter et al., 2009).
These reports convincingly demonstrate an important function of EGFR in the regulation
of keratinocyte proliferation and differentiation. However, only two reports have shed
new light into the molecular mechanisms by which EGFR signaling determines
epidermal keratinocyte cell fate. In the first study, EGFR/ERK signaling was identified
as a negative regulator of the expression of Notch 1, whose signaling promotes
keratinocyte differentiation by down-regulating the expression of p53. The
transcriptional suppression of p53 was shown to be involved by the EGFR effector c-Jun
(Kolev et al., 2008). The second study, using an organotypic raft model, identified DSG1
as a suppressor of EGFR signaling. DSG1 is required to suppress the sustained
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activation of EGFR/ERK signaling in the granular layer and acts together with other
desmosomal proteins such as DSG2 and DSC3 to support a signaling network that
balances keratinocyte proliferation and differentiation to maintain epidermal tissue
homeostasis (Getsios et al., 2009). These studies have demonstrated that epidermal
homeostasis is regulated spatiotemporally, in part, by EGFR signaling.
The EGFR in Dermatological Diseases
Defective epidermal differentiation and disrupted skin barrier are primary features of
many human skin diseases such as psoriasis, allergic contact dermatitis, and atopic
dermatitis. Common characteristics among these diseases are epidermal hyperplasia and
abnormalities in expression of the EGFR and its ligands. In normal skin, the EGFR is
expressed throughout the entire epidermis, but is more concentrated at the basal cell layer
(Nanney et al., 1984). In psoriasis vulgaris, the level of EGFR expression is increased
two- to four-fold in active lesions, and the EGFR are persistently expressed in the stratum
spinosum and stratum corneum (Sporn et al., 1987). In addition, EGFR ligands such as
TGF-α (Pastore et al., 2005) and amphiregulin (Chokki et al., 2006) are released in the
psoriatic lesions, upregulating the expression of interleukin (IL)-8, a cytokine whose
induction serves as a secondary amplification mechanism leading to epidermal
hyperplasia (Reich et al., 2001). IL-8 can contribute to the activation of the
metalloprotease-dependent release of EGFR ligands by acting on its specific G-proteincouple receptor (Tanida et al., 2004). In lesional skin of atopic dermatitis (AD) and
allergic contact dermatitis, the expression of the EGFR prominently extends to the
suprabasal layers. TGF-α is stained quite faintly in basal keratinocytes of normal skin.
On the other hand, TGF-α is detected clearly throughout the basal and suprabasal
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keratinocyte layers in patients with psoriasis, AD, and allergic contact dermatitis (Mascia
et al., 2003). High levels of EGFR are also present in seborrheic keratoses and
acrochodons of patients with dysplastic nevus syndrome who are pregnant or taking sex
steroid hormones (Ellis et al., 1990). Seborrheic keratoses and acrochodons (skin tags)
are characterized histologically by hyperkeratosis, epidermal acanthosis, and
papillomatosis (Lever and Schaumburg-Lever, 1990). This increase is thought to be due
to the increased EGF and estrogen levels, as seen in pregnancy (Ellis et al., 1990). EGFR
distribution is also affected in the viral diseases of skin. The level of EGFR is decreased
and abnormally distributed in verruca vulgaris as well as in molluscum contagiosum, a
pox virus (Nanney et al., 1988). Further, elevated mRNA and protein levels of the EGFR
are observed in cancers derived from epidermal cells, such as melanomas (de Wit et al.,
1992; Derynck et al., 1987). In keratinocyte cancer cell lines and tumors, NOTCH1 gene
expression and activity are significantly reduced. EGFR signaling has been identified to
play an essential role in the negative regulation of NOTCH1 gene transcription in normal
human keratinocytes and cancer cells (Kolev et al., 2008). In cancer cells, inhibition of
EGFR signaling induces NOTCH1 gene expression through p53. Suppression of Notch
signaling by EGF may lead to apoptosis (Kolev et al., 2008). These findings have
emphasized the importance of the EGFR as targets of cancer therapy and skin diseases.
Because the EGFR plays a critical role in cancer progression, wound healing, and
skin inflammatory diseases, anti-EGFR therapies have been introduced as treatment
options. Currently, anti-EGFR monoclonal antibody (cetuximab) and EGFR tyrosine
kinase inhibitors (gefitinib and erlotinib) have been approved for patients with colorectal
and non-small-cell lung cancer. However, a common adverse effect of these agents is
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pustular or aceneiform eruption which can be severe enough to lead to treatment
modification or cessation (Agero et al., 2006; Perez-Soler et al., 2005). It has been
suggested by many clinical trials that these skin lesions or rashes are an indicator of
effective target inhibition and activity of EGFR-targeted agents (Perez-Soler and Saltz,
2005). The lesions may also be derived from the impairment of many EGFR-dependent
homeostatic functions of the skin (Lacouture, 2006). These observations strongly suggest
that chronically reduced activity of EGFR in skin may not be an appropriate treatment for
inflammatory disorders associated with epithelial hyperproliferation.
Specific Research Objectives
Aim 1: Determine the Role of the EGFR in Epidermal Barrier Function
EGFR signaling is an essential regulator of fundamental functions in mammalian
cells including proliferation, migration and survival (Jost et al., 2000; Pastore et al.,
2008). Molecular events driven by EGFRs to mediate both proliferation and migration in
human epidermal keratinocyte have been extensively studied using both experimental and
computational approaches (Citri and Yarden, 2006; Pastore et al., 2008). However, little
is known about EGFR-dependent mechanism on keratinocyte differentiation. Using
NHEK cultured in serum-free medium to investigate the effect of different
pharmacologic and physiologic factors on keratinocyte proliferation and differentiation
reveals that proliferation and differentiation are controlled in an integrated manner
(Wilke et al., 1988; Wille et al., 1984). Subsequent studies aiming to establish the
molecular mechanisms underlying this effect have identified confluent cell density as a
primary biological mechanism that regulates keratinocyte commitment to terminal
differentiation and differentiated gene expression (Poumay and Pittelkow, 1995). Later
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studies using gene expression profiles by microarray have identified large sets of
differentiation-related genes in keratinocytes subjected to confluence-induced
differentiation (Paragh et al., 2010). Although EGFR activation is known to regulate the
expression of a few of these differentiation-related genes (Gibbs et al., 1998; Marchese et
al., 1990; Monzon et al., 1996; Poumay and Pittelkow, 1995), its role in regulating gene
expression at a genome-wide level has not yet been studied. Furthermore, using the
confluence-induced differentiation model, we showed recently that in addition to
blocking the expression of cornified envelope precursor genes, EGF also suppressed the
expression of critical genes in the sphingolipid and ceramide biosynthetic pathway
(Sutter et al., 2009). Specifically, EGF inhibits the expression of genes such as FLG,
UDP-glucose ceramide glucosyltransferase (UGCG), and sphingolipid delta(4)desaturase (DEGS2), that are involved in the cornification and epidermal barrier function
of the skin (Sutter et al., 2009). Because lipid biosynthesis is essential for maintenance of
the epidermal barrier (Holleran et al., 2006), we performed further studies to identify
differentiation associated metabolic processes that are regulated by EGFR signaling.
We combined genome-wide microarray and functional analyses to explore the effects
of EGF, a ligand of the EGFR, on normal human epidermal keratinocytes undergoing
density-induced differentiation. We identified 2,676 density-dependent EGF-regulated
genes. Contrary to the effects of density, EGF downregulated the expression of 91% of
the density-upregulated genes and upregulated 96% of the density-downregulated genes,
suggesting that EGF plays a critical role in inhibiting keratinocyte differentiation.
Specifically, EGF significantly reduced free fatty acid synthesis by half, suppressing the
expression of ELOVL4, PTPLB and TECR, enzymes that form stearic acid and oleic acid,
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two major fatty acid components in the SC. EGF also inhibited mRNA levels of genes
encoding enzymes in the de novo and salvage ceramide pathways, causing a decrease in
ceramides 1, 3, 6, 7, 8, as well as the acyl-glucosylceramides. Our expression and protein
results strongly suggest that activation of EGFR signaling inhibits cornified envelope
formation by altering levels of enzymes and structural proteins essential for the synthesis
of this differentiated structure. Further, we showed that EGF caused a significant
reduction in levels of tight junction proteins such as CLDN1 and TJP1, leading to an
increase in paracellular permeability and disruption of tight junction barrier function.
EGF impaired the epidermal barrier integrity as a whole by increasing the transepidermal
water loss in organotypic culture. Finally, bioinformatics and statistical analyses
revealed that genes associated with skin diseases were enriched in the set of EGFregulated genes. Our work advances the current understanding of EGFR signaling in
regulating epidermal barrier function. We identified many new EGFR-regulated genes
and, more importantly, connected the function of these genes to major processes involved
in epidermal differentiation. These findings provide a reference for subsequent studies of
EGFR in the regulation of epidermal cell fate and homeostasis and may lead to novel
therapeutic approaches for the treatment of dermatological diseases.
Aim 2: Identify the EGFR Signaling Pathway(s) that Mediate(s) Its Identified
Effects on Epidermal Barrier Function
In normal human epidermis, keratinocytes undergo ongoing renewal by a process
called homeostasis, during which stem cells in the basal layer of the epidermis replace the
keratinocytes that are constantly lost or shed during terminal differentiation. A model of
epidermal homeostasis has been proposed and modified with rate constants to
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demonstrate that the number of stem cells is determined by the surrounding transit
amplifying cells. The transit amplifying cells are in turn in equilibrium with cells that
have withdrawn reversibly from the cell cycle and can commit to terminal differentiation
by withdrawing irreversibly from the cell cycle (Figure 6) (Okuyama et al., 2004; Wilke
et al., 1988). This dynamic model, together with our previous observations that EGFR
signaling affects keratinocyte cell fate by regulating the expression levels of genes
responsible for the basal and suprabasal phenotypes, has led us to hypothesize that EGF
not only affects the essential processes required for epidermal barrier performance, but

Figure 6. Dynamic Model of Keratinocyte Stem Cell Renewal and Differentiation
(Okuyama et al., 2004)
This model shows a dynamic equilibrium between proliferative and terminal
differentiated keratinocytes. The number of stem cells is determined by the surrounding
transit amplifying cells which are in turn in equilibrium with cells that have withdrawn
reversibly from the cell cycle and can commit to terminal differentiation by withdrawing
irreversibly from the cell cycle.

also the transition between growth arrested reversible cells and transit amplifying cells (k2),

by inhibiting and inducing the transcription factors (TFs) that regulate differentiation

and proliferation, respectively. Our next aim is to understand the gene regulatory
networks that control the homeostatic effects of EGF. Identifying regulatory networks
and mapping TFs with their targets is a central problem and an ultimate goal in
understanding the underlying mechanisms of cellular responses such as growth control
and cell-cycle progression. Transcription factors are mediators that determine when and
which genes are to be expressed. Understanding the factors that regulate the expression
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of downstream target genes provides insight into the mis-regulated gene expression that
is found in many human diseases.
To accomplish this task, we performed a time course microarray experiment. In this
experiment, we had time-matched controls for each time point in order to identify the
effects of EGF on gene expression over time. The data analysis revealed that EGF
determined keratinocyte cell fate through a complex transcriptional regulatory network.
After controlling for false discovery rate at 1%, EGF temporally changed the mRNA
levels of 3,033 genes. Among these genes, we identified 245 TFs that were significantly
changed by EGF. Specifically, we found that EGF controlled keratinocyte homeostasis
by inhibiting the expression of pro-differentiation TFs and keratinocyte differentiation
markers, while inducing the gene expression of proliferation transcription factors and
proliferative markers. We also observed that MEK signaling pathway appeared to be the
dominating pathway that was activated by EGF in epidermal keratinocyte. EGF signaled
primarily through MEK and PKC signaling pathways to inhibit TFs that promote
differentiation and induced those that promote proliferation primarily through MEK and
PKC signaling pathways. When MEK signaling pathway was not involved, PKC
signaling pathway appeared to mediate the up-regulation of some keratinocyte prodifferentiation TFs expression.
In summary, these findings provide a new mechanistic understanding of how EGFR
activation controls gene expression at genome-wide level and uses signal transduction to
repress keratinocyte differentiation and impair the epidermal barrier integrity, as well as
shed light on the role of EGFR imbalance in skin pathogenesis.
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MATERIALS AND METHODS
Keratinocyte Cell Cultures
Microarray 1
Neonatal foreskin NHEKs (Lonza Walkersville Inc.) were grown in basal
keratinocyte-SFM (KSFM) (Invitrogen) supplemented with 5 ng/ml EGF and 50 µg/ml
bovine pituitary extract (BPE). Fifth-passage NHEKs were grown to either 50% or 100%
confluent cell density before treatment with basal medium, or medium containing EGF
(10 ng/ml) or TGF-α (50 ng/ml) for 48 hr, with the treatment medium being replaced
once at 24 hr (Sutter et al., 2009).
Microarray 2
Neonatal foreskin NHEKs were grown in the same condition as above. Fifthpassage NHEKs were grown to 100% confluent cell density. Cultures were treated with
+/-EGF (10 ng/ml) after 48 hours of the last addition of complete medium. RNAs were
then harvested at 1, 2, 4, 8, 16, and 24 hours after this initial treatment +/- EGF. The zero
time (t0) point controls were changed to basal medium, and RNAs were immediately
harvested. For statistical analysis, there were 3 replicates at each time point. In order to
control for variation in plating, cells were pooled from two individual plates before
harvesting RNA.
RNA Extraction and cDNA Microarray
Microarray 1
Total RNA was isolated using RNA Stat-60 (Tel-Test). The mRNA levels were
measured using the Affymetrix Human Gene 1.0 ST arrays according to the standard
GeneChip® Whole Transcript Sense Target Labeling assay manual.
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Arrays were

washed and stained in the Affymetrix Fluidics Station 400. After hybridization, the
arrays were scanned using the Affymetrix GeneChip Scanner 3000 7G. The microarray
data have been submitted to the National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus repository (GSE32217).
Microarray 2
Total RNA was isolated using RNA Stat-60 (Tel-Test). The mRNA levels were
measured using the Affymetrix Human Genome U133 Plus 2.0 arrays according to the
standard GeneChip® Expression assay protocol. Biotinylated cRNAs were prepared
according to the standard Affymetrix protocol from 8 ug of total RNA (Enzo BioArray
High Yield RNA Transcript Labeling Kit). Following fragmentation, 20 ug of cRNA
were hybridized for 16 hr at 45ºC. Arrays were washed and stained as described above.
Array Data and Statistical Analysis
Microarray 1
The 16 Human Gene 1.0 ST arrays were preprocessed using dChip (Li and Hung
Wong, 2001). Genes with at least 1.5 fold difference when comparing the 100% cell
density untreated samples to the 50% cell density untreated samples were exported for
further analysis. Two-way ANOVA was used to identify differentially expressed genes
by either density or treatment factors using JMP Genomics 4.1 (SAS, Cary, NC). The
multiple hypothesis problem was corrected by Benjamini-Hochberg false discovery rate
control at the 0.05 level (Benjamini and Hochberg, 1995). Pair-wise comparisons were
performed using the Tukey’s Honestly Significant Difference test.
The 1,083 genes that are associated with the epidermis in the literature were
identified using GeneIndexer (Homayouni et al., 2005). The keywords used for this
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analysis were epidermal differentiation, epidermal barrier, skin, cornified envelope,
keratinocyte, and epidermis, with a 0.1 score cut off. GeneIndexer utilizes Latent
Semantic Indexing, a vector space model for information retrieval, to identify both
explicit and implicit gene-to-keyword associations contained within titles and abstracts in
Medline citations (Homayouni et al., 2005). Functional Annotation Clustering from
DAVID (htt://david.abcc.ncifcrf.gov/) was used to obtain the 72 highly enriched genes
associated with ectoderm development. Biological process and cellular component
categories were extracted from the DAVID analysis results. Genes related to skin
diseases were generated by combining the results obtained from Chilibot (Chen and
Sharp, 2004) and IPA (Ingenuity® Systems, www.ingenuity.com). Figure 7 in Chapter 3
shows a detail flow chart of this data analysis.
Microarray 2
The GC-robust multiarray average (GC-RMA) (Wu et al., 2004) was used to adjust
background intensity levels, and to normalize and combine the probe pair intensities into
an estimate of gene expression for each probe set in the data. A function from
Affymetrix Microarray Suite (MAS) 5.0 (Liu et al., 2002b) was used to detect the
Present (P) and Absent (A) calls of the gene expression values. Only probe sets that had
at least 2 P calls out of 3 replicates at any treatment time were selected for further
analysis. The data was then filtered by keeping probe sets that were upregulated or
downregulated with at least 2.6-fold change at any time point compared to its
corresponding time point control. Probe sets that showed significantly differential
expression profiles across all groups in the time-course experiment were identified at a 1
percent false discovery rate using maSigPro (Conesa et al., 2006). maSigPro controls for
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false discovery rate by applying the Benjamini-Hochberg procedure (Benjamini and
Hochberg, 1995). maSigPro first adjusts a general regression model for the data using
least-square technique to identify differentially expressed genes. Then, the differences
between experimental groups are identified using stepwise regression analysis. Each
probe set was fitted to a polynomial regression of up to 3 degrees. The best regression
model for each probe set was selected using a “two.ways.backward” stepwise regression.
In the current Affymetrix technology, one gene can be represented by multiple probe sets.
To avoid this redundancy in our data set, we selected only probe sets having the smallest
regression model p-value. Figure 20 in Chapter 4 shows a detail flow chart of this data
analysis.
Quantitative RT-PCR
Microarray 1
Total RNA (1 µg) was reverse transcribed using the SuperScript First-Strand cDNA
Synthesis System (Invitrogen). Real-time PCR reactions were performed with Absolute
Blue SYBR Green Fluorescein (Cat# AB-4219/B, Thermo Scientific) using four different
samples in each group. The Ct values for all genes were normalized to that of tubulin,
alpha 1C (TUBA1C), and the relative value for the control samples (no EGF and 50% cell
density) was set as one arbitrary unit. Primer sequences are listed in Table 1. The ∆-∆ Ct
method was used to analyze the relative changes in gene expression (Livak and
Schmittgen, 2001).
Microarray 2
Total RNA (2 µg) was reverse transcribed using superscript first strand cDNA
synthesis system (Invitrogen). Real time PCR reactions were performed with SYBR
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Green Supermix (BioRad) using three different samples in each group. The Ct values for
all genes were normalized to that of cyclophillin PPIA, and the relative value for the
control samples (t0) was set as one arbitrary unit. Primers sequences are listed in Table 2.
The Delta-Delta Ct method was used to analyzed the relative changes in gene expression
(Livak and Schmittgen, 2001).
Antibodies and Immunoblotting
Cell lysates were prepared with lysis buffer containing 62.5 mM Tris-HCl pH 6.8, 2%
sodium dodecylsulfate SDS and 1% β-mercaptoethanol. After washing the plates twice
with cold phosphate buffered saline (PBS), 250 µl of the lysis buffer was added to each
plate on ice. The cells were then scraped into 1.5 ml tubes (Cat# 05-048-129, Fisher
Scientific). The tubes were boiled for 5 minutes, centrifuged at 10,000 rpm at 4°C for 20
min using the Eppendorf Centrifuge 5415C. The supernatants were removed to new
tubes and stored at -80°C. Protein samples were quantitated using the Micro BCA
protein assay kit (Cat# 23235, Fisher Thermo Scientific) as follow:
1) Five hundred µl of 0.1 M iodoacetamide and 500 µl of 6.25 mM Tris
HCl pH 6.8 were added to the cuvette.
2) Bovine serum albumin BSA (0, 2, 4, 8, 10, 15, and 20 µg) or protein samples (2
µl) were added to the above mix and incubated for 15 min at 37°C followed by a cooling
process of 5 min at room temperature.
3) Pierce reagent mix (50% Micro BCA Reagent A, 48% Micro BCA Reagent B,
and 2% Micro BCA Reagent C) was added to the above buffer and incubated for 60 min
at 60°C.
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4) The absorbance of each sample was recorded at 562 nm using the
spectrophotometer. Water was used as the blank.
Protein samples were separated by 6% or 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene
fluoride membranes (Millipore). Membranes were blocked with 5% nonfat dry milk in a
mixture of Tris-Buffered Saline and 1% Tween 20 (TBS-T), incubated with primary
antibodies, followed by incubation with horseradish peroxidase-conjugated goat antimouse (115-035-003), goat anti-rabbit (111-036-003), or donkey anti-goat (705-035-003)
IgG (Jackson ImmunoResearch) and development by enhanced chemiluminescence
(Pierce Fisher Thermo Scientific) on Kodak BioMax light film (Cat # Z370371).
Antibodies used for this study are listed in Table 3. ImageJ (Abramoff et al., 2004) was
used to quantitate each protein band.

Table 1. qRT-PCR Primers Used for Expression Validation of Microarray 1
Melting
Reverse complement
Gene
Forward primer (5’-3’)
Temperature
primer (5’-3’)
(°C)
KRT1
FLG
LAMA3
LAMC2
SPTLC3
KDSR
SGPP2
SGPL1
SPHK1
ASAH1
DEGS1
DEGS2
UGCG
GBA
SGMS2
CERK

tgtctggagaatgtgccccgaacg
gacaccccggatcctctcacc
caagaggcctccccacaaacagc
ctggcctggaccctgagaag
tgggatgggattcgcaactaactca
atgggccttttccgcactattg
agtggccccgtccctcctc
cctgttgggctgccttgatgc
ggtgcccgacgaggactttg
tgaaccgcaccagccaagaga
caggaggcggaggcagagg
gcgggtgtacaggctggcaaaaga
cctgcgggagcgttgtc
atcccgatggctctgctgttgtg
aagggggagatccgtgggttgt
gcctgccccaaacccactaacaa

ccgccgccacctccagaaccat
agctgccatgtctccaaactaaac
tggccccaacaatacagagtgagc
ccggccggcaagtgatt
ggggcagatgcacgatggaacct
agccacattcctgaagagcactg
gacgccacccagcacatcc
tccgggcgtgtagtaatgtgatgc
ccgcccgcacgtagaacag
ggcagtcccgcaggtaagtttc
aaagttcccccggtacccaagtta
acaagggcagcagtccagagcaca
ttgttgaggtgtaatcgggtgtag
gccctgctgtgccctctttagtca
cattgggtggcagcagcagtgt
tgccccggaaatcagagcctatc

59
55
55
61
57
57
57
55
59
57
55
55
55
57
57
57

All cDNAs were amplified using the melting temperature at which they had similar efficiency to that of
TUBA1C.
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Table 1. qRT-PCR Primers Used for Expression Validation of Microarray 1
(cont.)
Melting
Reverse compliment
Gene
Forward primer (5’-3’)
Temperature
primer (5’-3’)
(°C)
LASS3
LASS4
PTPLB
TECR
IVL
LOR
KRT10
CLDN1
TJP1
GJA1
ELOVL4
KLF4
GATA3
ABCA12
ALOX12B
PRDM1
BDNF
FBXW7
CST6
TGM1
SLC27A4
DLX3
PIGA
CDSN
OCLN
CGN
CLDN16
CLDN4
TUBA1C

gccccacaccgaccccacat
ggagacgccggaaccaggat
ggcacgcggaagaagaagg
agccccacgccaccattg
ggccacccaaacataaataaccac
caggggcaccgatgggcttagag
tgaaaccgagtgccagaata
cgatgaggtgcagaagatga
tggtcggaaaacatgctacaca
accaaccgctcccctctcg
acgtgacgccggctgaggaga
ccggcgggaagggagaag
ggcccggcaggacgaga
tctcgccgaagtatatgggatgtt
accccacctcgccacctcacc
tcccgaacatgaaaagacgataaa
ggcccaatgaagaaaacaataagg
acgttaacagggcaccagtgg
tgggcagcaacagcatctacta
tccgcccacgacacagacacatc
aggcgggcggggtagga
accgccgttccaagttcaaga
acggggtgcctggactaata
agggcccatcgtctcgcactc
ggcagggtgtgggaagcaggac
ttcccctctttgccattcctacct
gtcatactcagcccctcgcacaga
ccgcgccctcgtcatcatcag
ctacccccgcatccacttcc

aacaaagcgagcccctgagaaagt
aggccgcccacgaaggag
cacccggctgtcatcacca
gggccccgcgtactctgttag
cacctagcggacccgaaataagt
tgaggcactggggttgggaggtag
cgtagccgccgccgaaactt
ccagtgaagagagcctgacc
aggccatggaaccagtctcaca
tcccgcctgccccattc
cccgggagaaagacgaggaggtg
aggggcgccaggttgctac
gtagggcgggtaggtggtgatg
gcttcggggagatgtgattgg
caccgccccagttgcaaagtctct
ctctccgggataagggtagtgaag
gcgggcagggtcagagtg
cacccgttttcaagtcccatagtt
cctcggggacttatcacatctg
gcaggggccgcagcagaaga
gccgggtctcagcagggttta
aggcggctgctgctgtaagtg
tggcctcgctgatgtctgataagt
acccaccacctcgtagccaccata
gacgcgggagtgtaggtgtggtgt
accagacccccggcactttatcat
tgaaccaaaagccagggagaaaag
ataaggccggccaacaggaacacc
ggggcaccaatccacaaactg

59
55
57
59
55
58
59
53
59
55
57
59
57
55
55
57
57
55
57
59
55
59
53
59
59
59
59
59
53, 57, 59

All cDNAs were amplified using the melting temperature at which they had similar efficiency to that of
TUBA1C.
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Table 2. qRT-PCR Primers Used for Expression Validation of Microarray 2
Melting
Reverse compliment
Gene
Forward primer (5’-3’)
Temperature
primer (5’-3’)
(°C)
ATF3
BCL6
BMP2
BMP6
BNC1
CDH1
CDKN1A
CDKN1B
CDKN2A
CTNNB1
E2F7
EAF2
EGR1
ELF1
ELF5
ETS1
ELK3
FOS
FOSB
FOSL1
FOXN1
HES1
ID2
ID3
IRX3
IRX5
ITGA6
ITGB4
JUN
KLF6
LBH
MAF
MAFB
MAFF
MEIS1
MITF
MSX2
MXD1
MYC
NFKB
NFKBIZ
PBX1
PIR
POU2F3

ttcatcggcccacgtgtattgtcc
gaagccctatccctgtgaaatg
gtgtccccgcgtgcttcttag
ggcgcccttgtctcagtcatt
tcgacccttcacagttcccatcac
ccatcaggcctccgtttct
ggcggcagaccagcatgacagatt
cgtaggggcgctttgttttgttcg
catggtgcgcaggttcttggtgac
gtaccggagcccttcacatc
ggatcgggcctgtggacttca
atagcgcagcgggattctcaca
gcgcagtgccatccaacgacag
aaccgtcagtgtggcttcctctcc
agcgcctgccttctcttg
aactcgggggccaggactcttt
gaggagccgcccgaacacagc
cagcccgccctcgtctcct
tcgccctccctcctcgctctgt
acccccacactcatgaccacacc
caccaccccagccaccacctc
ctggagaggcggctaaggtgtttg
cagtcctgtgaggtccgttagg
ggtgcgcggctggtacgag
acccgcaccccgccttctacc
gcccggcgtacagcaccag
tttttggcgtggctgacttacatc
gccgccgcctggtaaaca
gacggcgcccccagtgtg
tttgggggaagggggttgttg
cagtggagagcggggagttgtgt
cccccggcgatgagacg
cggcggaccctgaagaacc
cgtgggccctgtcttcctctt
gactcgggcgctttgcttca
ctacggccacgggaacagga
gaagggccaaggcgaaaagact
acgggctcatcttcgcttgtgc
cggggctttatctaactcgctgta
gccgtccagcgccatctcact
aagggcccgattcgttgtctgat
tccccctccccctcctcatcct
gagggtccggagaagcattgg
gccaggtggagccaggaaatg

ctcccgccttgatggttctctgct
tctggcgcaagtgaagtcg
gctgggggtggggtctctgttt
ctagagccggcagtccagaagtta
cggcggaccctgaagaacc
gtggcaatgcgttctctatcc
gcagggggcggccagggtat
ggctcgcctcttccatgtctctgc
cgtgagccgcgggatgtga
gtcgccacaccttcattccta
ctgtacgggctgctcggttctg
ttttctagccgacattctccagtatca
ttggcggcagggtaggcaggag
ctgtggctgctgctccgttttc
ggcgcttagtccagtattcag
ctagggcagcagcaggaatgaca
tgagaagggtgaggcggatgaaata
ctgcgctcggcctcctgtc
ccaccccctgtccccaaagtcac
gggggaaggggaggagacattg
ccggggctgccaagtcacct
ggtgccgctgttgctggtgtag
tggtgatgcaggctgacaatagtg
ggggccatcagggggtccag
ctcctcgcgctcgctcccataa
ggggcgccgcgtaaggat
gcagcaggcccgaggttaggac
caggacacgccggatgacag
gccgcccctccccaacc
gaaggggctgaggtcggtgagtt
cggggcagtgaatggggaaata
tggagttggcgaaaggtgtgatac
ccaggaccggccacgactc
tctgccccatccccaacctac
gcgggtccccatacatcgtg
ttacaaacaacaagcccaaaccact
aggcgggatgggaagcacag
aggtgtcgctgctctcgctgaa
gcccgcccgctgctatg
agccctcagcaaatcctccaccac
tccccgggcgttggtgttt
cccccggctcttcctcttctgc
cccggcccgcagtcatc
ggccgggaaccagcacaag

60
55
59
57
61
57
59
59
59
57
60
57
55
56
55
59
61
59
61
59
61
57
59
59
60
59
60.3
56
59
59
57
56
56
59
57
55
59
57
58
59
59
59
59
57

All cDNAs were amplified using the melting temperature at which they had similar efficiency to that of
TUBA1C.
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Table 2. qRT-PCR Primers Used for Expression Validation of Microarray 2
(cont.)
Gene

Forward primer (5’-3’)

PPIA
PRDM1
PRMT6
RB1
RELA
RFX2
SIN3A
SKIL
SMAD1
SMAD3
SMAD7
TCF4
SOX2
SOX9
TGIF1
TP63
THOC4
TRIM16
TWIST2
ZNF323

gcagagggttaaggcgcagactac
tcccgaacatgaaaagacgataaa
acaggcccgggaggtggtg
cgtcatgccgcccaaaac
ctccgcgggcagcatcc
accgccgccgccatagagac
gcccctgcccctcctgtgtat
gtcggaggctgttcttactggtgtg
cacccgtttcctcactctcccaatag
aggcgtgcggctctactaca
tgacgcgggaggtggatgg
gaggcgggggaggtgttgagatt
tcggcggcggcaggat
cagcactcgccgcagcagat
gattcttcgggattggctgtatga
agtttcccgtccatctcccttag
ccgtggcgctggaggttt
cttggcagggagacggaggaaca
gcggcgctacagcaagaagtcg
ccggggtttgcaataagggagtc

Reverse compliment primer
(5’-3’)
taaggtgggcagagaaggggtttt
ctctccgggataagggtagtgaag
gtcgctgatgggggctatgaaga
acctcccaatactccatccacaga
atcccggcagtcctttcctacaa
cctgctggggtacctgctgaac
ttgggtgatgatggctgctatgaact
agggtcaatgcaatggtctggttt
ataagcaaccgcctgaacatctcctc
ctccccagcctttgacgaa
ctgatgaactggcgggtgtagca
gggaggggacggagggaagg
ggcgggcgggggtgtc
gtgtcggcgatgggggtgta
acggcgggaaattgtgaactg
aatgacagcccttgaccagaatg
cacgcggatttgctggtctg
atcagggcagcagaaggcagacagt
cagagggcagcgtggggatgat
aaaggccggaaatgcgtcagc

Melting
Temperature
(°C)
56, 57, 59
57
59
57?
57
59
57
59
59
55
57
55
59
57
59
57
55
57
59
59

All cDNAs were amplified using the melting temperature at which they had similar efficiency to that of
TUBA1C.

Transepithelial Electrical Resistance (TER) and Paracellular Permeability
The TER was determined on confluent monolayers of NHEKs grown on
polycarbonate Transwell™ filters (0.4-µm pore size, 12-mm diameter, 1.12 cm2; Cat #
3401; Corning, Inc.) with the Endohm device in the resistance mode (World Precision
Instruments) at 48, 72, and 96 h after the transfer into high Ca2+ (1.8 mM) with or without
EGF (10 ng/ml). TER values (Ohms) were calculated by subtracting the blank values
from the bare filter with medium and multiplying by the surface area of the filter. Before
the TER measurement, the Endohm device was equilibrated with the culture medium at
room temperature for 15 min.
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Table 3. Antibodies Used for Immunoblotting and Immunofluorescence Assays
Primary Antibody
Catalog Number
A. Immunoblotting
KRT1
NLC-K1

Secondary Antibody

Source

Dilution

Leica Microsystems

1:4000

Source

Dilution

Goat anti-mouse

Jackson ImmunoResearch

1:10,000

FLG

NCL-Filaggrin

Leica Microsystesms

1:300

Goat anti-mouse

Jackson ImmunoResearch

1:10,000

DSG1

27B2

Molecular Probes

1:330

Goat anti-mouse

Jackson ImmunoResearch

1:10,000

TJP1

ZO1-1A12

Molecular Probes

1:400

Goat anti-mouse

Jackson ImmunoResearch

1:10,000

GRHL1

HPA005798

Sigma-Aldrich

1:400

Goat anti-rabbit

Jackson ImmunoResearch

1:15,000

CLDN1

MH25

Molecular Probes

1:250

Goat anti-rabbit

Jackson ImmunoResearch

1:15,000

KLF4

sc-20691

Santa Cruz

1:250

Goat anti-rabbit

Jackson ImmunoResearch

1:15,000

FOXN1

ARP30053_T100

Avia System Biology

1:200

Goat anti-rabbit

Jackson ImmunoResearch

1:15,000

POU2F3

ARP32537_P050

Avia System Biology

1:2000

Goat anti-rabbit

Jackson ImmunoResearch

1:15,000

ELF5

sc-9645

Santa Cruz

1:200

Donkey anti-goat

Jackson ImmunoResearch

1:30,000

Molecular Probes

1:15

AlexaFluor 488 goat
anti-rabbit IgG H+L

Molecular Probes

1:1000

AlexaFluor 594 goat
anti-mouse IgG H+L

Molecular Probes
(A11005)

B. Immunofluorescence
CLDN1
MH25
TJP1

ZO1-1A12

Molecular Probes

1:40
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(A11008)
1:1000

Paracellular flux assays were performed on confluent monolayers of NHEKs grown
on polycarbonate Transwell™ filters (0.4-µm pore size, 12-mm diameter, 1.12 cm2, Cat #
3401; Corning, Inc.). Frozen P3 NHEKs were grown in KSFM supplemented with 5
ng/ml EGF and 50 µg/ml BPE. When cells were approximately 80% confluent, they
were trypsinized and 9.4 x 104 NHEKs in 500 µl were plated on the filters and left
overnight to attach. The flux was measured 48, 72, and 96 h after the transfer into high
Ca2+ medium (1.8 mM) with or without EGF (10 ng/ml). Two different tracers were used,
a 3 kDa FITC-dextran (Cat # D3305; Molecular Probes, Inc.), and a 40 kDa Texas Reddextran (Cat# D1829; Molecular Probes, Inc.). The tracers were suspended in P buffer
(10 mM Hepes, pH 7.4, 1 mM sodium pyruvate, 10 mM glucose, 3 mM CaCl2, 145 mM
NaCl). Media in the apical and basal compartments of the keratinocyte sheet grown on
the Transwell™ filters were replaced with 164 µl or 600 µl of P buffer, respectively. The
plates were incubated in 37°C to equilibrate for at least 30 min. Next, 36 µl of P buffer
containing either one of the tracers was added to the apical compartment at a final
concentration of 1 mg/ml. Cells were incubated at 37°C for 3 h. The basal compartment
media was diluted 1:7 (v/v) with the P buffer before equal-volume aliquots (100 µl) were
collected for measurement. The amounts of 3 kDa and 40 kDa dextrans were determined
in a fluorometer (FLx800™; BioTek Instruments, Inc.) on a flat-bottom 96-well plate
(Cat# 353296, BD Falcon). The amount of diffusible dextrans was calculated from a
titration curve of known concentration of the tracers.
Organotypic Cultures
The sources for reagents and materials used for this experiment are listed in Table 4.
Neonatal Dermal Fibroblasts (ND Fibroblasts, Lonza) (seventh passage) were maintained
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Table 4. Sources and Catalog numbers for Reagents and Materials Used in the Organotypic Culture Experiment
Item
Source
Cat #
Adenine
Sigma
A2786-5G
strontium chloride
Sigma
439665-5G
L- serine
VWR/Ameresco Solar
S4311-25G
choline chloride
Sigma
C7527-100G
Ethanolamine
Sigma
E0135-100ML
O-phosphoryl –ethanolamine
Sigma
P0503-1G
selenious acid
Sigma
211176-10G
Triiodothyronine
Sigma
T0281-10MG
Hydrocortisone
Sigma
H0888-1G
Progesterone
Sigma
P8783-1G
Transferring
Invitrogen
11107018
calcium chloride
Sigma
C4901-100G
bovine insulin
Sigma
I0516 or I6634
linoleic acid/bovine serum albumin mixture
Sigma
L9530-5ML
fibroblasts normal human dermal neonatal (CI-1-F)
Lonza
CC-2509
Ham's F12
Fisher/Hyclone
10-080-CV
Fetal bovine serum
Fisher/Hyclone
SH30070
DMEM with 4.5 g/l glucose
Fisher/Media Tech
MT-15-017-CM
L-Glutamine
Sigma
G7513-20ML
sodium pyruvate
Sigma
S8636-100ML
penicillin/streptomycin (10,000 units/10,000 µg, 100mls)
Fisher
SV30010
Transwell inserts (3.0µm polycarbonate membrane insert, 6 well)
Corning
3414
sterile cotton pads
Fisher
19-064-585
type 1 collagen
BD Biosciences
354236
ascorbic acid
Acros Organics
401475000
HEPES
Sigma
H4034

49

in DMEM with 4.5 g/l glucose supplemented with 4 mM L-Glutamine, 0.11 mg/ml
sodium pyruvate, 10% FBS with 100 units of penicillin and 100 µg of streptomycin/ml.
This medium was defined as fibroblast growth medium. Fifth passage NHEKs were
maintained in KSF medium supplemented with 5 ng/ml EGF and 50 µg/ml bovine
pituitary extract.
Organotypic cultures were prepared as described previously (Chen et al., 1995b).
Specifically, cultures were grown on polycarbonate Transwell™ filters (3 µm pore size,
24 mm diameter) as follows:
1) Type 1 collagen (Cat# 354236, BD Biosciences) was mixed with DMEM which
had been supplemented with 10% FBS and 50 µg/ml ascorbic acid. The final collagen
concentration was 1.25 mg/ml. This was mixed on ice to prevent early gelation.
2) One ml of the collagen/media mix was put into each insert to cover the entire
bottom. This layer was allowed to harden for approximately 30 min at 37°C until the
collagen turned pink.
3) Type 1 collagen was mixed with ~20,000 fibroblasts/ ml to a final collagen
concentration of 1.0 mg/ml in DMEM supplemented with 10% FBS and 50 µg/ml
ascorbic acid. The collagen was added last and slowly to the mix. Everything was mixed
on ice to prevent early gelation.
4) Three ml of the collagen/fibroblast mix was put into each well.
5) The collagen was allowed to polymerize at 37°C for 2 h (Gangatirkar et al., 2007).
6) Two ml of fibroblast growth media (as described above) was placed in the bottom
well.

50

7) The following day, 2.5 ml and 1.5 ml fresh fibroblast growth media was placed in
the bottom well and the insert, respectively (this volume was recommended by Corning).
By this time, the cellular collagen layers had contracted some (note: the more fibroblast
the more contraction).
8) The gel was allowed to contract for 5-7 d after initial plating in a incubator at
37°C. After 6 d of incubation at 37°C, the gel was washed and NHEKs (1.5 x 105 cells in
50 µl) were seeded on top using micro pipette tip. The inserts were incubated for 5 min
at room temperature to allow medium to soak into the collagen.
9) The inserts were then transfered to the incubator and the cells were allowed to
attach for 2 h.
10) Plating medium (Chen et al., 1995b) was added to cover the gel (2.5 ml in the
well and 0.5 ml in the insert).The plating medium was DMEM/Ham’s F12 (3:1)
Mediatech/Hyclone) supplemented with a final concentration of 1.9 mM calcium chloride
(Sigma), 7.25 mM L-Glutamine (Sigma), 0.18 mM adenine (Sigma), 1 mM strontium
chloride (Sigma), 1 mM L-serine (VWR), 0.64 mM choline chloride (Sigma), 0.1 mM
ethanolamine (Sigma), 0.1 mM O-phosphoryl-ethanolamine (Sigma), 2 µg/ml linoleic
acid/bovine serum albumin mixture (ratio 1:100, Sigma), 53 nM selenous acid (Sigma), 5
µg/ml insulin (Sigma), 5 µg/ml transferrin (Invitrogen), 20 pM triiodothyronine (Sigma),
0.4 µg/ml hydrocortisone (Sigma), 10 nM progesterone (Sigma), 50 mM Hepes, 10 ng/ml
EGF and 100 units penicillin and 100 µg/ml streptomycin (Hyclone).
11) This medium was changed every 2-3 d for the next 5 d.
12) The cultures were kept submerged for 5 d. The organotypic cultures were then
raised to the air-liquid interface using cotton filter pads.
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13) Two ml of cornification medium (Chen et al., 1995a) with or without EGF (20
ng/ml) was put into the bottom well. The cornification medium used for this period was
DMEM/Ham’s F12 (1:1) with all supplements as in plating media, but without the EGF
and progesterone.
14) The medium was changed every 2-3 d. Only 1.5 ml of media was used from this
point forward. Cotton pads were changed every 1 week. At the time the cotton pads
were changed, 2 ml of cornification media was used. After that, 1.5 ml of media was
used at every meida change. Topical treatment of 30 µl 1x PBS with or without EGF (20
ng/ml) was done at every media change throughout the air-exposure period. The cultures
were harvested after 14 d of air exposure.
Histology
Cultures were fixed with buffered formalin (10%) obtained from the histology lab for
at least 1-2 hour at room temperature. Since the tissues were very fragile, they were
embedded in agar (1%) mixed with buffered formalin. The 1% agar was made as follow:
1) Combine 90 ml ddH2O + 1 g agarose
2) Weigh the flask with agarose to be able to adjust for water evaporated during
boiling.
3) Boil gently until thoroughly dissolved.
4) Add water to weight measured in 2).
5) Add 10 ml of 10% neutral buffered formalin in a 15 ml tube and mix well.
6) Put the quantity to be used immediately into a small bottle with a dropper top.
Store this in either a 60°C oven (keeping the bottle tightly stoppered), or while in use in a

52

60°C water bath in a chemical safety hood if formalin is used. To melt, put a 15 ml tube
in a beaker containing water that had been boiled using a microwave.
7) Pour the rest of the agar into a sterile 100 ml bottle. Allow to solidify. Store at
room temp (expiration 2 months). When needed, warm the bottle in a microwave (loosen
the cap of the bottle), then aliquot the required amount.
8) The tissues were embedded in agar as follows:
a) Working on a clean piece of glass, place a small amount of the agar on the
glass. Observe the change in its consistency. When it begins to solidify, place the tissue
in the agar. Orient the tissue as you would if you were embedding into a paraffin block.
Drop more agar over the tissue. Continue to do this until the tissue is surrounded by the
agar and a small mound of agar is formed. If the agar is allowed to solidify too much
between applications the layers will peel away from each other. Large bubbles should
also be avoided during this process.
b) When the mounded agar is solid, trim the excess away with a scalpel to
form a roughly square shape. Slide the scalpel under the agar/tissue mound and gently
lift it into a processing cassette. Close the cassette and placed in 70% alcohol. Take to
the histology lab for further processing.
Transepidermal Water Loss (TEWL) Measurement
The TEWL measurement protocol was adapted from Urtti et al., 2008. The TEWL
(g/m2h) was measured using a VapoMeter (Delfin Technologies Oy) with the nail adapter
(4.5 mm in diameter). Organotypic cultures grown on filters were removed from the
inserts by moving the scalpel carefully and gently around the edges of the insert. The
cultures were placed on Whatman filter paper soaked with 1x PBS and allowed to
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equilibrate with ambient air for 15 min at room temperature before TEWL measurements
were taken. TEWL measurements were carried out at 24-25°C and 27-35% humidity.
Indirect Immunofluorescence and Confocal Microscopy
Fifth passage NHEKs (17,000 cells in 500 µl) were plated in each chamber of glass
culture slides (Cat # 354118, BD Falcon) that had been coated with fetal bovine serum
for 1 h. Last feed was given to the cells at 100 % confluent cell density. Forty eight hour
after the last feed, a pre-treatment with basal medium with or without EGF (10 ng/ml) in
the presence of 1.8 mM Ca2+ was given to the cells. After the 24 h pre-treatment, the
medium was changed to basal medium containing the exact same treatment of EGF (10
ng/ml) and 1.8 mM Ca2+ as in the pre-treatment medium. After 96 h of EGF treatment,
cells were fixed in 4% paraformaldehyde (in PBS) for 15 min and then washed with PBS
3 times (5 min/wash). Slides were blocked with 5% normal goat serum and 0.1% NP-40
in PBS for 30 min, followed by 30 min of incubation with CLDN1 (MH25) and TJP1
(ZO1-1A12, Molecular Probes) antibodies diluted in blocking solution (16.67 µg/ml and
12.5 µg/ml, respectively). Cells were then washed 3 times with PBS (10 min/wash) and
incubated for 30 min with secondary antibodies: 1:1,000 AlexaFluor 488 goat-anti-rabbit
IgG H+L (A1108, Molecular Probes), and 1:1,000 AlexaFluor 594 goat-anti-mouse IgG
H+L (A11005, Molecular Probes). Before removing the chambers, cells were rinsed with
PBS 3 times (10 min/rinse). The glass slides were then mounted with Prolong® Gold
antifade reagent with DAPI (Cat# P36931; Molecular Probes) (use one small
drop/chamber, regardless of whether the chamber was empty). To help the mounting
media spread evenly, slides were warmed at 37°C for 10-25 min and left overnight in the
dark to dry.
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Fluorescent images were captured using the Zeiss LSM 710 laser scanning confocal
microscope with the ZEN 2009 software (Zeiss). During image acquisition, all images
were taken with a 40x objective lens at identical settings (pixel dwell, 12.6 µs; master
gain, 823; digital gain, 1.00; digital offset, -157.41; pinhole, 90 µm; and 2% laser power).
For presentation, brightness and contrast levels were adjusted across the entire images
using Adobe Photoshop.
Cornified Envelope Assay
Fifth passage NHEKs were grown to confluence and pretreated with vehicle (0.1%
DMSO) or PD153035 (300 nM) 2 h before treatment. Basal medium with or without
EGF (10 ng/ml) was added in the presence of vehicle or PD153035 (300 nM) for 24 h.
The medium was replaced with fresh medium containing the same treatments. After 72 h,
the cell envelope competence assay (n = 3) was performed as previously described (Cline
and Rice, 1983) with modifications.
1) Cells were washed twice with 5 ml 1 x PBS containing 0.02% EDTA (Cat #
E5134-500G, Sigma) and then trypsinized with 1 ml 0.05% Trypsin/EDTA solution (Cat
# 25300054, Invitrogen) for 3 min at 37°C. Plates were shaken gently until most of the
cells came off the plates.
2) Two ml of trypsin neutralizing solution (Cat # CC5002, Lonza) was added to each
plate and the cells were resuspended and transferred to a 15 ml tube.
3) Two ml of PBS were used to collect the remaining cells on the plates, which were
added to the same 15 ml tube. Cells were counted by using 2 x 10 µl of cell suspension
directly with a hemocytometer, using phase contrast (do not add trypan blue) to
determine the total number of cells both alive and dead.

55

4) Cells were centrifuged at 200 x g for 10 min using the IEC CL31R Multispeed
centrifuge (Thermo Scientific).
5) Cells were then resuspended vigorously in serum-free media (3 ml for 100 mm
plate, 2 ml for 60 mm plate, 1 ml per 6-well dish well).
6) They were incubated with 10 µg/ml of calcium ionophore A23187 (C7522,
Sigma-Aldrich) for 5 h at 37°C in a gentle Hybaid rocker with speed of rotation was set
to 12 (National Labnet Company).
7) Cells were centrifuged at 2,500 x g for 5 min using the IEC CL31R Multispeed
centrifuge (Thermo Scientific).
8) Cells were suspended in 10mM Tris/HCL pH 7.5 + 1% SDS and 1% 2mercaptoethanol by strong vortexing and pipetting (use 400 µl for 100 mm plates, 250 µl
for 60 mm plates, and 125 µl for each 6-well dish well).
9) The remaining cornified envelopes were then counted immediately.
10) The percentage cornified envelopes was estimated by dividing the number of
envelopes counted by the initial cell number.
Lipid Extraction
Fifth passage NHEKs were maintained in KSFM supplemented with 5 ng/ml EGF
and 50 µg/ml bovine pituitary extract. Pre-treatment in basal medium with or without
EGF (10 ng/ml) began 48 h after the last feed with complete medium at confluence. After
24 h of pre-treatment, the medium was changed to basal medium with or without EGF
(10 ng/ml) in the presence of 1.8 mM Ca2+. After 48 h of treatment, cell pellets were
extracted by the Bligh-Dyer method (Bligh and Dyer, 1959), and split into the aqueous
and organic phases. The organic phases were dried under nitrogen gas, redissolved in
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chloroform (Cat # 650498, Sigma)/methanol (Cat # L6804, Fisher) (1:1) and stored at 20°C until used. The 3.5 ml aqueous phase was discarded as no further analysis was
required of this phase.
High Performance Thin-layer Chromatography (HPTLC)
Extracted lipids from the organic phase were separated using one-dimensional
HPTLC on 10 cm x 10 cm silica plates using the “ceramide development system” as
previously described (Ponec and Weerheim, 1990). Specifically, ceramides were
separated as follows:
1) Cleaning Plates. To remove possible impurities that could interfere with lipid
separation, plates were washed in 60:40 solution of methanol/ethyl acetate (Cat #
33000000, Pharmco-AAPER), followed by 30:20:50 solution of chloroform/ethyl
acetate/diethyl ether. Then, the plates were air dried.
2) Activation. After evaporation of all solvents, the plates were activated for 15 min
at 130°C in the Isotemp oven (Fisher Scientific).
3) Sample Application. Each lane was approximately 1cm wide. Three µl of a
standard mixture containing linoleic acid, Cholesterol, Cer(NS), Cer(AP), and
Glucosylceramide was applied to each plate. Each of these standards had a final
concentration of 0.2 µg/µl. Standards for cholesterol and linoleic acid, ceramide NS and
GC, and ceramide AP, were from Sigma-Aldrich, Avanti Polar Lipids, and Evonik
Industries, respectively. Then, 28 µl of the - EGF sample and 28 µl of the + EGF sample
were added to the next two spots on the plate, respectively.
NOTE: Application of sample drops was done on a 6 mm streak, as opposed to a dot.
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4) Development. All developments were carried out at room temperature. Plates
were placed “face down” in the Latch-Lid Chromatotank chamber (General Glass
Blowing Company)
5) Ceramide development system. Plates were put in the chamber with 25 ml of
a) chloroform (Cat # 650498, Sigma). By capillary action, chloroform rose on the
plate. When it reached a 15 mm height of the TLC plate, the plate was removed from the
chamber and dried under an air stream at 40°C on the heat block of the Reacti-Therm III
Heating Module for 10 minutes. During this time, the solvent was removed from the
chamber. When the plate was dried, 25 ml of the next solvent was poured into the
chamber.
b) chloroform/acetone (Cat # 179124, Sigma)/methanol (Cat # L6804, Fisher)
(18:2:4). When the solvent reached a 10 mm height of the TLC plate, the plate was
removed from the chamber and processed as described in a) above.
c) chloroform/methanol/hexyl acetate (AC14850-0010, Acros Organics)/acetone
(21.5:1:0.5:2.5). When the solvent reached a 70 mm height of the TLC plate, the plate
was removed from the chamber and processed as described in a) above.
d) chloroform/acetone/methanol (19:1:5) When the solvent reached a 20 mm
height of the TLC plate, the plate was removed from the chamber and processed as
described in a) above.
e) chloroform/methanol/diethyl ether/ethyl acetate/hexyl acetate/acetone
(18:1:1:1:0.5:4). When the solvent reached a 75 mm height of the TLC plate, the plate
was removed from the chamber and processed as described in a) above.
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f) hexane (Cat#34859, Sigma)/diethyl ether/ethyl acetate (Cat # 33000000,
Pharmco-AAPER) (20:4:1). When the solvent reached a 90 mm height of the TLC plate,
the plate was removed from the chamber and dried under air stream at 40°C on the
heating block of the Reacti-Therm III Heating Module for 10 minutes.
6) Staining. After final drying, plates were heated for 5 min at 130°C using the
Isotemp Oven (Fisher Scientific). Plates were submerged into a staining solution
containing acetic acid, H2SO4, H3PO4, H2O (5:1:1:95) and 3.0% copper (II) sulfate for 10
sec.
7) After staining, the plates were dried at 60°C on a heating block of the ReactiTherm III Heating Module for and then charred at 180°C for 10 min. A FOTO/Analyst®
Investigator/Eclipse workstation was used to estimate the quantities of each band relative
to each other on a plate, while ImageJ was used to get a more precise density
measurement on a 100 megabytes image of the plate.
Assignment of lipid bands. Our separation method closely follows the “ceramide
development system” presented by Ponec & Weerheim (Ponec et al., 2003). This
method separates the lipids according to their polarity with the least polar lipids at the top
of the HPTLC plate. Cer9 presents just below ceramide Cer2 (Jungersted et al., 2010;
Ponec and Weerheim, 1990). Cer2 presents as two bands, a large upper band and a
smaller, lower band (Breiden et al., 2007; Ponec and Weerheim, 1990). Jungersted and
colleagues do not show the second band of Cer2. This led to initial concern as to how to
assign the bands seen on our plates. However, Ponec and Weerheim show that Cer9
presents as a much lighter band than Cer2. This matched our data best, and we agreed
the much lighter band below the second band of Cer2 as Cer9. Cer8 appears below

59

ceramide Cer5 in (Breiden et al., 2007; Ponec and Weerheim, 1990). Hence, we assigned
our bands accordingly.
Inhibition of EGFR Signaling Pathways Studies
Chemicals used to inhibit PI3K, MEK, p38, PKC, and Rac1 were wortmannin (Cat #
681675, Calbiochem), U0126 (Cat # 662005, Calbiochem), SB20358 (Cat # 559389,
Calbiochem), Gö6983 (Cat # 365251, Calbiochem), NSC23766 (100 µM, Cat # 553502,
Calbiochem), respectively. Fifth passage NHEKs were grown in KSFM supplemented
with 5 ng/ml EGF and 50 µg/ml bovine pituitary extract. After 48 hours of the last
addition of complete media, plates were randomized and pre-treated 60 min in basal
media with either wortmannin (400 nM), U0126 (10 µM), SB20358 (20 µM), Gö6983
(10 µM), or 0.1 % DMSO (D2650-5X5ML, Sigma). Cells were then treated with or
without EGF (10 ng/ml) for 4 h or 24 h. For statistical analysis, 3 replicates were isolated
at each time point. Another separate experiment was done with NSC23766 (100 µM, Cat
# 553502, Calbiochem). NHEKs were grown as previously described. After 48 h of the
last addition of complete media, plates were randomized and pre-treated for 16 h in basal
media with NSC23766. Then, cells were treated with or without EGF (10 ng/ml) for 4 or
24 h. For statistical analysis, 3 replicates were isolated at each time point.
Statistical Analysis
The statistical tests that were used to determine significance between groups were
carried out using Prism 3.0 or Microsoft Excel 2007. The specific test used for each
analysis is listed in each figure legend.
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EGFR REGULATION OF EPIDERMAL BARRIER FUNCTION
EGF Affects Keratinocyte Cell Fate
Cell density is a major determinant of keratinocyte cell fate (Poumay and Pittelkow,
1995), acting through intercellular signaling mechanisms to affect the expression of
thousands of genes (Gazel et al., 2003; Radoja et al., 2006). However, the role of EGF in
regulating these genes has yet to be described. Our interest was to determine the
genome-wide effects of EGFR activation on epidermal barrier function. Using
microarray technology, we identified 4,685 density-dependent genes (Figure 7). Of these
genes, 2,676 genes were found to be regulated by EGF. Contrary to the effects of density,
EGF repressed the expression levels of 91% of the density-induced genes and elevated
the level of expression of 96% of the density-repressed genes. The former observation
suggested that EGF plays a critical role in inhibiting keratinocyte differentiation.
Specifically, EGF affected 1,039 genes that had explicit, as well as implicit, relationships
to epidermal differentiation, based on the literature. In order to display the microarray
profiles of the epidermis associated genes, we prioritized 72 genes of the 1,039 genes that
were highly annotated to epidermal differentiation (Figure 7). A heat map of the 72
genes is shown in Figure 8A. Among the 72 genes, EGF down-regulated 83% of the
density-induced genes and up-regulated all of the density-repressed genes. To validate
this observation, we performed qRT-PCR on well-established suprabasal (KRT1 and FLG)
and basal (LAMA3 and LAMC2) expressed genes (Figure 8B). As qRT-PCR results
confirmed this relationship and the genes in these clusters appeared to associate with the
differentiating or proliferating cell compartments of the epidermis, we further explored
this association for all 72 genes. An intriguing finding regarding the 72 genes was that
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Figure 7. Diagram of the Gene Expression Data Analysis Workflow for
Microarray 1
On Human Gene 1.0 ST arrays, probes are grouped into transcript clusters. A known or
putative gene can be represented by one or more transcript clusters. Contrary to the effects of
density, EGF repressed the expression levels of 91% of the density-induced genes and elevated
the levels of expression of 96% of the density-repressed genes. This observation suggested that
EGF plays a critical role in inhibiting keratinocyte differentiation. Hence, we used
GeneIndexer to find 1,039 genes that had explicit, as well as implicit, relationships to epidermal
differentiation. In order to display a visible heatmap of the microarray profile of the epidermis
associated genes, we reduced the 1,039 genes to 72 genes that were highly annotated to
epidermal differentiation. Our interest was to determine the biological effects of EGF on
keratinocyte differentiation. During keratinocyte differentiation, most of the differentiation
markers and suprabasal genes are induced (Table 5). Hence, our analysis was focused on the
density-induced genes. From the list of density-induced genes, we identified genes associated
with skin diseases, as dysregulation of the EGFR signaling pathways have been associated with
skin diseases. We also performed gene ontology, KEGG, and bioinformatics analyses on the
density-induced EGF-responsive genes.
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most of the density-upregulated genes are expressed in the suprabasal layers (spinous,
granular, and cornified layers) whereas most of the density-downregulated genes are
expressed in the basal layer of the epidermis (Table 5). This observation suggests that
EGF may affect the mRNA levels of genes expressed not only in the differentiating
keratinocytes but also in the proliferative keratinocytes; thus, affecting the homeostasis of
the epidermis. To determine the physiological relevance of this observation, we
compared the effects of EGF and TGF-α, an endogenous ligand expressed in human
keratinocytes (Coffey et al., 1987) on mRNA level of epidermal keratinocyte genes. We
observed that they produced almost identical responses (Figure 8C), supporting the use of
EGF to study the action of EGFR signaling in our study.
Activation of EGFR signaling in NHEKs is shown to be essential for the G1/S cell
cycle progression and for the inhibition of CE formation and differentiation-related genes
(Kobayashi et al., 1998; Sun and Green, 1976). Inhibition of EGFR signaling opposes
these effects and promotes terminal differentiation (Peus et al., 1997; Sutter et al., 2009).
Recently, a study using organotypic cultures indicated that DSG1 is required to suppress
the sustained activation of EGFR/ERK signaling in the granular layer and acts together
with other desmosomal proteins such as DSG2 and DSC3 to support a signaling network
that balances keratinocyte proliferation and differentiation to maintain epidermal tissue
homeostasis (Getsios et al., 2009). Here, EGF decreased RNA and protein levels of
DSG1 and atranscription factor known to regulate its expression, GRHL1 (Figure 8D).
Mice lacking Grhl1 develop hair loss and plamoplantar keratoderma as observed in
humans with DSG1 mutations (Wilanowski et al., 2008). This cross-regulation between
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Figure 8. EGFR Regulation of Keratinocyte Cell Fate
(A) Heat map profile of log2 ratio of 72 genes identified by GeneIndexer and DAVID as highly
enriched in ectoderm development (Figure 7). NHEKs were grown to either 50% or 100%
confluent cell density before treatment with basal medium, or medium containing EGF (10 ng/ml)
for 48 h, with the treatment medium being replaced once at 24 h. The ratios of the means are
color-coded to show relative RNA expression. Samples with no EGF and 50% confluent cell
density are set as control and color-coded in black. Green indicates down-regulation while red
indicates up-regulation of relative gene expression compared to control. Samples grown to 100%
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Figure 8. EGFR Regulation of Keratinocyte Cell Fate (cont.)
density with EGF (10 ng/ml) were compared to those without EGF in the same cell density
condition, in order to visualize the effects of EGF on density-dependent gene expression (n = 3-4).
(B) Validation by qRT-PCR (n = 3-4) of EGF effects on genes known to be expressed in the
suprabasal (KRT1 and FLG) and basal (LAMA3 and LAMC2) layers of the epidermis. *p < 0.017,
**p< 0.01.
(C) The effects of TGF-α (50 ng/ml) on genes expressed in the suprabasal (KRT1 and FLG) and
basal (LAMA3 and LAMC2) layers as measured by qRT-PCR (n = 4). *p < 0.017, **p< 0.01.
(D) Densitometry (left panel) of protein immunoblots (right panel) for DSG1 and GRHL1 (n = 3).
Values are normalized to the loading control ACTB. Cells were grown to 100 % confluent cell
density before switching to basal medium with or without EGF (10 ng/ml). The media was
replaced with fresh basal media containing the same treatements after 24 h. Cell lysates were
harvested 24 h after the last media change.
All bars represent means ± SD. Student’s t-test was used to evaluate for statistical significance.
*p < 0.05, **p< 0.01, ***p < 0.001. Ŝidák-Bonferonni corrections were used in (B) and (C) with
p-value cut off indicated.

DSG1 and EGFR provides a specific example of a mechanism for regulating epidermal
homeostasis.
EGF Affects All Major Processes of Epidermal Differentiation
One goal of this research was to determine the biological effects of EGF on
keratinocyte differentiation. As shown in Figure 8A, during skin differentiation, most of
the genes known to be expressed in the suprabasal layers of the epidermis are upregulated.
Therefore, we used 1,298 density-upregulated EGF-responsive genes to uncover aspects
of epidermal differentiation that are regulated by EGF. Gene ontology (GO) analysis was
performed to identify biological processes and cellular components overrepresented
among the 1,298 genes. In Table 6, only nonredundant categories with the largest
number of genes and p-value < 10-3 or p-value < 10-2 are shown for biological process
and cellular component, respectively. Since our goal was to understand how EGF
regulates the epidermal barrier function, we focused on these categories: lipid
biosynthesis, cornified envelope, and cell-cell junction, as they play critical roles in the
formation of epidermal barrier. Our next task was to explore these aspects in detail.
65

Table 5. Literature Support for the Granular- or Basal Stratum-specific Expression
of the 72 Genes in Ectoderm Development
Transcript Gene
Gene Name
ID
Symbol
A. Granular Expressed Genes
7920165
FLG
filaggrin
7920185
LCE3D
late cornified envelope 3D
7920155
HRNR
hornerin
7905563
LOR
loricrin
7963491
KRT1
keratin 1
7905548
SPRR3
small proline-rich protein 3
7920146
RPTN
repetin
8124862
CDSN
corneodesmosin
7920252
S100A7
S100 calcium binding protein A7
8015104
KRT10
keratin 10
8109001
SPINK5
serine peptidase inhibitor, Kazal type 5
7947481
ELF5
E74-like factor 5 (ets domain transcription factor)
8012309
ALOX12B arachidonate 12-lipoxygenase, 12R type
8046124
DHRS9
dehydrogenase/reductase member 9
7963534
KRT4
keratin 4
8102232
LEF1
lymphoid enhancer-binding factor 1
7931859
CALML5
calmodulin-like 5
7920182
LCE3E
late cornified envelope 3E
7920196
SPRR2D
small proline-rich protein 2D
8026398
CASP14
caspase 14, apoptosis-related cysteine peptidase
8081826
UPK1B
uroplakin 1B
8015323
KRT13
keratin 13
8163002
KLF4
Kruppel-like factor 4 (gut)
7948420
FABP5
fatty acid binding protein 5 (psoriasis-associated)
7978222
TGM1
transglutaminase 1
7988050
TGM5
transglutaminase 5
8015357
KRT9
keratin 9
7941401
OVOL1
ovo-like 1(Drosophila)
7963479
KRT2
keratin 2
8060432
TGM3
transglutaminase 3
7902810
LMO4
LIM domain only 4
8067839
KGFLP1
keratinocyte growth factor-like protein 1
8015376
KRT16
keratin 16
8157216
UGCG
UDP-glucose ceramide glucosyltransferase
7944537
POU2F3
POU class 2 homeobox 3
7898916
GRHL3
grainyhead-like 3 (Drosophila)
8038670
KLK5
kallikrein-related peptidase 5
7921099
CRABP2
cellular retinoic acid binding protein 2
7939314
EHF
ets homologous factor
7920191
LCE3A
late cornified envelope 3A
8161478
KGFLP2
keratinocyte growth factor-like protein 2
8095728
EREG
epiregulin
8147766
FZD6
frizzled homolog 6 (Drosophila)
7963406
KRT6B
keratin 6B
7920205
SPRR2A
small proline-rich protein 2A
7947015
TSG101
tumor susceptibility gene 101
*The literature was manually collected from Pubmed.
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Reference*

Radoja et al, 2006 ;Toulza et al, 2007
Marshall et al, 2001
Makino et al, 2001
Radoja et al, 2006; Toulza et al, 2007
Toulza et al, 2007
Mischke et al, 1996
Boehnke et al, 2007
Radoja et al, 2006; Toulza et al, 2007
Eckert et al, 2006
Grone et al, 2004
Radoja et al,2006; Galliano et , 2005
Oettgen et al, 1999
Radoja et al, 2006; Toulza et al, 2007
Everts et al, 2007
Wanner et al, 1996
Merrill et al, 2001
Toulza et al, 2007
Marshall et al, 2001
Katou et al, 2003
Toulza et al, 2007
Lobban et al, 1998
Murakami and Saito, 1990
Radoja et al, 2006
Radoja et al, 2006; Oettgen et al,1999
Toulza et al, 2007
Radoja et al, 2006
Knapp et al, 1986
Nair et al, 2006
Virtanen et al, 2010
Radoja et al, 2006
Sugihara et al, 1998 (basal)
Le et al, 1998
Radoja et al, 2006; Sutter et al, 2009
Toulza et al, 2007
Yu et al, 2006
ishida-Yamamoto et al, 2005
Radoja et al, 2006
Tugores et al, 2001
Marshall et al, 2001

Romanowska et al, 2009 (basal)
Wojcik et al, 2000
Radoja et al, 2006; Mischke et , 1996
Oh et al, 2002

Table 5. Literature Support for the Granular- or Basal Stratum-specific
Expression of the 72 Genes in Ectoderm Development (cont.)
Transcript Gene
ID
Symbol
B. Basal Expressed Genes
7936144
COL17A1
7939341
CD44
8067409
LAMA5
7967685
STX2
7950336
C2CD3
7924029
LAMB3
8095907
FRAS1
7991080
BNC1
8011759
PFN1
8022176
LAMA1
7938154
ILK
7908072
LAMC2
8137670
PDGFA
8076757
CELSR1
8165217
NOTCH1
8085475
WNT7A
8054872
TFCP2L1
8013788
FLOT2

Gene Name

Reference*

collagen, type XVII, alpha 1
CD44 molecule (Indian blood group)
laminin, alpha 5
syntaxin 2
C2 calcium-dependent domain containing 3
laminin, beta 3
Fraser syndrome 1
basonuclin 1
profilin 1
laminin, alpha 1
integrin-linked kinase
laminin, gamma 2
platelet-derived growth factor alpha polypeptide
cadherin, EGF LAG seven-pass G-type receptor 1
Notch homolog 1, translocation-associated (Drosophila)
wingless-type MMTV integration site family, member 7A
transcription factor CP2-like 1
flotillin 2

7897803
PLOD1
procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1
8072242
NF2
neurofibromin 2 (merlin)
8037537
ERCC2
excision repair cross-complementing, group 2
8020551
LAMA3
laminin, alpha 3
8103822
VEGFC
vascular endothelial growth factor C
8015337
KRT15
keratin 15
7962000
PTHLH
parathyroid hormone-like hormone
8105302
FST
follistatin
*The literature was manually collected from Pubmed.

Radoja et al, 2006
Kaya et al, 1997
Tateishi et al, 2010
Butt et al, 1996
Radoja et al, 2006
Pavlakis et al, 2008
Tseng, 1998
ubiquitously expressed
Miner et al, 2004
Lorenz et al, 2007
Meng et al, 2003
Radoja et al, 2006
Devenport and Fuchs, 2008
Baldi et al, 2004 (suprabasal)
Radoja et al, 2006
Sasaki et al, 2008 (lipid
rafts)
Radoja et al, 2006
Stamenkovic and Yu, 2010
Radoja et al, 2006
Radoja et al, 2006
Grone et al, 1994
Mukhopadhyay et al, 2006

Table 6. Significant Gene Ontology Terms Associated with the 1,298 Densityupregulated EGF-responsive Genes
Number of genes
Category
p-value
Biological Process
46
ectoderm development
7.88E-14
21
epidermal cell differentiation
1.44E-08
13
keratinization
8.67E-06
39
lipid biosynthesis process
3.06E-04
Cellular Component
8
cornified envelope
3.63E-04
24
intermediate filament cytoskeleton
7.89E-04
12
late endosome
8.83E-04
23
cell-cell junction
5.90E-03
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EGF Decreases Free Fatty Acid (FFA) and Ceramide Biosynthesis
Lipid organization is essential for the epidermal barrier function. It plays an
important role in cohesion and desquamation of the SC as well as in prevention of excess
water loss from the human body and penetration of unwanted influences from the
environment (Elias and Menon, 1991; Ponec and Weerheim, 1990). The major lipid
components isolated from the cornified epidermal layers are ceramides (Cer), cholesterol,
and free fatty acids (FFA). The biosynthesis of these lipid classes requires the presence
of many enzymes. Hence, we studied the effect of EGF not only on all lipid classes in
cultures of NHEKs, but also associated this effect with the changes in expression of
genes encoding lipid biosynthetic enzymes. The lipid biosynthesis process was enriched
in the GO analysis (Table 6). Moreover, using Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analysis, the sphingolipid metabolism pathway was also
overrepresented (p-value = 0.008374) (Figure 6 and 8). This indicates that EGF may alter
lipid components in epidermal keratinocytes. We explored this possibility by mining and
validating the microarray expression profiles of genes encoding enzymes in the
sphingolipid and free fatty acid biosynthetic pathways. Figure 9 highlights the effects of
EGF from the microarray data on the expression of density-dependent genes in the
KEGG sphinglolipid metabolism pathway, with 71% of the RNAs encoding enzymes in
this pathway being significantly altered by EGF. Cers found in the SC are generated via
two pathways: (1) de novo synthesis which builds Cers from less complex molecules, and
(2) the salvage pathway which breaks down more complex sphingolipids to release
sphingosine, which is then re-acylated to form Cers (Figure 10). These Cers are then
packaged into lamellar bodies (LB) as glucosylCer (GlcCer) and sphingomyelin (SM).
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Following extrusion of the LB at the intersection of SG and SC, the GlcCer and SM are
hydrolyzed back to Cers (Uchida and Holleran, 2008). We observed that EGF decreased
expression of enzymes not only in the de novo pathway, but also in the salvage pathway.
In the de novo synthesis, EGF decreased the expression of SPTLC3, a gene encoding for
an enzyme catalyzing the rate limiting step of the pathway, LASS3, the gene encoding for
the major epidermal dihydroceramide synthase, and DEGS2, the gene encoding for the
major epidermal dihydrocermide desaturase/4-hydroxylase that produces the
phytoceramides. In the salvage pathway, EGF decreased the expression of SGPP2,
ASAH1, ACER1, and LASS3 (Figure 10 and 11). The expression of UGCG and SGMS2,
enzymes which make GlcCer and SM from Cer, respectively (Uchida and Holleran,
2008), was down-regulated by EGF (Figure 10 and 11). Treatment with EGF showed no
significant effect on the expression levels of GBA and SMPD3 (Figure 10). qRT-PCR
validated all microarray expression profiles of other genes (SPHK1 and SPGL1) in the
sphingolipid biochemical pathway (Figure 10), except the expression of SPGL1. These
results suggest that ceramide production is significantly reduced as EGF regulates many
biosynthetic enzymes including those catalyzing the rate limiting steps.
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Figure 9. Sphingolipid Metabolism from the KEGG Pathway Database
An overlay of genes in the list of 1,298 density-upregulated EGF-responsive genes on the
KEGG sphinglolipid metabolism pathway (Figure 7). Transcripts for biosynthetic
enzymes that are significantly affected by density from the microarray were selected to
be studied for the effects of EGF. Light green indicates down-regulation by EGF, while
light red indicates up-regulation by EGF. The star indicates a significant difference
between control and EGF treated samples at 100% confluent cell density, using the
Tukey-Kramer honestly significant difference test.
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Figure 10. Sphingolipid Biochemical Pathways
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Figure 10. Sphingolipid Biochemical Pathways (cont.)
This pathway was constructed based on (Uchida and Holleran, 2008) and (Feng and
Prestwich, 2005). The initial condensation, catalyzed by SPTLC, is also the rate-limiting
step for de novo synthesis, forming 3-ketodihydro-sphingosine (Hornemann et al., 2009).
This product is then rapidly reduced to sphinganine, which is then acylated by a member
of the LASS family of enzymes to form dihydroceramide. LASS3 is the most relevant
isozyme for ceramides of the epidermal barrier due to its fatty acyl-CoA chain length
specificity (Stiban et al.). Dihydroceramide is then desaturated by DEGS1/2 or
hydroxylated by DEGS2 (exclusively), to form ceramides and phytoceramides,
respectively. Cer5 and Cer2 may also be formed via the salvage pathway by LASS
acylation of sphingosine that is already present in the cell. These reactions occur in the
endoplasmic reticulum. At this point, the pool of newly formed ceramides and
phytoceramides are trafficked to the Golgi apparatus. UGCG glycosylates all ceramides
and phytoceramides to form glucosylceramides. SGMS catalyzes the addition of choline
phosphate (from phosphatidylcholine) to Cer5 and Cer2 to form sphingomyelin. These
two products (glucosylceramides and sphingomyelin) are packaged into the lamellar
bodies, which are extruded at the intersection of the stratum granulosum and stratum
corneum.
Effects of EGF (relative fold changes) determined by qRT-PCR are shown. * indicates
that the effects of EGF are significant by t-test (p < 0.05).

We then investigated the next lipid component, FFA. We first built the FFA
biochemical pathway based on the KEGG fatty acid biosynthesis pathway (Figure 12).
The microarray expression of all enzymes in the FFA biochemical pathway was validated
by qRT-PCR. EGF inhibited 3 out of 4 major steps of fatty acid elongation as it downregulated the RNA levels of ELOVL3, ELOVL4, and ELOVL6 (condensation), PTPLB
(dehydration), and TECR (reduction) significantly (Figure 13). The down-regulation of
PTPLB and TECR expression would lead to less stearic acid formation, which in turn
restricts the production of oleic acid. These acids contribute about 50% to the fatty acid
composition in the SC (Lampe et al., 1983). Based on these results, we hypothesized that
EGF could decrease total ceramide and FFA production in epidermal keratinocytes.
To test our hypothesis, we used high performance thin-layer chromatography
(HPTLC). We observed that levels of cholesterol were unchanged, while levels of FFA
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Figure 11. qRT-PCR Analysis of Transcripts Encoding Sphingolipid Biosynthetic
Enzymes
Validation of microarray expression profiles of genes encoding sphingolipid biosynthetic
enzymes. NHEKs were grown to either 50% or 100% confluent cell density before
treatment with basal medium, or medium containing EGF (10 ng/ml) for 48 h, with the
treatment medium being replaced once at 24 h . † denotes comparison between the
untreated samples (confluent density effect). * denotes the comparison between control
and EGF at 100% confluent cell density. All bars indicate means ± SD (n = 3-4).
Student’s t-test with Ŝidák-Bonferonni correction was used (where applicable) to evaluate
statistical significance. ††p < 0.01, †††p < 0.001, *p < 0.0253 (Ŝidák-Bonferonni
correction p-value cut off), **p < 0.01, ***p < 0.001.

were reduced by 57%. Several Cer species were also significantly decreased. Inhibition
of genes encoding for enzymes in the de novo and salvage ceramide pathways by EGF, as
shown in the qRT-PCR results (Figure 10 and 11), corresponds to a decrease in some 6hydroxylated Cers, i.e. Cer7 and Cer8 (Figure 14). EGF also reduced the production of
acylGC, a product associated with expression levels of the Cer and GlcCer synthases
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(LASS3, LASS4 and UGCG, respectively). The 11% reduction in acylGC synthesis likely
led to a decrease in Cer1 (Figure 14), a VLCFA containing Cer and the most abundant
acylCer in the epidermis. Cer3 and Cer6 production were also diminished, corresponding
with the inhibition by EGF of the expression of DEGS2 (Figure 11 and 14), the enzyme
that makes phytoceramides (Ternes et al., 2002). Our microarray and qRT-PCR suggests
that the reduction of Cer7 is possibly due to the down-regulation of FA2H (Figure 11),
the enzyme that produces the 2-hydroxylated ceramides (Uchida et al., 2007).

Figure 12. The Free Fatty Acid Biosynthetic Pathway
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Figure 12. The Free Fatty Acid Biosynthetic Pathway (cont.)
This pathway was constructed based on the KEGG pathway for FFA synthesis combined
with one cycle through the four enzymes that catalyze the four consecutive reactions of
fatty acid elongation (Jakobsson et al., 2006). Initial fatty acid synthesis, catalyzed by
FASN occurs in the cytosol; elongation occurs in the ER. The initial step of elongation is
catalyzed by the ELOVL family of enzymes, and is also the rate-limiting step (Jump,
2009). The majority of the fatty acids present in the epidermal barrier are elongated by
ELOVL3 and ELOVL6. ELOVL1 and ELOVL4 catalyze the elongation of the very long
chain fatty acid present in the ceramides of the epidermal barrier (Ohno et al.).
Additionally, FA2H (not shown in this figure) hydroxylates FFA to form 2-OH FFA.
These 2-OH FFA are part of the pool of FFA that are acylated to sphingoid bases to form
ceramides as discussed in Figure 10. Ceramides containing 2-OH FFA include Cer7,
Cer6, and Cer5, and are critical for proper formation of the epidermal barrier (Uchida et
al., 2007). Effects of EGF (relative fold change) determined by qRT-PCR are shown.
KS, keto acylsynthase; ACP, acyl carrier protein. * indicates that the effects of EGF are
significant by t-test (p < 0.05).

Figure 13. qRT-PCR Analysis of Transcript Encoding FFA Biosynthetic Enzymes
Validation of microarray expression profiles of genes encoding FFA biosynthetic
enzymes. NHEKs were grown to either 50% or 100% confluent cell density before
treatment with basal medium, or medium containing EGF (10 ng/ml) for 48 h, with the
treatment medium being replaced once at 24 h. † denotes comparison between the
untreated samples (confluent density effect). * denotes the comparison between control
and EGF at 100% confluent cell density. All bars indicate means ± SD (n = 3-4).
Student’s t-test with Ŝidák-Bonferonni correction was used (where applicable) to evaluate
statistical significance. ††p < 0.01, †††p < 0.001, *p < 0.0253 (Ŝidák-Bonferonni
correction p-value cut off), **p < 0.01, ***p < 0.001.
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Figure 14. EGF Decreases FFA and Total Ceramide Amount
Densitometric measurements (left) of TLC plates (right). NHEKs were grown to 100%
confluent cell density before basal medium or medium with EGF (10 ng/ml) was added.
The media was replaced with fresh basal media containing the same treatments after 24 h
in the presence of 1.8 mM Ca2+. Lipids were extracted 48 h after the last media change.
CHOL, cholesterol; FFA, free fatty acid. The ceramide structures are classified according
to the sphingoid base (S: sphingosine; P: phytosphingosine; H: 6-hydroxysphingosine)
and the N-acyl fatty acid (A: α-hydroxy group, O: ω-hydroxy group, E: acylated in the ωOH position). All bars indicate means ± SD (n = 3). * p < 0.05; ** p < 0.01, *** p <
0.001. Standards (0.2 µg/µl each) (right panel) for cholesterol (CHOL) and linoleic acid
(FFA), ceramide NS (Cer2), ceramide AP (Cer6), and glucosylceramide (GC) were used.
Assignment of lipid bands is described in details in Chapter 2. On the TLC plate, STD,
standard; - EGF, control; + EGF, treatment with EGF (10 ng/ml). Note: semi-synthetic
enanpiomeric mixtures were used as standards for Cer6 and for GC.

EGFR Signaling Inhibits Cornified Envelope Competence
The CE structure is formed beneath the plasma membrane of the corneocytes, the
terminally differentiated keratinocytes. These structures are covalently bound to Cer
lipids in order to provide the effective physical and water barrier functions of the skin.
CE formation requires deposition of many proteins that are catalytically cross-linked by
the TGM1 enzyme (Elias et al., 2000). The CE was the first cellular component enriched
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by GO analysis (p-value = 3.64E-04) (Table 6). This observation led us to investigate the
effect of EGF on genes in this category as well as other genes encoding proteins involved
in the CE formation. We identified 76 density-upregulated genes that contributed to CE
synthesis in epidermal keratinocyte, based on the published literature (Appendix A). Of
these genes, EGF significantly altered mRNA levels of 45 of the identified genes
including genes encoding TGMs, SPRRs, late cornified envelope (LCEs), and S100s.
These proteins are known to be the primary proteins participating in the synthesis of CE
(Candi et al., 2005). The expression profiles of TGM1, LOR, KRT10, KRT1, and FLG
were validated by qRT-PCR (Figure 8B and 15). The results of this analysis were
consistent with previous studies (Drozdoff and Pledger, 1993; Marchese et al., 1990;
Poumay and Pittelkow, 1995), suggesting a reliable effect of EGF on the 40 novel genes
identified as EGF regulated in this study.
We further confirmed our microarray data by protein immunoblotting analysis.
Cornified envelopes consist of keratins that are enclosed in insoluble proteins that are
grouped into bundles by FLG (Candi et al., 2005). Hence, we wanted to determine
whether EGF activated the EGFR to lower the protein levels of KRT1 and FLG by using
PD153035, a specific and potent EGFR tyrosine kinase inhibitor. In concordance with the
microarray and qRT-PCR data, EGF significantly reduced the levels of proFLG, a
precursor of FLG, and KRT1 proteins (Figure 16A). This effect was attenuated by the
EGFR inhibitor, PD153035. The significant induction of these two proteins in the
presence of the inhibitor alone indicates the presence of basal EGFR signaling
(Figure16A), possibly activated by TGF-α, an endogenous ligand of EGFR in
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Figure 15. qRT-PCR of Selected Genes Encoding CE Proteins
Validation of microarray expression profiles of some well known CE genes. NHEKs
were grown to either 50% or 100% confluent cell density before treatment with basal
medium, or medium containing EGF (10 ng/ml) for 48 hr, with the treatment medium
being replaced once at 24 hr (n = 3-4). Results are expressed as relative expression from
values obtained in response to samples grown to 50% confluent cell density without EGF
normalized to values obtained with TUBA1C. Bars represent means ± SD (n = 3-4). †
denotes comparison between the untreated samples. * denotes the comparison between
control and EGF at 100% cell density. *p < 0.0253 (cuf off p-value after ŜidákBonferroni correction), **p < 0.01, †p < 0.0253 (cut off p-value after Ŝidák-Bonferroni
correction), ††p < 0.01, ††† p < 0.001 by t-test.

keratinocytes (Coffey et al., 1987). Since activation of EGFR remarkably affected the
level of proteins forming the CE, we examined this signaling effect on CE competence.
Consistent with other studies (Monzon et al., 1996; Sun and Green, 1976), EGF caused a
significant decrease in the percentage CE (Figure 16B). However, this reduction was
reversed by PD153035, indicating that EGF worked through EGFR signaling to inhibit
CE synthesis. These data together with the expression and protein analysis results
strongly support the idea that EGFR activation inhibits CE formation by altering levels of
enzymes and structural proteins essential for the synthesis of this differentiated structure.
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Figure 16. EGFR Signaling Inhibits CE Competence
The effects of EGFR signaling on CE proteins and competence.
(A) Densitometry (above) of immunoblots (below) of Profilaggrin (ProFLG) and keratin
1 (KRT1). ACTB is a loading control. NHEKs were grown to confluence and pretreated
with 0.1% DMSO or PD153035 (300 nM) 2 hours before treatment. Basal medium with
or without EGF (10 ng/ml) was added in the presence of 0.1% DMSO or PD153035 (300
nM). The media was replaced with fresh basal media containing the same treatments after
24 h. Cell lysates were harvested 24 h after the last media change (n = 3).
(B) EGF effects on CE competence. NHEKs were grown and treated as described in (A).
CEs were isolated 3 days after the last media change (n = 3).
All bars denote mean ± SD. One-way ANOVA followed by Tukey’s Multiple
Comparison Test was performed. If there are different letters in two groups of a
comparison, the means of these two groups are significantly different.
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EGF Disrupts Tight Junction (TJ) Barrier Function
Cell-cell adhesion was enriched by GO analysis (p-value = 0.0059) (Table 6). In this
category we found desmosomal, gap junction, and tight junction (TJs) genes. Recently,
evidence has been presented that components of intercellular junctions, i.e. TJs, are
crucial for the development of the barrier function in the skin. Defects in TJ are observed
in patients with AD (De Benedetto et al., 2011). However, to our knowledge there has
not been a study of the effects of EGF on tight junction barrier function in NHEKs. First,
we validated the mRNA levels of TJ genes by qRT-PCR and found that EGF
significantly suppressed the expression of CLDN1, CLDN16, and TJP1 (Figure 17). Mice
lacking the CLDN1 gene show rapid postnatal lethality due to impaired TJ barrier
function, leading to excessive transepidermal water loss (TEWL) across the skin (Furuse
et al., 2002). TJP1, the first TJ component identified, is an intracellular membrane
scaffolding protein important for TJ structure and assembly (Stevenson et al., 1986). We
therefore investigated the effect of EGF (10 ng/ml) on protein levels of CLDN1 and TJP1
by immunoblot. Treatment with EGF caused a significant decrease in the levels of these
two proteins (Figure 18A). This result was confirmed using indirect immunofluoresence.
In untreated cultures, we observed that CLDN1 and TJP1 distributed around the
circumference of each cell at the apex of lateral membranes. CLDN1 colocalized with
TJP1 at areas of cell-cell contact. The staining of these two proteins was reduced
substantially in cultures treated with EGF (Figure 18B). These results indicate that EGF
inhibits the formation of the TJs, suggesting an increase in paracellular permeability of
the barrier.
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To determine the effect of EGF on TJ barrier function, we measured transepidermal
electrical resistance (TER) and paracellular tracer flux in NHEKs. The TER reflects the
transepithelial permeability of water-soluble ions and is a sensitive measure of barrier
integrity. A higher TER indicates a lower permeability across a membrane. The TER of
the control cultures was measured at 48, 72, and 96 h. The resistance increased 3-fold at
72 h compare to 48 h and remained unchanged at 96 h from the 72 h level (Figure 18C),
suggesting a much improved and stabilized permeability barrier function starting at 72 h.
However, when EGF was present, this permeability barrier function was significantly
disrupted, as indicated by lower TER readings at every time point (Figure 18C).
Consistent with the TER results at each time point, a significant increase in the flux of
dextrans was observed in the EGF-treated NHEKs compared to untreated ones (Figure
18D), indicating that EGF treatment results in a leaky barrier. The paracellular
permeability of TJs exhibits a strong size selectivity, which distinguishes the paracellular
route from the transcytosis route. Hence, different sizes of dextran molecules, 3 kDa and
40 kDa, were used to demonstrate the size selectivity of the TJ barrier. We demonstrated
that fewer 40 kDa molecules diffused across the membrane compared to the 3 kDa
dextran molecules, and that EGF increased the flux of both sizes of dextran molecules
across the TJ barrier (Figure 18D). Together, these results indicate that EGF disrupts the
permeability barrier function by inhibiting the levels of membrane proteins that form the
TJs in cultures of NHEKs.
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Figure 17. qRT-PCR of Genes Encoding Tight Junction Proteins
Validation of microarray expression profiles of genes encoding TJ proteins. NHEKs
were grown to either 50% or 100% confluent cell density before treatment with basal
medium, or medium containing EGF (10 ng/ml) for 48 hr, with the treatment medium
being replaced once at 24 hr. Results are expressed as relative expression from values
obtained in response to samples grown to 50% confluent cell density without EGF, and
normalized to the values obtained with tubulin alpha (TUBA1C). Expression of mRNAs
from the control is set to 1. Bars represent means ± SD (n = 3-4). † denotes comparison
between the untreated samples. * denotes the comparison between control and EGF at
100% confluent cell density. *p < 0.0253 (cut off p-value after Ŝidák-Bonferroni
correction), **p < 0.01, †p < 0.0253 (cut off p-value after Ŝidák-Bonferroni correction),
††
p < 0.01, ††† p < 0.001 by t-test.
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Figure 18. EGFR Signaling Disrupts Tight Junction Barrier Function in Epidermal
Keratinocytes
The effects of EGF on TJ barrier function.
(A) Densitometric measurements (left) of junctional protein immunoblots for CLDN1
and TJP1 (right). ACTB is a loading control. NHEKs were grown to confluence before
switching to basal medium with or without EGF (10 ng/ml) in the presence of 1.8 mM
Ca2+. The media was replaced with fresh basal media containing the same treatments
after 24 h. Cell lysates were harvested 72 h after the last media change (n = 3).
(B) Indirect immunofluorescence of CLDN1 and TJP1 in the presence or absence of EGF
(n = 3). NHEKs were grown as described in (A). Representative immunofluorescent
micrographs of the control and EGF (10 ng/ml) treated monolayers are shown. Scale bar,
50 µm.
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Figure 18. EGFR Signaling Disrupts Tight Junction Barrier Function in Epidermal
Keratinocytes (cont.)
(C) Transepithelial electrical resistance (TER) of keratinocytes grown on Transwell®
filters. NHEKs were seeded at confluence (94,000 cells/insert) and incubated overnight
before switching to basal medium or medium with EGF (10 ng/ml) in the presence of 1.8
mM Ca2+. The media was replaced with fresh basal media containing the same
treatments after 24 h. TER was measured 48, 72, and 96 h after EGF treatment (n = 6).
(D) Paracellular permeability as measured by 3- and 40-kDa dextran flux across the
samples in (C) above.
All bars represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Student’s t-test was
used to evaluate statistical significance in (A)-(C).

EGF Impairs the Epidermal Barrier Integrity and Preferentially Regulates Genes
Associated with Skin Diseases
One of the most important functions of the epidermal barrier is to prevent excessive
water loss. To acquire this function, the epidermis requires a permeability barrier
together with competent cornified envelopes that are covalently bound to a well
organized lipid matrix. To demonstrate the effect of EGF on epidermal barrier function
as a whole, we measured TEWL in organotypic cultures. The TEWL of control cultures
was 64 ± 7.4 g/m2·h, similar to what was reported previously (Nolte et al., 1993). EGF
caused a 29% increase in the rate of TEWL compared to control cultures (Figure 19A).
This increase was accompanied by changes in epidermal morphology. Large basal cells
and a less stratified SC with substantial nuclear retention were observed in the EGFtreated cultures (Figure 19B), consistent with a previous study (Chen et al., 1995b).
These results demonstrate that EGF impairs the epidermal barrier integrity and function,
significantly increasing TEWL.
Defective epidermal differentiation and disruption of epidermal barrier function are
primary features of many skin diseases. EGFR signaling plays a relevant role in the
control of skin inflammation. Abnormally high levels of the EGFR are observed in
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chronic inflammatory skin disorders including psoriasis (Sergi et al., 2000), atopic
dermatitis and allergic contact dermatitis (Mascia et al., 2003). Hence, we hypothesized
that EGF would alter expression of genes that are mis-regulated in skin disorders. Using
Ingenuity Pathway Analysis, Chilibot, and GeneIndexer, we identified 114 EGFregulated genes associated with skin diseases from the list of 1,298 density-upregulated
EGF-responsive genes (Appendix B and Figure 7). In parallel, we identified 43 EGFnonregulated genes associated with skin diseases from the list of 967 density-upregulated
EGF-nonresponsive genes (Figure 18C). Hence, we tested the null hypothesis that there
is no assocication between treatments (control versus EGF) and the number of skin
diseases genes regulated by these treatments. In order to test this hypothesis, the Fisher’s
exact test was used and the two tail p-value obtained from the test was 5.31E-5. This pvalue indicates that the null hypothesis should be rejected and that there is a strong
association between known skin disease genes and the different treatments. In addition,
the association tends to lie in the 114 known skin diseases and the set of EGF-responsive
genes (Figure 18C). Among the 114 skin disease genes, we found 11 genes that are
essential for the development of epidermal barrier function in mice (Appendix B). Figure
19D shows qRT-PCR results of the two transcription factors (KLF4 and GATA3) and two
ichthyosis genes (ALOX12B and ABCA12) that are in the list of essential genes.
Consistent with the expression data, the protein level of KLF4 was significantly inhibited
by EGF (Figure 19E). qRT-PCR validated the expression profiles of 91% of the 11
essential genes (Figure 19D and Figure 20), affirming the preferential effect of EGF on
important skin disease-related genes. Taken together, these results indicate that EGF
impairs epidermal barrier function, thus making the skin more prone to many types of
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disease by altering the expression of genes and proteins that contribute to these skin
diseases.

Figure 19. EGF Impairs Epidermal Barrier Integrity and Preferentially
Regulates Genes Involved in Skin Diseases
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Figure 19. EGF Impairs Epidermal Barrier Integrity and Preferentially Regulates
Genes Involved in Skin Diseases (cont.)
Effects of EGF on epidermal barrier integrity as a whole.
(A) EGF increases TEWL of organotypic skin cultures (n = 6). Cultures were incubated
with or without EGF (20 ng/ml) throughout the 14 days of air exposure.
(B) EGF induces abnormal keratinocyte morphology as shown by histology (hematoxylin
and eosin) of the organotypic cultures from (A). Scale bar, 20 µm.
(C) EGF preferentially regulates genes known to be associated with skin diseases. *The
Fisher’s exact test was used to determine if there was a significant association between
genes related to skin diseases and EGF (p-value = 5.31E-5).
(D) EGF decreases mRNA levels of genes that are essential for the development of
epidermal barrier function in mice (n = 3-4). Results are expressed as relative expression
from values obtained in response to samples grown to 50% confluent cell density without
EGF normalized to values obtained with TUBA1C. † denotes comparison between the
untreated samples. * denotes the comparison between control and EGF at 100% confluent
cell density. Two-way ANOVA followed by Bonferroni post-tests were used to evaluate
statistical significance. Additional essential genes are shown in Figure 20.
(E) Densitometry (above) of KLF4 immunoblot (below) (n = 3). Densitometry of control
samples are set to 1. ACTB is a loading control. NHEKs were grown to confluence
before basal medium or medium with EGF (10 ng/ml) was added. The media was
replaced with fresh basal media containing the same treatments after 24 h. Cell lysates
were isolated 24 h after the last media change (n = 3).
All bars represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Student’s t-test was
used to evaluate statistical significance in (A) and (E).
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Figure 20. qRT-PCR of Genes that are Essential for the Development of
Epidermal Barrier Function
Validation of microarray expression profiles of genes that are essential for the
development of epidermal barrier function in mice. NHEKs were grown to either
50% or 100% confluent cell density before treatment with basal medium, or medium
containing EGF (10 ng/ml) for 48 h, with the treatment medium being replaced once
at 24 h (n = 3-4). Results are expressed as relative expression from values obtained
in response to samples grown to 50% confluent cell density without EGF normalized
to values obtained with tubulin alpha (TUBA1C). Bars represent means ± SD. †
denotes comparison between the untreated samples. * denotes the comparison
between control and EGF at 100% confluent cell density. Two-way ANOVA
followed by Bonferroni post-tests were used to evaluate statistical significance. *p <
0.05, **p < 0.01, ††p < 0.01, ††† p < 0.001.
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IDENTIFICATION OF EGFR-DIRECTED TRANSCRIPTIONAL NETWORKS
THAT REGULATE THE HOMEOSTASIS OF EPIDERMAL KERATINOCYTES
Microarray Analysis and Data Mining
Our previous studies of NHEKs, demonstrated by genome-wide microarray,
functional, biochemical, and morphological data that the presence of EGF impairs
epidermal differentiation and barrier function via disrupting lipid biosynthesis, CE, and
TJ formation. In this second study, we wanted to further explore the molecular
mechanisms underlying these inhibitory effects of EGFR signaling in NHEKs. We
performed global gene expression analysis of EGF treated cells in a time series (t0, 1, 2, 4,
8, 16 and 24 h post EGF treatment) using the Affymetrix GeneChip™ Human Genome
U133 Plus 2.0 chip, which contains approximately 38,500 annotated genes. In this
analysis, 7,819 genes were up- or down-regulated by EGF by at least 2.6-fold (Figure 21).
Among these, EGF significantly alters the levels of RNA of 3,033 genes (about 39% of
those selected). These genes were then clustered using mFuzz, a soft clustering
algorithm (Kumar and Matthias, 2007). mFuzz produced 9 different clusters (Figure 22).
Genes in these clusters were then grouped into 2 groups: intermediate and late responsive
genes. Intermediate responsive genes were those that were affected by EGF at 4 and/or
8- 16 h, but not at 24 h (cluster 1, 4, 6, and 7 in Figure 22). Genes that have a sustained
EGF effect until 24 h are considered late responsive genes (cluster 2, 3, 5, 8, and 9 in
Figure 22). In this dataset, we found 1,238 intermediate responsive genes, 1,795 late
responsive genes, and did not identify any early genes.
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Figure 21. Diagram of the Gene Expression Data Analysis Workflow for
Microarray 2
On the HG-U133 Plus 2.0 arrays, a gene can be represented by one or more probe
sets. This diagram describes in detail the statistical analysis for the microarray
dataset and other bioinformatics analyses used to identify transcriptional regulators.
To determine the regulatory network underlying EGF effects, we identified genes
encoding for proteins involved in the transcriptional regulation using GeneIndexer
analysis with keywords such as “transcription factor, activator, coactivator,
repressor, corepressor, coactivator, regulators, and chromatin structures”. This
allowed us to identify 245 transcriptional regulators. Among these 245 genes, we
identified 32 transcriptional regulator genes known to be associated with the
epidermis, using GeneIndexer (Homayouni et al., 2005). In order to cluster the
3,033 EGF-regulated genes, we used the mFuzz method that is implemented in the
maSigPro package (Conesa et al., 2006).
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Figure 22. Clusters Produced by mFuzz Algorithm
The 3,033 significant genes were clustered using mFuzz. Probe sets in clusters 1, 4, 6,
and 7 are considered to be intermediate responsive probe sets. The genes in these
clusters respond maximally to EGF at 4 or 8 h, but do not respond to EGF at 24 h.
Probe sets in clusters 2, 3, 5, 8, and 9 are considered to be late responsive probe sets.
The genes in these clusters respond to EGF starting at 8 h and continue to respond to
the treatment up to 24 h. The effect of the control and EGF conditions is shown in red
and green, respectively. Dashed lines indicate best fitted curve for the data, while
straight lines show the connection of the mean at each time point. The expression
value is log base 2.
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EGF Influences Keratinocyte Cell Fate Through a Complex Transcriptional
Regulatory Network
Our previous work provides preliminary evidence that EGF controls keratinoctye cell
fate by affecting the expression of genes responsible for the basal and suprabasal cell
phenotypes via the regulation of multiple pro-differentiation TFs and signaling molecules
(Chapter 3). Consistent with our previous microarray (Figure 23) and qRT-PCR (Figure
24) results, EGF down-regulated the RNA levels of differentiation markers that are well
established to be expressed in the suprabasal layers (KRT1 and FLG) and up-regulated
RNA levels of proliferation markers that are expressed in the basal layer (ITGB4 and
BNC1). To determine the regulatory network underlying these EGF effects, we identified
genes encoding for proteins involved in the transcriptional regulation using GeneIndexer
analysis with the keywords “transcription factor, activator, coactivator, repressor,
corepressor, coactivator, regulators, and chromatin structures” (Figure 21). This allowed
us to identify 245 transcriptional regulators (Appendix C) from the list of 3,033
significant genes. Table 7 shows a subset of potentially important transcriptional
regulators in keratinocyte differentiation, based on the observation that their expression
levels were up- or down-regulated by EGF by at least 10-fold. We believe that these
genes may have important biological roles in keratinocyte differentiation, as they
responded strongly to the EGF treatment. Interestingly, the majority of these genes
responded most effectively to EGF starting at 8 h or beyond, suggesting that they may be
regulated by additional immediate early genes. Among these 245 genes, we identified 32
genes whose functions are known to be involved in the proliferation or differentiation of
keratinocytes (Figure 21 and Table 8). Intriguingly, EGF down-regulated the RNA
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levels of 86% of the differentiation regulators and up-regulated the expression of 80% of
the known regulators

Figure 23. Microarray Profiles of EGF-regulated Genes that are Responsible
for the Basal and Suprabasal Cell Phenotypes
Microarray profiles of suprabasal genes (KRT1 and FLG) and basal genes
(ITGB4 and BNC1). NHEKs were grown to 100 % confluent cell density before
receiving a last feed. After 48 h of last feed, cells were treated with or without
EGF (10 ng/ml) in basal medium for 0, 1, 2, 4, 8, 16, and 24 h. Red indicates
control samples while green indicates EGF treated samples (n = 3).
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Figure 24. EGF Affects the Expression of Genes Responsible for the Basal and
Suprabasal Cell Phenotypes
Validation of microarray expression profiles of the genes in Figure 23. These genes were
selected to confirm the effects of EGF on the expression of basal and suprabasal-specific
genes identified in microarray experiment 1. NHEKs were grown to 100 % confluent cell
density before receiving a last feed. After 48 h of last feed, cells were treated with or
without EGF (10 ng/ml) in basal medium for 0, 1, 2, 4, 8, 16, and 24 h. Results are
expressed as relative expression from values obtained in response to the t0 sample. Bars
represent means ± SD (n = 3). Two-way ANOVA with Bonferroni post-tests was used to
evaluate significant difference. *p < 0.05, **p < 0.001, ***p < 0.0001.
of proliferation (Table 8, Figure 25-27 and Figure 29-31). qRT-PCR results validated the
expression profiles of 78% of the 32 transcriptional regulators (Figure 28 and 32). Based
on the mFuzz clustering results, these genes were grouped into intermediate and late
genes. We noticed that there was an equal amount of pro-differentiation and proliferation
genes in each cluster (Table 8), indicating that EGF affects keratinocyte proliferation and
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differentiation simultaneously. Based on these results, we improved a proposed dynamic
model of epidermal homeostasis (Okuyama, 2004) to form an integrated model that
reveals the regulatory action of EGF in this process (Figure 33). In this model, EGF
suppresses genes (in green) that promote differentiation and induces genes (in red) that
promote proliferation of keratinocytes. These results support and expand on the
recognition of EGFR signaling as a key regulator of keratinocyte cell fate, affecting the
transition between growth arrested reversible cells and transit amplifying cells, affecting
k-2 in Figure 33 by inhibiting and inducing the transcription factors (TFs) that regulate
differentiation and proliferation, respectively.

Table 7. Literature Supporting the Transcriptional Regulatory Roles of Genes
That Are Up- or Down- Regulated by EGF by At Least 10 Fold at Any Time Point
Role in cell
development

EGF
MAX
FC1

EGF
MIN
FC2

Hr
MAX
FC3

Probe Set

Gene
Symbol

Type

221011_s_at

LBH

activator

159.74

16 h

204420_at

FOSL1

TF

77.30

8h

228964_at

PRDM1

repressor

34.29

4h

202768_at

FOSB

TF

33.03

2h

228033_at

E2F7

repressor

30.66

8h

206877_at

MXD1

repressor

29.95

4h

202935_s_at
206127_at

SOX9
ELK3

TF
repressor

27.98
24.38

16 h
16 h

209189_at

FOS

TF

Proliferation

24.33

4h

209878_s_at

RELA

TF

17.64

16 h

36711_at

MAFF

TF

Inhibit
proliferation
Proliferation

15.58

8h

229404_at

TWIST2

repressor

Differentiation

13.90

16 h

Differentiation

Proliferation

1

EGF Max FC: maximum fold change observed by EGF over the entire treatment time.
EGF Min FC: minimum fold change observed by EGF over the entire treatment time.
3
Hr Max FC: the time point at which the maximum EGF fold change was observed
4
Hr Min FC: the time point at which the minimum EGF fold change was observed.
2
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Hr
MIN
FC4

Reference
Briegel and
Joyner, 2001
Finzer et al,
2000
Magnusdottir
et al, 2007
Ulery et al,
2006
Endo-Munoz,
et al, 2009
Grandori et al,
2000
Pan et al, 2008
Wasylyk et al,
2005; Chen et
al, 2003
Ulery et al,
2006
Ghosh and
Karin, 2002
Motohashi et
al, 2004
Lee et al, 2003;
Isenmann et al,
2009

Table 7. Literature Supporting the Transcriptional Regulatory Roles of Genes
That Are Up- or Down- Regulated by EGF by At Least 10 Fold at Any Time Point
(Cont.)
Probe Set
226319_s_at

Gene
Symbol

Type

Role in cell
development

EGF
MAX
FC1

EGF
MIN
FC2

Hr
MAX
FC3

Hr
MIN
FC4

Reference

coactivator

12.26

16 h

Mertz et al,
2007

211834_s_at

LOC64481
1 ///
THOC4
TP63

Activator
repressor

11.58

16 h

224833_at

ETS1

TF

Proliferation

11.13

8h

220625_s_at

ELF5

activator

Differentiation

-29.70

24 h

210239_at

IRX5

TF

Differentiation

-15.05

8h

212148_at

PBX1

TF

Differentiation

-50.88

24 h

201566_x_at

repressor

Proliferation

-11.54

4h

219551_at

ID2 ///
ID2B
EAF2

activator

Differentiation

-11.40

8h

207826_s_at

ID3

corepressor

Differentiation

-13.90

4h

229638_at

IRX3

TF

Differentiation

-10.58

8h

204069_at

MEIS1

TF

Differentiation

-15.96

8h

207469_s_at

PIR

TF

-11.73

24 h

223275_at

PRMT6

chromatin
structure

-15.03

24 h

226872_at

RFX2

TF

Differentiation

-15.30

8h

228038_at

SOX2

activator

Differentiation

-11.43

8h

222146_s_at

TCF4

TF

Differentiation

-16.36

8h

222016_s_at

ZNF323

TF

-26.86

16 h

Yang et al,
1998; Senoo
et al, 2007;
Zhu et al,
2007
Jung et al,
2005
Choi and
Sinha, 2006;
Metzger et al
2008
Kerschenstei
ner et al,
2008
Van Dijk et
al, 1993
Murphy et
al, 2004
Xiao et al,
2006; Jiang
et al, 2007;
Maurus et al,
2005
Deed et al,
1993
Bilioni et al,
2005; Gan et
al, 2007
Wang et al,
2006
Pang et al,
2004
Miranda et
al, 2005;
Hyllus et al,
2007
Horvath et
al, 2004
Sharov et al,
2008
Nguyen et
al, 2009
Pi et al, 2002

1

EGF Max FC: maximum fold change observed by EGF over the entire treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the entire treatment time.
3
Hr Max FC: the time point at which the maximum EGF fold change was observed
4
Hr Min FC: the time point at which the minimum EGF fold change was observed.
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Table 8. Literature Supporting the 32 Transcriptional Regulators Known to Be
Associated with Keratinocyte
Gene
Symbol

EGF
MAX
FC1

EGF
MIN
FC2

Type of
transcript-tional
regulation

209878_s_at

RELA

17.645

-4.628

TF

210993_s_at

SMAD1

-1.049

-3.739

TF/activator

203313_s_at

TGIF1

3.5119

1.4239

corepressor of
SMAD2

Inhibits
proliferation
Inhibits
proliferation
Inhibits
proliferation

203140_at

BCL6

1.095

-5.005

TF/repressor

Differentiation

212420_at

ELF1

1.3569

-2.755

TF/activator

Differentiation

220625_s_at

ELF5

-1.026

-29.7

TF/activator

Differentiation

TF

Differentiation

Probe Set

FOXN1

Role in
keratinocyte
development

203394_s_at

HES1

2.4871

-1.526

TF/repressor

Differentiation

210239_at

IRX5

-1.148

-15.05

TF

Differentiation

223218_s_at

NFKBIZ

1.2235

-3.005

TF/activator

Differentiation

218902_at
212148_at

NOTCH1
PBX1

1.1415
1.2079

-2.735
-50.88

TF
TF/activator

Differentiation
Differentiation

207109_at

POU2F3

3.4036

-4.888

TF

Differentiation

228964_at

PRDM1

34.286

2.1633

TF/repressor

Differentiation

218284_at

SMAD3

2.6209

-1.12

TF/activator

Differentiation

204341_at

TRIM16
///
TRIM16L

2.6824

1.0004

coactivator

Differentiation

1

EGF Max FC: maximum fold change observed by EGF over the entire treatment time.
EGF Min FC: minimum fold change observed by EGF over the entire treatment time.
3
The literature was manually collected from Pubmed.
2
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Reference3

Seitz et al, 2000
He et al, 2001
Wotton et al,
1999; (Bartholin et
al., 2008; Lo et al,
2001)
Yoshida et al,
1996; (Shen et al,
2008)
(Oettgen et al,
1997); Oettgen et
al, 1996
(Oettgen et al,
1999); Choi and
Sinha, 2006;
Metzger et al 2008
Janes et al, 2004;
Schlake et al, 2000
Nguyen et al,
2006; (Sang et al,
2008)
Houweling et al,
2001;
(Kerschensteiner
et al, 2008)
Oonuma et al,
2007; Shiina et al,
2004; (Kitamura et
al, 2000; Trinh et
al, 2008)
Nguyen et al, 2006
Komuves et al,
2000; (Lu et al,
1994)
Sugihara et al,
2001; Shiina et al,
2004; Beck et al,
2007; Cabral et al,
2003
Magnusdottir et al,
2007; (Martins et
al, 2008)
Ashcroft et al,
1999; Descargues
et al, 2008;
Flanders et al,
2002
Beer et al, 2002;
Raif et al, 2009

Table 8. Literature Supporting the 32 Transcriptional Regulators Known to Be
Associated with Keratinocyte (cont.)
Probe Set

Gene
Symbol

EGF
MAX
FC1

EGF
MIN
FC2

Type of
transcripttional
regulation

Role in
keratinocyte
development

Reference3

210319_x_at

MSX2

-1.075

-6.691

TF/repressor

Jiang et al, 1999

1554980_a_at

ATF3

3.2036

1.001

1552487_a_at

BNC1

4.8369

1.3962

corepressor,
repressor of
Nrf2
TF

Differentiation
(Overexpression
of MSX2 causes
the skin to
become
hyperkeratotic)
Proliferation

1554411_at
228033_at

CTNNB1
E2F7

7.1994
30.665

1.281
1.142

coactivator
TF/repressor

Proliferation
Proliferation

224833_at

ETS1

11.131

1.3979

TF

Proliferation

209189_at

FOS

24.328

-2.458

TF

201566_x_at

ID2 ///
ID2B

1.0944

-11.54

TF/repressor

Proliferation (cFos is assumed
to be absent in
late stages of
keratinocyte
differentiation)
Proliferation

201465_s_at

JUN

3.1353

1.1422

TF

Proliferation

1555832_s_at

KLF6

9.6018

1.4543

TF/activator

Proliferation

36711_at

MAFF

15.576

1.6971

TF/activator

Proliferation

226066_at
206877_at

MITF
MXD1

1.5963
29.952

-4.607
1.0001

TF/activator
TF/repressor

Proliferation
Proliferation,
Differentiation

202431_s_at
206675_s_at

MYC
SKIL

1.9483
3.9287

-1.03
1.2144

TF/corepressor?
TF/repressor

Proliferation
Proliferation

204790_at

SMAD7

6.0035

1.1128

TF

Proliferation

1

Proliferation

EGF Max FC: maximum fold change observed by EGF over the entire treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the entire treatment time.
3
The literature was manually collected from Pubmed.
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Wang et al, 2007;
(Zhang et al, 2002)
Tseng and Green,
1994; (Zhang and
Tseng, 2007)
Zhu and Watt, 1999
Endo-Munoz et al
2009; (Li et al,
2008)
Nagarajan et al,
2009
Mehic et al, 2005;
Mils et al, 1997

Murphy et al, 2004;
(Boos et al, 2007;
Moskowitz et al,
2007)
Shinoda and Huang,
1995
Fitsialo et al, 2007;
(Warke et al, 2003)
Motohashi et al,
2004; Ye et al, 2006
Gleason et al, 2008
Vastrik et al, 1995;
Grandori et al,
2000; (Rottmann et
al, 2008; Lee et al,
2006)
Murphy et al, 2004
Fitsialo et al, 2007;
(Levy et al, 2007)
Liu et al, 2003

Figure 25. Microarray Expression Profiles of Intermediate Transcriptional
Regulators (BCL6, BNC1, ELF1, ELF5, ETS1, HES1) (Related to Table 8)
Microarray profiles of BCL6, BNC1, ELF1, ELF5, ETS1, HES1. NHEKs were grown
to 100 % confluent cell density before receiving a last feed. After 48 h of last feed,
cells were treated with or without EGF (10 ng/ml) in basal medium for 0, 1, 2, 4, 8,
16, and 24 h. These graphs are organized in alphabetical order. Red dots indicate
control samples. Green dots indicate EGF treated samples.
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Figure 26. Microarray Expression Profiles of Intermediate Transcriptional
Regulators (IRX5, KLF6, MAFF, MXD1, MYC, NFKBIZ) (Related to Table 8)
Microarray profiles of IRX5, KLF6, MAFF, MXD1, MYC, NFKBIZ. NHEKs were
grown to 100 % confluent cell density before receiving a last feed. After 48 h of last
feed, cells were treated with or without EGF (10 ng/ml) in basal medium for 0, 1, 2,
4, 8, 16, and 24 h. These graphs are organized in alphabetical order. Red dots
indicate control samples. Green dots indicate EGF treated samples.
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Figure 27. Microarray Expression Profiles of Intermediate Transcriptional
Regulators (TGIF1 and TRIM16) (Related to Table 8)
Microarray profiles of TGIF1 and TRIM16. NHEKs were grown to 100 % confluent
cell density before receiving a last feed. After 48 h of last feed, cells were treated
with or without EGF (10 ng/ml) in basal medium for 0, 1, 2, 4, 8, 16, and 24 h.
These graphs are organized in alphabetical order. Red dots indicate control
samples. Green dots indicate EGF treated samples.
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Figure 28. qRT-PCR Expression Profiles of Intermediate Transcriptional
Regulators (Related to Figures 25-27)
Validation of microarray expression profiles of the genes in Figures 25-27. NHEKs
were grown to 100 % confluent cell density before receiving a last feed. After 48 h
of last feed, cells were treated with or without EGF (10 ng/ml) in basal medium for
0, 1, 2, 4, 8, 16, and 24 h. These graphs are organized in alphabetical order. Results
are expressed as relative expression from values obtained in response to t0 samples.
Bars represent means ± SD (n = 3). Two-way ANOVA with Bonferroni post-tests
was used to evaluate significant difference. * p < 0.05, ** p < 0.001, *** p < 0.0001.
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Figure 29. Microarray Expression Profiles of Late Transcriptional
Regulators (ATF3, CTNNB1, E2F7, FOS, ID2, JUN) (Related to Table 8)
Microarray profiles of ATF3, CTNNB1, E2F7, FOS, ID2, JUN. FOXN1
microarray profile is not shown as it was detected as absent. NHEKs were grown
to 100 % confluent cell density before receiving a last feed. After 48 h of last
feed, cells were treated with or without EGF (10 ng/ml) in basal medium for 0, 1,
2, 4, 8, 16, and 24 h. These graphs are organized in alphabetical order. Red dots
indicate control samples. Green dots indicate EGF treated samples.
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Figure 30. Microarray Expression Profiles of Late Transcriptional
Regulators (MITF, MSX2, NOTCH1, PBX1, POU2F3, PRDM1) (Related to
Table 8)
Microarray profiles of MITF, MSX2, NOTCH1, PBX1, POU2F3, PRDM1. NHEKs
were grown to 100 % confluent cell density before receiving a last feed. After 48
h of last feed, cells were treated with or without EGF (10 ng/ml) in basal medium
for 0, 1, 2, 4, 8, 16, and 24 h. These graphs are organized in alphabetical order.
Red dots indicate control samples. Green dots indicate EGF treated samples.
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Figure 31. Microarray Expression Profiles of Late Transcriptional Regulators
(RELA, SKIL, SMAD1, SMAD3, SMAD7) (Related to Table 8)
Microarray profiles of RELA, SKIL, SMAD1, SMAD3, SMAD7. NHEKs were grown
to 100 % confluent cell density before receiving a last feed. After 48 h of last feed,
cells were treated with or without EGF (10 ng/ml) in basal medium for 0, 1, 2, 4, 8,
16, and 24 h. These graphs are organized in alphabetical order. Red dots indicate
control samples. Green dots indicate EGF treated samples.
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Figure 32. qRT-PCR Analysis of Late Transcriptional Regulators (Related
to Figures 29-31)
Validation of microarray expression profiles of the genes in Figures 29-31.
NHEKs were grown to 100 % confluent cell density before receiving a last feed.
After 48 h of last feed, cells were treated with or without EGF (10 ng/ml) in basal
medium for 0, 1, 2, 4, 8, 16, and 24 h. These graphs are organized in alphabetical
order. Results are expressed as relative expression from values obtained in
response to t0 samples. Bars represent means ± SD (n = 3). Two-way ANOVA
with Bonferroni post-tests was used to evaluate significant difference. * p < 0.05,
** p < 0.001, *** p < 0.0001.
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Homeostasis of Epidermal Keratinocytes
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Figure 33. An Integrated Model of Homeostasis of Epidermal Keratinocytes
A dynamic model of epidermal homeostasis (Okuyama et al., 2004) has been
proposed. In this model, there is an equilibrium between the stem cell, transit
amplifying cell populations, and cells that have withdrawn reversibly versus
irreversibly from the cell cycle. Boxes that are above the dynamic model list signals
regulating the identified forward rate constants; those below the ---- line identify
reverse constants). Boxes that are below the dynamic model identify cell markers
that are currently used to discriminate the different compartments. EGF suppresses
the expression of genes that are highlighted in green and induces those that are in red.
The expression of these genes have been validated by qRT-PCR. Most of them are
found to be significant by our microarray data.
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Immunoblot analysis was performed on several pro-differentiation TFs including FOXN1,
POU2F3, and ELF5. Consistent with the expression data, the protein levels of these TFs
were significantly inhibited by EGF at 48 h (Figure 34). This indicates that EGF inhibits
keratinocyte differentiation by down-regulating TFs involved in the terminal
differentiation of keratinocytes.

Figure 34. EGF Inhibits Pro-differentiation Transcription Factors.
EGF decreases protein levels of the pro-differentiation TFs FOXN1, POU2F3,
and ELF5. NHEKs were grown to 100 % confluent cell density before
receiving a last feed. After 48 h of last feed, cells were treated with or without
EGF (10 ng/ml) in basal medium for 24 h. Then, they were switch to basal
medium containing with or without EGF (10 ng/ml) in the presence of 1 mM
Ca2+. Cell lysates were harvested 24 h after the last media change. ACTB is a
loading control (n = 3). Bars represent means ± SD. Student’s t-test was used
to evaluate statistical significance (p < 0.05).

MEK and PKC Appear to be Primary EGFR Signaling Pathway that Affects
Keratinocyte Differentiation
To identify the EGFR-dependent signaling pathways that mediate the EGF effects in
epidermal keratinocytes, we treated NHEKs with wortmannin (400 nM), U0126 (10 µM),
SB20358 (20 µM), Gö6983 (10 µM), or NSC23766 (100 µM) to specifically inhibit PI3K,
MEK, p38, PKC, and RAC, respectively. We performed qRT-PCR on the genes
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identified in Table 7 and Table 8 after 4 and 24 h of treatment with these 4 chemicals.
We noticed that there was a significant overlap in the signals that altered the expression
of individual genes. The MEK signaling pathway appeared to be a dominating pathway
that was activated by EGF in epidermal keratinocytes. EGF signaled primarily through
the MEK and PKC signaling pathways to decrease the expression of the TFs that promote
differentiation and increase the expression of those that promote proliferation. When the
MEK signaling pathway was not involved, the PKC signaling pathway appeared to
mediate the up-regulation of some keratinocyte pro-differentiation TFs expression
(Tables 9 and 10).
Table 9. Rank Order of Inhibitor Effects on EGF-downregulated Transcriptional
Regulators Based on qRT-PCR Analysis
Gene
Symbol

Molecular
function

Role in cell
development

MITF
ID2
NOTCH1

TF/activator
repressor
TF

Proliferation
Proliferation
Differentiation

IRX5
FOXN1
POU2F32,3
BCL62

TF
TF
TF
TF/repressor

Differentiation
Differentiation
Differentiation
Differentiation

2

ELF5
IRX3
RFX2
SOX2
ID3
MEIS1
4
PIR
3
PRMT6
NFKBIZ
TCF4
ELF1
PBX1
SMAD1
EAF2
MSX2

TF/activator Differentiation
TF
Differentiation
TF
Differentiation
TF
Differentiation
TF
Differentiation
TF
Differentiation
TF
Differentiation
chromatin structure
TF/activator Differentiation
TF
Differentiation
TF/activator Differentiation
TF/activator Differentiation
TF/activator Antiproliferatio
n
TF/activator Differentiation
repressor
Differentiation

Rank order of inhibitor release
PI3K > PKC
MEK
MEK > Rac1
MEK
MEK
MEK > PKC > PI3K
PI3K
PI3K
MEK
Rac1
Block PKC, EGF suppressed IRX3 even more
PI3K
MEK > PKC > PI3K
MEK > PKC
PI3K > Rac1
MEK > PKC > Rac1
PKC
PKC> MEK
not validated5
not validated**
not validated**
not validated**

Observed
time point1
24 h
4h
4h
24 h
4h
4h
24 h
4 h and 24 h
24 h
4 h and 24 h
4 h and 24 h
4h
4 h and 24 h
4h
24 h
24 h
24 h

not validated**
not validated**

1

Time point where the suppression by EGF was released by an inhibitor.
Block PKC, EGF suppressed the mRNA of the genes even more.
3
Block Rac1, EGF suppressed the mRNA of the genes even more.
4
Block PI3K, EGF suppressed the mRNA of the genes even more.
5
not validated: qRT-PCR results using samples from microarray and inhibitor studies did not validate the microarray expression
profile for EGF.
2
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Table 10. Rank Order of Inhibitor Effects on EGF-upregulated Transcriptional
Regulators Based on qRT-PCR Analysis
Gene
Symbol
E2F7

repressor

Role in cell
development
Proliferation

ETS1

TF

Proliferation

KLF6

activator

Proliferation

CTNNB1
SMAD7
BNC1

coactivator
TF/activator
TF

Proliferation
Proliferation
Proliferation

ATF3

corepressor, repressor
of Nrf2
TF
corepressor of
SMAD2

Proliferation

PRDM1

repressor

Differentiation

TRIM16
SMAD3
HES1
RELA

coactivator
activator
repressor
TF

Differentiation
Differentiation
Differentiation
Antiproliferation

TWIST2

repressor

Growth

ELK3
SOX9

repressor
TF

FOSL1
FOSB2

TF
TF

MAFF2
SKIL2
MXD12

TF/activator/repressor
repressor
repressor

LBH2,3

activator

ZNF323
THOC4
JUN
TP63
MYC

TF
coactivator
TF
activator/repressor
TF/corepressor?

FOS
TGIF1

Molecular function

Proliferation
Inhibit
proliferation

Proliferation
Proliferation
Proliferation,
Differentiation

Proliferation
Proliferation
Proliferation

1

Rank order of inhibitor
suppression
MEK = PI3K
PI3K > MEK
MEK > PKC = PI3K > Rac1
PKC > MEK = PI3K
MEK > Rac1
MEK > PKC
PKC
MEK > PKC > Rac1
MEK
PI3K > MEK
PKC = PI3K

Observed
time point1
4h
24 h
4h
4h
24 h
4h
4h
4h
24 h
4h

MEK > PKC > PI3K
MEK ~ PKC; PI3K

4 h and 24 h
4h

PI3K
MEK > PKC > PI3K
MEK > Rac1 > PKC = PI3K
MEK
MEK > PKC
MEK, PI3K = PKC
MEK
MEK > PKC
MEK > PI3K > Rac1
MEK > Rac1
MEK > PKC > Rac1
MEK > PKC
Rac1
MEK > PKC > PI3K
MEK > PKC
Rac1 = PKC
MEK > PKC
MEK = PKC
PKC > MEK

24 h
4h
24 h
4h
4 h and 24 h
24 h
4h
24 h
4h
24 h
4 h and 24 h
4h and 24 h
24 h
4 h and 24 h
4h
24 h
4h
4h
4 h and 24 h

MEK > PKC > Rac1
PKC > MEK
none of the pathway4
not validated5
not validated5
not validated5
not validated5

4h
24 h

Time point where the induction by EGF was blocked by an inhibitor.
Block PI3K, EGF induced the mRNA of the gene even more.
3
Block Rac1, EGF induced the mRNA of the gene even more.
4
none of the pathway: EGF did not signal through any of the inhibited pathways to upregulate the expression of the gene
5
not validated: qRT-PCR results from the microarray and inhibitor studies did not validate the microarray expression
profile.
2
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EGF Increases the Expression of MIRN21 to Promote Keratinocyte Proliferation
MicroRNAs are approximately 22 nucleotides long, non-coding RNA molecules that
bind to the 3’ untranslated regions (UTR) of target mRNAs to influence the translation or
stability of the transcripts. MicroRNAs have been shown to be involved in hair follicle
morphogenesis, cutaneous wound healing, psoriasis, autoimmune disorders, and skin
carcinogenesis (Bostjancic and Glavac, 2008). In our study, we noticed that microRNA21 (MIRN21) was significantly upregulated 7.6 and 5.0 fold by EGF at 4 and 8 h,
respectively (Figure 28A). This increase was validated by qRT-PCR (Figure 28B).
MIRN21 is the only microRNA that is over-expressed in 11 types of solid tumors,
including stomach, prostate, head and neck, esophagus, glioblastoma, neuroblastoma,
cholangiocarcinoma, breast, lung, colorectal, and pancreatic cancer (Lu et al., 2008;
Medina and Slack, 2008). Increased expression of MIRN21 is observed in skin with
psoriasis and atopic eczema as compared to healthy skin (Sonkoly et al., 2007).
Moreover, activation of EGFR signaling has been shown to increase expression of
MIRN21 in lung cancer in never-smokers (Seike et al., 2009). To test the role of
MIRN21 in our study, the expression of programmed cell death 4 (PDCD4), a known
MIRN21 target, was examined. The RNA level of PDCD4 was significantly decreased
by EGF at 16 and 24 h as observed by both microarray and qRT-PCR results (Figure 28).
Inhibition of MIRN21 has been shown to suppress cell proliferation in HeLa cervical
carcinoma and hepatocellular cancer cells (Meng et al., 2007; Yao et al., 2009). Since
MIRN21 appears to be an EGFR-regulated factor that plays a role in skin diseases and
affects cell proliferation, we hypothesized that EGF increases the expression of MIRN21
to promote keratinocyte proliferation by suppressing its target genes. In order to prove
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this hypothesis, other experiments need to be performed. First, more validation should be
done on other MIRN21 targets such as phosphatase and tensin homologue (PTEN),
tropomyosin 1 (TPM1), tissue inhibitor of metalloproteinase 3 (TIMP3), sprout homolog
2 (SPRY2), nuclear factor I/B (NFIB), and AT-rich interactive domain 1A (ARID1A).
The interpretation of the results on MIRN21 target genes should be placed in the context
of their functions. Keratinocytes should be transfected with either anti-MIRN21 or a
control inhibitor, and then treated with or without EGF (10 ng/ml). Cell proliferation
assay using bromodeoxyuridine (BrdU) and luciferase reporter gene assays can then be
done on these cells. A microarray experiment using RNA from control and anti-MIRN21
cells can be used to identify MIRN21 functionally important targets that contribute to
keratinocyte proliferation and differentiation.
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Figure 35. Expression Profiles of MIRN21 and One of Its Target Genes
The effects of EGF on expression of MIRN21 and PDCD4, a target of
MIRN21.
(A) Microarray expression profiles of MIRN21 and one of its target genes,
PDCD4. NHEKs were grown to 100 % confluent cell density before receiving
a last feed. After 48 h of last feed, cells were treated with or without EGF (10
ng/ml) in basal medium for 0, 1, 2, 4, 8, 16, and 24 h. Red dots indicate control
samples. Green dots indicate EGF treated samples.
(B) qRT-PCR results of the genes in (A). Results are expressed as relative
expression from values obtained in response to t0 samples. Bars represent
means ± SD (n = 3). Two-way ANOVA with Bonferroni post-tests was used to
evaluate significant difference. *p < 0.05, **p < 0.001, ***p < 0.0001.
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DISCUSSION
Our results provide a vast new understanding of how activation of the EGFR
abrogates epidermal permeability barrier function by regulating the expression of
enzymes catalyzing lipid biosynthesis, protein precursors of the cornified epithelium, and
proteins of intercellular TJs. Establishing an epidermal permeability barrier in utero is
required for both mice and humans to survive the transition from an aqueous in utero to a
terrestrial ex utero environment. To complete this barrier acquisition, terminally
differentiated epidermal cells, lipids, and tight junctions are all required.
The permeability barrier relies on the lipid matrix in the SC, which mainly consists of
ceramides, free fatty acids, and cholesterol (Mimeault et al., 2004). Two previous
qualitative studies have investigated the effects of EGF on keratinocyte lipid biosynthesis.
In the first (Ponec et al., 1997), a slight decrease in Cer content was observed in
keratinocytes cultured at the air-liquid interface at 37°C for 14 days in the presence of
EGF compared to control. In the second (Gibbs et al., 2000), EGF was reported to
decrease the amounts of phospholipids and glucosphingolipids in organotypic cultures of
keratinocytes compared to native skin. Neither study identified the molecular mechanism
underlying these effects of EGF, nor provided sufficient statistical analysis. A recent
study of NHEKs showed that ACER1 expression is strongly inhibited by EGF and highly
induced during epidermal keratinocyte differentiation. This enzyme breaks down
ceramide to sphingosine, which can also be derived from sphingosine-1-phosphate (S1P).
Sphingosine and S1P are two bioactive lipids that mediate apoptosis, proliferation, and
differentiation in keratinocytes (Sun et al., 2008). Here, we provided evidence that EGF
decreased several key enzymes affecting free fatty acid and ceramide biosynthesis.
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Abnormal levels of these lipid classes have been observed in many skin disorders
including psoriasis and atopic dermatitis (Harding et al, 2002; Okamoto et al, 2003;
Zheng et al, 2003). It has been reported that the content of the FFA fraction containing
20–26 carbon atoms and the total ceramide amount are significantly reduced in atopic
dermatitis and bullous ichthyosiform erythroderma (Paige et al, 1994). Cer1 is of great
importance to the organization of the lipid matrix of the SC. It is the only ceramide that
can connect the lipid disks in the matrix, allowing the fusion and stabilization of the
intercellular lipid lamellae (Bouwstra et al, 1998). A decrease in the Cer1 content of the
SC will most likely result in a decrease in the lipids organization. The level of Cer1 is
markly decreased in non-erythrodermic lamellar ichthyosis (Paige et al, 1994), and skin
psoriasis plaques (Gniadecki et al, 1998). Cer3 and Cer6 make the lipid matrix more
coherent through the interaction with other lipid components, and thus enhance the
permeability barrier function. Deficiencies of Cer1 and Cer6 are found in Sjögren-Larson
syndrome, a genetic disease characterized by ichthyosis, spastic paraplegia and mental
retardation (Paige et al, 1994). Collectively, these results strongly support the
physiologic connection of the observed effects of EGF on the FFA and ceramide
deficiencies which are seen in the SC of patients with psoriasis, AD, and ichthyosis.
The formation of the lipid matrix and CEs takes place concomitantly in the upper
granular layer and is essential for maintenance of barrier function (Candi et al., 2005).
EGF is known to have an inhibitory effect on the formation of CEs (Sun and Green,
1976). However, the mechanisms underlying the loss of CE after EGF treatment has been
restricted to the reduction of few intermediate filaments and their binding proteins (KRT1,
KRT10, and FLG), CE precursors (LOR, and IVL), and TGM1 (Gibbs et al., 1998;
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Marchese et al., 1990; Monzon et al., 1996; Poumay and Pittelkow, 1995; Reiss and
Sartorelli, 1987). Consistent with these studies, we observed a significant reduction in
CE competence as well as inhibition of KRT1, KRT10, TGM1, FLG, and LOR expression.
More importantly, we demonstrated that these effects of EGF were through the activation
of the EGFR, as inhibition of the EGFR tyrosine kinase blocked these effects.
Furthermore, we identified many previously unrecognized EGF-repressed genes,
including most of the well characterized proteins that participate in the synthesis of the
CE including multiple TGM, SPRR, LCE and S100 proteins (Appendix A) (Candi et al,
2005). Our results greatly advance the current understanding of the molecular
mechanisms of EGFR signaling and its inhibition of keratinocyte differentiation.
The regulation of TJ proteins by EGF has been studied in several cell lines including
Madin-Darby Canine Kidney cells, TMK-1 gastric cancer cells, and Caco-2 cells
(Yoshida et al, 2005; Singh et al, 2004; Samak et al, 2011). However, to our knowledge,
there has not been a study of the effects of EGF on TJ barrier function in NHEKs. In
NHEK cultures, a continuous network of TJs assemble as the epidermal barrier forms
(Yuki et al., 2007). Our experiments demonstrated that EGF reduced levels of CLDN1
and TJP1 by approximately 70%, and this preceded a remarkable 50% reduction in TJ
function based on both electrical resistance and permeability assays. TER reflects smallpore water ions permeability, whereas the flux of dextrans measures the permeability of
large barrier breaks. These results indicate that EGF disrupts TJ function, making the
barrier more susceptable to environmental allergens, one of the characteristics observed
in skin of patients with AD.
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One of the most important functions of the epidermal barrier is to prevent excessive
water loss. TEWL is a technique used to measure the water content property of the skin.
High TEWL indicates aberrant barrier function and is associated with various human skin
diseases such as atopic dermatitis, psoriasis, contact dermatitis, and ichthyosis (Effendy
et al., 1995; Tagami and Yoshikuni, 1985; Tomita et al., 2005; Werner and Lindberg,
1985). To demonstrate the effect of EGF on epidermal barrier function as a whole, we
measured TEWL in organotypic cultures, a model to study in vitro the skin barrier
function (Pasonen-Seppanen et al., 2001; Regnier et al., 1992). This in vitro model allows
us to compare the effect of EGF on the uniform architecture and metabolism that would
otherwise be impossible to obtain in animal models. In addition, there are no limitations
in performing laboratory tests on organotypic cultures, whereas making assessment of a
product or a treatment on animals is more costly. Here, we showed that EGF increased
TEWL in organotypic cultures, indicating that the epidermal barrier integrity is impaired
by the treatment. This suggests that EGF plays an active role in making the skin more
susceptible to skin diseases.
The regulation of gene expression drives all developmental and differentiation
processes. In eukaryotes, TFs define the state of expression and hence the execution of
downstream differentiation/morphogenetic events by coordinately integrating signals
from upstream developmental/growth factor signaling pathways. Our studies identified
several EGF-suppressed TFs including KLF4 and GATA3 that are essential for the
initiation and progression of epidermal differentiation. Each of these TFs activates
distinct aspects of terminal differentiation. KLF4 is necessary and sufficient for the
establishment of a functional epidermal barrier since targeted deletion results in loss of
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barrier function and ectopic expression accelerates the formation of the epidermal barrier
(Jaubert et al., 2003; Segre et al., 1999). Genes encoding structural components of the
CE are misregulated in Klf4-/- mutants. Specifically, Krt1 and Lor are downregulated
while Sprr2a, whose promoter possesses a functional KLF4 binding site, is upregulated
in Klf4-/- skin (Fischer et al, 1996; Segre et al., 1999). This direction is concordant with
the effect of EGF on KRT1, LOR, and SPRR2A, suggesting that the deleterious effect of
EGF on KLF4 alters expression of CE genes, leading to an inhibition in CE assembly as
demonstrated here and in other studies (Sun and Green, 1976; Monzon et al, 1996).
Similarly, epidermal-specific deletion of Gata3 in mice results in an impaired epidermal
barrier and perinatal lethality (de Guzman Strong et al., 2006). However, in contrast to
Klf4, the Gata3 deletion strongly affects the expression of genes involved in lipid
biosynthesis, with the null allele mice showing significantly lower expression of several
critical genes in this pathway including Alox12b, Elovl3 and 4, and Acer1 (de Guzman
Strong et al., 2006). In the present study, we showed that EGF repressed the expression
level of GATA3 by 62%. This reduction was paralleled by significantly lower levels of
expression of multiple lipid metabolism genes including ALOX12B (30%), ACER1 (71%)
and ELOVL3 (76%) and 4 (27%). Of note, mice lacking Alox12b or Elovl4 die
perinatally due to defective skin permeability barrier function and severe dehydration.
Furthermore, Alox12b null mice show significant decreases in certain ω-hydroxyCers that
are covalently bound to the CE (Epp et al., 2007), and skin grafts from Alox12b null mice
exhibit an ichthyosiform phenotype (de Juanes et al., 2009). Elovl4 null mice show
significant decreases in FFA having chain lengths longer than C26, and ceramides with
ω-hydroxy VLCFAs (Cameron et al., 2007; Epp et al., 2007; Li et al., 2007b). Free
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VLCFAs are required for ceramide synthesis in epidermal barrier and are essential for the
highly organized stratum corneum to prevent water penetration. Together, these data
suggest that EGF-mediated suppression of GATA3 could be detrimental to the integrity of
the permeability barrier, as major components of the lipid matrix are significantly
reduced.
Evidence for additional levels of EGFR-mediated regulation is observed in the
example of TIAM1 (T-lymphoma invasion and metastasis 1), a RAC-specific guanine
nucleotide exchange factor, whose level of expression is significantly decreased by EGF.
In epithelial cells, RAC1 regulates the formation and function of adheren and TJs in
epithelial cells (Lozano et al, 2003). Epidermal keratinocytes from TIAM1-deficient mice
show impaired junction maturation by lowering levels of TJ proteins such as CLDN1 and
TJP1, and TJ barrier function (Mertens et al, 2005). In wild-type keratinocytes, the
TIAM1-dependent activated RAC1 binds to PAR3 (protease-activated receptor 3) and
threonine phosphorylates PKCζ (protein kinase C, zeta) of the polarity complex (PAR3PAR6-aPKC) to control the TJ formation (Mertens et al., 2005). Based on these
observations, it seems reasonable to hypothesize that EGF diminishes TIAM1-mediated
RAC signaling, and thereby inactivates the polarity complex, leading to the reduction of
CLDN1 and TJP1 proteins and inhibition of TJ biogenesis. This, in turn, disrupts the
permeability barrier function, making the barrier more permissive to many environmental
allergens. This increased sensitivity to allergens is one of the characteristics observed in
skin of patients with AD (de Benedetto et al., 2011).
In the epidermis, keratinocyte cell fate is tightly regulated by orchestrating large scale
changes in gene expression. Here, as previously reported (Okuyama et al., 2004; Wilke et
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al., 1988), cell density affected the expression of at least four thousand genes, directing
the progression of keratinocytes through a terminal differentiation program. Shown here,
EGF counter-regulated more than 50% of these genes, producing the opposite effects on
keratinocytes compared to density. Moreover, EGF down-regulated genes are reported to
be expressed in suprabasal layers, whereas EGF up-regulated genes are reported to be
expressed in the basal layer. EGF is known to suppress keratinocyte differentiation by
inhibiting mRNA and protein levels of early and late differentiation markers (Drozdoff
and Pledger, 1993; Marchese et al., 1990; Poumay and Pittelkow, 1995). Here, we
observed that EGF suppressed the differentiation program by both inhibiting and
promoting the expression of genes related to the differentiation or proliferation of
keratinocytes, respectively, providing a new view of how EGF is regulating epidermal
homeostasis.
Adding to this new view, we found that EGF down-regulated DSG1, an important
signaling molecule of epidermal tissue homeostasis. The induction of DSG1 is required
to maintain the epidermal barrier integrity and suppress EGFR-mediated ERK1/2
signaling, to promote keratinocyte differentiation (Getsios et al., 2009). The expression of
this gene was increased about 12-fold by cell density. However, the induction of DSG1
and its direct transcription factor GRHL1 (Wilanowski et al., 2008) was abolished by
EGF, indicating that EGF creates a feedback regulation between EGFR and DSG1. This
reciprocal action of DSG1 and EGFR to repress one-another provides a specific example
of a mechanism for regulating epidermal homeostasis. Taken together, this raises the
possibility that EGF functions as a key regulator that controls cell fate by altering gene
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expression through modulating the expression of TFs involved in the terminal
differentiation process.
The epidermis is a dynamic tissue in which highly regulated mechanisms exist to
balance keratinocyte proliferation and differentiation and maintain epidermal tissue
homeostasis. EGF appears to disrupt this balance by down- and up-regulating RNA and
protein levels of pro-differentiation and pro-proliferation transcription factors,
respectively. An example of a keratinocyte differentiation regulator is FOXN1, a winged
helix/forkhead transcription factor, which is reported to regulate the balance between
proliferation and differentiation in self-renewing epithelia (Prowse et al., 1999). In mice,
rats, and humans, loss-of-function mutations of FOXN1 leads to nude phenotypes that are
characterized by the abnormal development of the epidermis, the lack of visible hair, and
the absence of the thymus (Flanagan, 1966; Pantelouris and Macmenamin, 1973). In
murine epidermis and hair follicles, loss of Foxn1 expression impairs terminal
differentiation, as the stratum corneum, the inner root sheath, and the hair cuticle and
cortex fail to form properly (Kopf-Maier et al., 1990). Ectopic expression of Foxn1 in
the epidermis using the Ivl promoter induces hyperproliferation and defects in
differentiation (Prowse et al., 1999). In cultures of primary keratinocytes from wild-type
mice, Foxn1 is induced during the early stages of terminal differentiation (Baxter and
Brissette, 2002). The RNA levels of FOXN1 were significantly blocked by EGF starting
at 4 h and remained repressed through 24 h, leading to a loss of protein at 48 h. Another
important regulator of keratinocyte differentiation is POU2F3 (also known as SKN-1A),
a TF containing a POU domain. This TF is a candidate for -determining cell fate in skin
(Andersen et al., 1993; Goldsborough et al., 1993). POU2F3 is expressed primarily in
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the suprabasal layers of the epidermis where it directly regulates expression of KRT10
(Andersen et al., 1993), SPRR2A (Fischer et al., 1996), and IVL (Welter et al., 1996)
genes. In mice, in vivo ablation mutation of Pou2f3 does not reveal a specific function of
the gene (Andersen et al., 1997). However, in in vitro raft cultures, POU2F3 plays an
important role in maintaining epidermal homeostasis by primarily promoting keratinocyte
proliferation, and secondarily by enhancing subsequent keratinocyte differentiation
(Hildesheim et al., 2001). RNA levels of POU2F3 were down-regulated by EGF
significantly at 16 and 24 h, while its protein expression was repressed at 48 h by EGF.
Another important regulator of keratinocyte differentiation is ELF5, a member of an
epithelium-specific subclass of the Ets domain transcription factor family. The ELF5
transcript is not expressed in undifferentiated keratinocytes, but is induced during
keratinocyte differentiation. A potential target for ELF5 is SPRR2A gene (Oettgen et al.,
1999). RNA and protein levels of ELF5 were down-regulated significantly by EGF
starting at 8 h. In our study, EGF also suppressed RNA levels of NOTCH1 at 4 h. EGFR
signaling is reported as negative regulator of the expression of NOTCH1, an important
regulator of cell-fate decision, thereby blocking the action of NOTCH1 to promote
keratinocyte differentiation in cell culture and skin explants (Kolev et al., 2008). These
examples of EGFR signaling as a negative regulator of the expression of FOXN1,
POU2F3, ELF5, and NOTCH1, support a model where EGFR signaling influences
keratinocyte cell fate by regulating the expression of multiple pro-differentiation
transcription factors, each affecting distinct aspects of cell differentiation.
Besides down-regulating pro-differentiation TFs, EGF appeared to up-regulate many
transcriptional regulators involved in keratinocyte proliferenation. For example, EGF
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significantly increased the transcript levels of ETS1 at 4 and 8 h. ETS1 is an oncogene
that functions as a TF. In mice, Ets1 is mainly expressed in undifferentiated
keratinocytes of the skin and its expression is downregulated as cells commit to terminal
differentiation program (Nagarajan et al., 2009). Ectopic expression of ETS1 in
differentiated keratinocytes of transgenic mice results in major epidermal defects
including shiny, taut, and translucent skin. These mice die shortly after birth due to rapid
dehydration (Nagarajan et al., 2010). Induction of ETS1 leads to an increase in cellular
proliferation in the basal layer, absence of the granular layer, and retention of nuclei in
the stratum corneum. Overexpression of ETS1 results in premature expression of the
early differentiation marker KRT10, whereas the expression of late differentiation
markers such as LOR and FLG are decreased (Nagarajan et al., 2010). Another antidifferentiation regulator that was up-regulated by EGF is SMAD7. SMAD7 has an
antagonistic effect on TGFβ signaling, a potent inhibitor of cellular proliferation in skin
keratinocytes (Munger et al., 1992). It is suggested that SMAD7 may participate in a
negative feedback loop to control TGFβ responses in normal epidermis (He et al., 2001).
Mouse Smad7 protein decreases normal differentiation of primary mouse keratinocytes
(Liu et al., 2003). EGF also upregulated RNA levels of MXD1, a transcriptional
repressor belongs to a subfamily of MAX-interacting proteins. The MYC/MAX/MAD
network plays a role in cell proliferation, differentiation, and death (Grandori et al., 2000).
The MXD1 protein can inhibit cellular growth in vitro (Vastrik et al., 1995). MXD1 is
highly expressed in differentiating epidermal keratinocytes, whereas its expression is
absent in proliferating basal epidermal cells (Lymboussaki et al., 1996). These results
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indicate that EGF also controls transcriptional regulators involved in keratinocyte
proliferation to affect epidermal homeostasis.
EGFR signaling regulates fundamental aspects in skin biology, including cellular
proliferation and differentiation, wound healing, and hair follicle morphogenesis
(Schneider et al., 2008). The MAPKs, PI3K, and PLC are the three majors signaling
cascades of EGFR signaling. The MAPKs include ERKs, JNKs, and the p38 kinases
(Gazel et al., 2008). In cultured keratinocytes, JNK activation inhibits epidermal
differentiation (Gazel et al., 2006). The p38 pathway is activated in keratinocytes by
oxidative stress, UV light, proinflammatory signals, psoriasis, and wound healing
(Kobayashi et al., 2003). It plays an important role in the pathogenesis of pemphigus
vulgaris and mediates keratinocyte migration (Li et al., 2004). Activation of ERK
produces very similar effects to those of p38 activation (Yano et al., 2004). The PI3K
/Akt pathway is activated early during differentiation in cultured keratinocytes and in the
intact epidermis. This activation is a key determinant of keratinocyte differentiation and
survival (Calautti et al., 2005). EGFR also activates PLC pathway which affects cell
migration (Dittmar et al., 2002). Because of the diverse effects of these signaling
pathways on keratinocytes, we hope to identify, by inhibiting these signaling pathways,
the regulatory networks that control the identified transcription factors and regulate
keratinocyte homeostasis. Unfortunately, we found that these pathways significantly
overlap in the TF genes that they target even though there are distinct and unique effects
among these EGFR signaling pathways. We noticed that EGF affects keratinocyte
differentiation and proliferation transcriptional regulators late in time (starting at 8 h after
EGF treatment), indicating that these genes may be activated following the synthesis of
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immediate early gene products. Our study design did not capture immediate early genes
that are transiently and rapidly transcribed in response to the addition of EGF treatment.
The transcription of immediate early genes does not require de novo protein synthesis.
We now believe that immediate early genes determine the genomic response of
keratinocyte to the density and EGF treatment, and that EGFR signaling should be
mapped to these genes, once identified. As a result, another study design will need to be
performed at early times such as 1, 5, 10, and 30 min, in the presence or absence of
cycloheximide, an inhibitor of protein synthesis (Godchaux et al., 1967).
Human and nonhuman genetic studies have identified a large number of genes
associated with dermatological diseases. Intriguingly, we have shown that among the
density-induced genes when compared to the list of EGF-nonresponsive genes, EGFresponsiveness significantly enriches for genes associated with skin disease. For example,
EGF resulted in a 67% reduction in the levels of ABCA12. Loss of function of ABCA12
leads to lipid trafficking defects and decreases in the total amount of Cer (Yanagi et al.,
2010). Mutations in this gene are causally associated with Harlequin ichthyosis
(Akiyama et al., 2005). Similarily, EGF reduced by 29% the level of SLC27A4, a gene
encoding the long chain fatty acid transporter. Mutations in this gene are associated with
ichthyosis premature syndrome (Klar et al., 2009). In contrast to these examples, EGF
up-regulates the level of expression of S100A7, a transglutaminase substrate/CE
precursor that is highly elevated in psoriasis and AD (Glaser et al., 2009; Madsen et al.,
1992). While these three genes are exemplary of the effects of EGF on known human
skin disease genes, it is important to note that 111 similarly responsive skin disease genes
and another 1184 genes not yet associated with skin disease have been identified by this
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research. These data provide a new understanding of the molecular mechanisms by which
EGF affects epidermal homeostasis and show how imbalance in this signaling pathway
may lead to system-wide pathogenesis.
In conclusion, our results provide a systems level understanding of EGFR signaling in
repressing keratinocyte differentiation and impairing functional epidermal barrier
integrity. Epidermal homeostasis appears to be controlled by the spatial and temporal
expression and activity of the EGFR, its ligands, and suppressors thereof. Activation of
EGFR preferentially regulates genes known to be associated with skin disease,
highlighting the importance of EGFR in skin pathology. Our data provide a valuable
resource for further dissecting the molecular events and genetic basis in dermatological
diseases.
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Appendix A - Literature Support of Genes Involved in Cornified Envelope
Formation (Refer to Chapter 3, Figure 16)
Transcript
cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Function in
skin

References

-3.04

Significant
Index for
EGF
effect3
1

7931859

CALML5

10.11

8026398

CASP14

calmodulinlike 5
caspase 14

Enzyme

9.19

-1.99

1

Enzyme

31.89

1.34

1

CE

11.77

-1.93

1

CE

4.03

-2.17

1

CE

cathepsin D

2.70

-1.44

1

Enzyme

CTSL2

cathepsin L2

3.03

1.71

1

Enzyme

8026424

CYP4F22

18.64

-2.35

1

Enzyme?

8036079

DMKN

cytochrome
P450, family 4,
subfamily F,
polypeptide 22
dermokine

(Mehul et
al., 2001)
(Lippens et
al., 2000)
(Simon et
al., 1997)
(Taylor et
al., 2009)
(Contzler et
al., 2005)
(Egberts et
al., 2004)
(Cheng et
al., 2006)
(Lefevre et
al., 2006)

8179716

CDSN

7964834

CPM

7920178

CRNN

corneodesmosi
n
carboxypeptida
se M
cornulin

7945663

CTSD

8162652

8.63

-1.34

1

CE

8022728

DSC1

desmocollin 1

16.56

-2.81

1

Cell adhesion

8020724

DSG1

desmoglein 1

11.67

-1.60

1

Cell adhesion

8020762

DSG3

1.62

1.19

1

Cell adhesion

8127767

ELOVL4

11.12

-1.92

1

Fatty acid
elongase

(Cameron
et al., 2007)

7920165

FLG

desmoglein 3
(pemphigus
vulgaris
antigen)
elongation of
very long chain
fatty acids-like
4
filaggrin

55.43

-1.54

1

CE, EDC

7920175

FLG2

65.91

-1.82

1

CE

(Dale et al.,
1985;
Kalinin et
al., 2002)
(Wu et al.,
2009a)

7965606

HAL

44.86

-3.76

1

Enzyme

8103769

HPGD

25.24

-1.77

1

CE

filaggrin
family member
2
histidine
ammonia-lyase
hydroxyprostag
landin
dehydrogenase
15-(NAD)

1

Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
EGF FC: fold change between control and EGF at 100% confluent cell density.
3
Indicates whether the effect of EGF on the gene is statistically significant; 1: significant, 0: non-significant
CE: cornified envelope; EDC: epidermal differentiation complex on human chromosome 1q21
2
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(Bazzi et
al., 2007)
(King et al.,
1996;
Taylor et
al., 2009)
(Getsios et
al., 2009)
(Koch et
al., 1997)

(Eckhart et
al., 2008)
(Taylor et
al., 2009)

Appendix A - Literature Support of Genes Involved in Cornified Envelope
Formation (Refer to Chapter 3, Figure 16) (cont.)
Transcript
cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Function in
skin

References

-2.20

Significant
Index for
EGF
effect3
1

7920155

HRNR

hornerin

48.67

CE

2.33

-1.14

1

12.23

2.31

1

keratin 1

42.74

-3.35

1

KRT10

keratin 10

22.67

-2.50

1

7963479

KRT2

keratin 2

3.75

-1.95

1

7963534

KRT4

keratin 4

12.95

-6.29

1

7963502

KRT77

keratin 77

11.77

-3.04

1

8036072

KRTDAP

21.19

-2.07

1

7905525

LCE1B

4.48

3.22

1

CE, EDC

7920193

LCE1C

1.54

1.25

1

CE, EDC

7920191

LCE3A

2.01

3.00

1

CE, EDC

7920185

LCE3D

52.44

1.81

1

CE, EDC

7920182

LCE3E

9.82

2.57

1

CE, EDC

7905563

LOR

keratinocyte
differentiationassociated
protein
late cornified
envelope 1B
late cornified
envelope 1C
late cornified
envelope 3A
late cornified
envelope 3D
late cornified
envelope 3E
loricrin

Tryptic
enzyme,
desquamation
marker of
keratinocyte
late
differentiation
Structural
proteins
Structural
proteins
Structural
proteins
Structural
proteins
Structural
proteins
Regulator of
keratinocyte
differentiation

(Henry et
al.; Makino
et al., 2001)
(Borgono
et al., 2007)

8038670

KLK5

7905515

KPRP

kallikreinrelated
peptidase 5
keratinocyte
proline-rich
protein

7963491

KRT1

8015104

44.32

-19.49

1

CE, EDC

7898413

PADI1

2.97

1.70

1

Deiminase
filaggrin and
KRT1

8001007

PRSS8

2.23

1.34

1

7920146

RPTN

35.51

-2.27

1

serine
protease
CE, EDC

peptidyl
arginine
deiminase, type
I
protease,
serine, 8
repetin

1

Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
EGF FC: fold change between control and EGF at 100% confluent cell density.
Indicates whether the effect of EGF on the gene is statistically significant; 1: significant, 0: non-significant
CE: cornified envelope; EDC: epidermal differentiation complex on human chromosome 1q21
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(Kong et
al., 2003)

(Stoler et
al., 1988)
(Ming et
al., 1994)
(Collin et
al., 1992)
(Bazzi et
al., 2007)
(Bazzi et
al., 2007)
(Tsuchida
et al., 2004)

(Jackson et
al., 2005)
(Jackson et
al., 2005)
(Jackson et
al., 2005)
(Jackson et
al., 2005)
(Jackson et
al., 2005)
(Kalinin et
al., 2002;
Mehrel et
al., 1990)
(Dong et
al., 2008)

(Leyvraz et
al., 2005)
(Krieg et
al., 1997)
(Kalinin et
al., 2002)

Appendix A - Literature Support of Genes Involved in Cornified Envelope
Formation (Refer to Chapter 3, Figure 16) (cont.)
Transcript
cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Function in
skin

References

-2.64

Significant
Index for
EGF
effect3
1

7920238

S100A12

16.11

7920252

S100A7

7920244

S100A8

8109001

SPINK5

7920205

SPRR2A

7920196

SPRR2D

7905548

SPRR3

7978222

TGM1

S100 calcium
binding protein
A12
S100 calcium
binding protein
A7
S100 calcium
binding protein
A8
serine
peptidase
inhibitor, Kazal
type 5
small prolinerich protein 2A
small prolinerich protein 2D
small prolinerich protein 3
transglutamina
se 1

CE, EDC

(Kalinin et
al., 2002)

27.47

1.98

1

CE, EDC

(Eckert and
Lee, 2006)

4.68

-1.31

1

CE, EDC

(Taylor et
al., 2009)

21.52

-1.38

1

Serine
Protease
Inhibitor

(Descargue
s et al.,
2005)

1.52

1.80

1

CE, EDC

9.40

1.35

1

CE, EDC

36.63

-2.34

1

CE, EDC

5.36

-1.38

1

Enzyme

transglutamina
se 3

3.13

-1.86

1

Enzyme

transglutamina
se 5
alpha-2macroglobulinlike 1
aspartic
peptidase,
retroviral-like
1
cornifelin

5.01

-1.85

1

Enzyme

4.23

1.09

0

protease
inhibitor

(Gibbs et
al., 1993)
(Katou et
al., 2003)
(Hohl et al.,
1995)
(Kalinin et
al., 2002;
Matsuki et
al., 1998)
(Kalinin et
al., 2002;
Zhang et
al., 2005b)
(Candi et
al., 2002)
(Galliano et
al., 2006)

8060432

TGM3

7988050

TGM5

7953775

A2ML1

8052828

ASPRV1

11.24

-1.01

0

Protease,
desquamation
?

(Bernard et
al., 2005)

8037179

CNFN

14.77

1.05

0

CE

22.59

1.13

0

EDC

12.42

1.14

0

CE

3.90

-1.12

0

protease
inhibitor

(Michibata
et al., 2004)
(Marenholz
et al., 2001)
(Zeeuwen
et al., 2002)
(Kalinin et
al., 2002;
Takahashi
et al., 1998;
Takahashi
et al.,
2001a)

7905486

CRCT1

7941505

CST6

8082058

CSTA

cysteine-rich
C-terminal 1
cystatin E/M
cystatin A
(stefin A)

1

Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
EGF FC: fold change between control and EGF at 100% confluent cell density.
3
Indicates whether the effect of EGF on the gene is statistically significant; 1: significant, 0: non-significant
CE: cornified envelope; EDC: epidermal differentiation complex on human chromosome 1q21
2
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Appendix A - Literature Support of Genes Involved in Cornified Envelope
Formation (Refer to Chapter 3, Figure 16) (cont.)
Transcript
cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Function in
skin

References

1.20

Significant
Index for
EGF
effect3
0

8020740

DSG4

desmoglein 4

1.50

Cell adhesion

1.57

-1.06

0

Cell adhesion

envoplakin

1.50

1.08

0

Cell adhesion

IVL

involucrin

7.79

-1.15

0

CE, EDC

8038770

KLK14

kallikreinrelated
peptidase 14

1.50

1.08

0

8038695

KLK7

kallikreinrelated
peptidase 7

11.31

-1.07

0

serine-type
endopeptidase
,
desquamation
Chymotryptic
enzyme,
desquamation

(Bazzi et
al., 2006;
Whittock
and Bower,
2003)
(Kalinin et
al., 2002)
(DiColandr
ea et al.,
2000;
Kalinin et
al., 2002)
(Kalinin et
al., 2002;
Robinson
et al., 1997;
Taylor et
al., 2009)
(Stefansson
et al., 2006)

8116780

DSP

desmoplakin

8018579

EVPL

7905533

8015133

KRT23

54.47

-1.13

0

Structural
proteins

7905528

LCE1A

2.13

1.17

0

CE, EDC

7905523

LCE1D

1.76

-1.11

0

CE, EDC

7905507

LCE2A

2.77

1.03

0

CE, EDC

7905505

LCE2B

1.56

-1.03

0

CE, EDC

7905503

LCE2C

4.74

1.39

0

CE, EDC

7905500

LCE2D

3.23

1.38

0

CE, EDC

7908672

PKP1

keratin 23
(histone
deacetylase
inducible)
late cornified
envelope 1A
late cornified
envelope 1D
late cornified
envelope 2A
late cornified
envelope 2B
late cornified
envelope 2C
late cornified
envelope 2D
plakophilin 1

1.89

-1.04

0

Cell adhesion

7999253

PPL

periplakin

3.51

1.10

0

Cell adhesion

7905571

S100A9

S100 calcium
binding protein
A9

4.19

1.29

0

CE, EDC

1

Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
EGF FC: fold change between control and EGF at 100% confluent cell density.
3
Indicates whether the effect of EGF on the gene is statistically significant; 1: significant, 0: non-significant
CE: cornified envelope; EDC: epidermal differentiation complex on human chromosome 1q21
2
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(Nin et al.,
2009;
Taylor et
al., 2009)
(Taylor et
al., 2009)

(Jackson et
al., 2005)
(Jackson et
al., 2005)
(Jackson et
al., 2005)
(Kalinin et
al., 2002)
(Jackson et
al., 2005)
(Jackson et
al., 2005)
(Smith and
Fuchs,
1998)
(Kalinin et
al., 2002)
(Kalinin et
al., 2002;
Taylor et
al., 2009)

Appendix A - Literature Support of Genes Involved in Cornified Envelope
Formation (Refer to Chapter 3, Figure 16) (cont.)
Transcript
cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Function in
skin

References

-1.17

Significant
Index for
EGF
effect3
0

8093950

S100P

6.69

8036103

SBSN

S100 calcium
binding protein
P
suprabasin

CE, EDC

(Taylor et
al., 2009)

25.63

-1.07

0

CE, EDC

sciellin

11.33

-1.08

0

CE, EDC

small prolinerich protein 1A
small prolinerich protein 1B
(cornifin)
small prolinerich protein 2B
small prolinerich protein 2E

3.94

-1.16

0

CE, EDC

1.88

-1.03

0

CE, EDC

(Park et al.,
2002)
(Baden et
al., 2005)
(Robinson
et al., 1997)
(Robinson
et al., 1997)

7969493

SCEL

7905544

SPRR1A

7905553

SPRR1B

7920201

SPRR2B

46.13

-1.08

0

CE, EDC

7920214

SPRR2E

31.50

-1.19

0

CE, EDC

7920217

SPRR2G

small prolinerich protein 2G

18.90

-1.01

0

CE, EDC

7905536

SPRR4

small prolinerich protein 4

8.31

1.29

0

CE, EDC

1

Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
EGF FC: fold change between control and EGF at 100% confluent cell density.
3
Indicates whether the effect of EGF on the gene is statistically significant; 1: significant, 0: non-significant
CE: cornified envelope; EDC: epidermal differentiation complex on human chromosome 1q21
2
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(Taylor et
al., 2009)
(Cabral et
al., 2001;
Katou et
al., 2003)
(Cabral et
al., 2001;
Katou et
al., 2003)
(Cabral et
al., 2001)

Appendix B - List of 114 Genes Related to Skin Diseases Based on Literature (Refer
to Chapter 3, Figure 19)
Transcript
Cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Skin
Diseases

Level
expressed in
skin disease

References

8058708

ABCA12

ATP-binding
cassette, subfamily A
(ABC1),
member 12

8.07

-1.25

ichthyosis

(Akiyama et
al., 2005; Zuo
et al., 2008)

8079153

ABHD5

4.76

-1.97

7932616

ABI1

abhydrolase
domain
containing 5
abl-interactor 1

1.94

-1.35

Chanarin
Dorfman
syndrome
psoriasis

Knockout mice
die shortly after
birth as water
rapidly
evaporates from
their skin;
glucosylceramide
s transport
(Jiang et al,
2009), Harlequin
ichthyosis
(Yanagi et al,
2010)
Mutation

7938390

ADM

adrenomedullin

2.38

-1.79

8131614

AHR

aryl hydrocarbon
receptor

2.26

-2.17

8012309

ALOX12
B

19.23

-1.34

ichthyosis

7983910
8122058

AQP9
ARG1

arachidonate
12-lipoxygenase,
12R type
aquaporin 9
arginase, liver

26.04
16.45

-1.79
-8.41

psoriasis
psoriasis

8149534

ASAH1

2.18

-1.71

atopic
dermatitis

7947230

BDNF

Nacylsphingosine
amidohydrolase
(acid
ceramidase) 1
brain-derived
neurotrophic
factor

1.78

-1.52

Decreased in
atopic
dermatitis

8014008

BLMH

2.07

-1.66

dermatitis

Decrease

8116818

BMP6

1.88

-1.43

psoriasis

Overexpressed

8075600

BPIL2

28.94

-1.50

psoriasis

Elevated

(Mulero et al.,
2002)

7931859

CALML5

bleomycin
hydrolase
bone
morphogenetic
protein 6
bactericidal/perm
eabilityincreasing
protein-like 2
calmodulin-like 5

10.11

-3.04

psoriasis

Elevated

8026398

CASP14

(Mehul et al.,
2006)
(Walsh et al.,
2005)

atopic
dermatitis
skin
carcinogenesis

Decreased
Consitutive
activation
Knockout mice
died within 3-5
hours after birth
Elevated
Elevated

Knockout mice is
lethal
(embryonic
lethal);
Decreased
knockout mice
died

caspase 14,
9.19
-1.99
Psoriasis
Decrease
apoptosis-related
cysteine
peptidase
8079117
CCBP2
chemokine
1.93
-1.87
atopic
Elevated
binding protein 2
dermatitis
1
Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
2
EGF FC: fold change between control and EGF at 100% confluent cell density.
Bolded entries are genes essential for the development of epidermal barrier in mice.
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(Schleinitz et
al., 2005)
(Sticherling et
al., 1992)
(Kindt et al.,
2007)
(Ikuta et al.,
2009; Tauchi
et al., 2005)
(Epp et al.,
2007)
(Mesko et al.)
(BruchGerharz et al.,
2003)
(Arikawa et
al., 2002;
Eliyahu et al.,
2007)
(Bartoletti et
al., 2002;
Groneberg et
al., 2007)
(Schwartz et
al., 1999)
(Blessing et
al., 1996)

(Vestergaard et
al., 2003)

Appendix B - List of 114 Genes Related to Skin Diseases Based on Literature
(Refer to Chapter 3, Figure 19) (cont.)
Transcript
Cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Skin
Diseases

Level
expressed in
skin disease

References

8097461

CCRN4L

3.65

-2.44

atopic
dermatitis

Elevated

(Yamagami et
al., 2005)

8133876

CD36

17.85

-8.66

atopic
dermatitis

Dysregulated

(Niebuhr et al.,
2009)

8179716

CDSN

CCR4 carbon
catabolite
repression 4-like
(S. cerevisiae)
CD36 molecule
(thrombospondin
receptor)
corneodesmosin

31.89

1.34

psoriasis

(Allen et al.,
2001; Leclerc
et al., 2009)

8063386

CEBPB

CCAAT/enhance
r binding protein
(C/EBP), beta

2.43

-1.75

8179351

CFB

1.57

-1.38

Decreased

8167603

CLCN5

1.93

-1.28

7921099

CRABP2

2.24

-1.69

psoriasis

Elevated

(Weemaes et
al., 1977)
(Wang et al.,
2000)
(Siegenthaler
et al., 1992)

7945663

CTSD

complement
factor B
chloride channel
5
cellular retinoic
acid binding
protein 2
cathepsin D

mild
epidermal
hyperplasia;
resistant to
carcinogeninduced skin
tumorigenesis
atopic
dermatitis
Dent's disease

Conditional
knockout mice
results in
neonatal death
due to epidermal
tearing upon
mechanical
stress
Knockout mice
developed a mild
epidermal
hyperplasia

2.70

-1.44

psoriasis

Decreased

8162652

CTSL2

cathepsin L2

3.03

1.71

Decreased

7995552

CYLD

1.81

-1.65

7929466

CYP2C18

8.15

-5.00

psoriasis

Decreased

(Helsby et al.,
1998)

8026424

CYP4F22

18.64

-2.35

lamellar
ichthyosis
type 3

Mutations

(Lefevre et al.,
2006)

7942613

DGAT2

16.71

-2.30

psoriasis

Decreased;
knockout mice are
lipopenic and die
shortly after birth

8046124

DHRS9

14.50

-2.05

Epstein-Barr
virus lytic
infection

(Liu et al.,
2008;
Wakimoto et
al., 2003)
(Jones et al.,
2007)

8016609

DLX3

cylindromatosis
(turban tumor
syndrome)
cytochrome
P450, family 2,
subfamily C,
polypeptide 18
cytochrome
P450, family 4,
subfamily F,
polypeptide 22
diacylglycerol Oacyltransferase
homolog 2
(mouse)
dehydrogenase/re
ductase (SDR
family) member
9
distal-less
homeobox 3

atopic
dermatitis
psoriasis

2.10

-1.36

atopic
dermatitis,
psoriasis

Knockout mice
died midgestation

8022728

DSC1

16.56

-2.81

dermatitis

(Hwang et al.;
Mayer et al.,
2010; Morasso
et al., 1999)
(Chidgey et al.,
2001)

desmocollin 1

Mutation

SNPs

Deficient mice
developed
dermatitis
1
Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
2
EGF FC: fold change between control and EGF at 100% confluent cell density.
Bolded entries are genes essential for the development of epidermal barrier in mice.
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(Sterneck et
al., 2006; Zhu
et al., 1999)

(Chen et al.,
2000)
(Cheng et al.,
2009)
(Oudot et al.,
2009)

Appendix B - List of 114 Genes Related to Skin Diseases Based on Literature
(Refer to Chapter 3, Figure 19) (cont.)
Transcript
Cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Skin
Diseases

Level
expressed in
skin disease

References

8020724

DSG1

desmoglein 1

11.67

-1.60

Decrease

8020762

DSG3

desmoglein 3
(pemphigus
vulgaris antigen)

1.62

1.19

(Descargues et
al., 2006)
(Capon et al.,
2009; Chen et
al., 2007)

7905220

ECM1

2.89

1.43

8127767

ELOVL4

extracellular
matrix protein 1
elongation of
very long chain
fatty acids like 4

11.12

-1.92

Netherton
syndrome
pemphigus
vulgaris;
overexpressed
in head and
neck cancer
lipid
proteinosis
Stargardt’s
disease

8095728

EREG

epiregulin

1.78

-1.51

dermatitis

8147049

FABP5

6.04

-1.88

atopic
dermatitis

7920165

FLG

fatty acid binding
protein 5
(psoriasisassociated)
filaggrin

55.43

-1.54

Mutation

8128956

FYN

1.59

-1.37

atopic
dermatitis
epidermal
hyperplasia

7926105

GATA3

2.05

-1.62

atopic
dermatitis

Knockout mice
died at E11; lipid
defect; increase
in atopic
dermatitis

8121749

GJA1

gap junction
protein, alpha 1,
43kDa

2.02

-1.55

Mutation

7970448

GJB6

6.25

-2.22

8006940

GRB7

2.73

1.49

7905733

HAX1

1.64

-1.62

8114572

HBEGF

2.86

8072678

HMOX1

7920155

HRNR

gap junction
protein, beta 6,
30kDa
growth factor
receptor-bound
protein 7
HCLS1
associated
protein X-1
heparin-binding
EGF-like growth
factor
heme oxygenase
(decycling) 1
hornerin

knockout mice
die after birth
or survive up
to 5 hours
after birth;
oculodentodig
ital dysplasia
hidrotic
ectodermal
dysplasia
atopic
dermatitis

8139488

IGFBP3

FYN oncogene
related to SRC,
FGR, YES
GATA binding
protein 3

Knockout mice
lead to neonatal
death
Deficient mice
developed chronic
dermatitis
Elevated

Increase

(Mirancea et
al., 2007)
(Li et al.,
2007b;
Vasireddy et
al., 2007)
(Shirasawa et
al., 2004)
(Yamane et al.,
2009)

(Scharschmidt
et al., 2009)
(Li et al.,
2007a)
(Arakawa et
al., 2004; de
Guzman
Strong et al.,
2006;
Pandolfi et al.,
1995)
(Gong et al.,
2006;
Paznekas et al.,
2003)

Mutation

(Essenfelder et
al., 2004)

Decreased

(Yoon et al.,
2005)

psoriasis

Elevated

-3.12

psoriasis

Elevated

(Mirmohamma
dsadegh et al.,
2003)
(Zheng et al.,
2003)

3.94

1.93

Elevated

48.67

-2.20

atopic
dermatitis
atopic
dermatitis
psoriasis

Elevated

insulin-like
7.15
-6.11
Elevated
growth factor
binding protein 3
1
Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
2
EGF FC: fold change between control and EGF at 100% confluent cell density.
Bolded entries are genes essential for the development of epidermal barrier in mice.
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(Kirino et al.,
2008)
(Wu et al.,
2009b)
(Ozden et al.,
2008)

Appendix B - List of 114 Genes Related to Skin Diseases Based on Literature
(Refer to Chapter 3, Figure 19) (cont.)
Transcript
Cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Skin
Diseases

Level
expressed in
skin disease

References

8044574

IL1RN

2.77

1.27

dermatitis,
psoriasis

SNPs

(Oudot et al.,
2009)

7909261

IL20

interleukin 1
receptor
antagonist
interleukin 20

1.70

-1.54

psoriasis

Elevated

8129837

IL20RA

6.61

-2.79

psoriasis

Haplotype

8048227

IL8RB

7.82

-1.75

psoriasis

Elevated

8050719

ITSN2

2.42

-1.22

Elevated

8039884

KIR2DL5
A

1.57

-1.29

atopic
dermatitis
psoriasis

(Wang et al.,
2006)
(Kingo et al.,
2008)
(Nomura et al.,
2003)
(Hashida et al.,
2003)
(Suzuki et al.,
2004)

8163002

KLF4

6.29

-1.37

8038633

KLK1

kallikrein 1

2.32

-1.66

8038747

KLK12

11.22

-1.41

8038670

KLK5

2.33

-1.14

8038683

KLK6

18.60

1.41

8038707

KLK8

5.21

-1.17

7963491

KRT1

kallikrein-related
peptidase 12
kallikrein-related
peptidase 5
kallikrein-related
peptidase 6
kallikrein-related
peptidase 8
keratin 1

42.74

-3.35

8015104

KRT10

keratin 10

22.67

-2.50

8015323

KRT13

keratin 13

6.48

-3.18

8015376

KRT16

keratin 16

2.91

-1.17

7963479

KRT2

keratin 2

3.75

-1.95

7963534

KRT4

keratin 4

12.95

-6.29

7963406

KRT6B

keratin 6B

1.61

-1.10

interleukin 20
receptor, alpha
interleukin 8
receptor, beta
intersectin 2
killer cell
immunoglobulinlike receptor, two
domains, long
cytoplasmic tail,
5A
Kruppel-like
factor 4 (gut)

Elevated

Skin
squamous
cell
carcinoma,
hyperplasia,
dysplasia
atopic
dermatitis
atopic
dermatitis
atopic
dermatitis
atopic
dermatitis
atopic
dermatitis
hyperkeratosis
; ichthyosis

Knockout mice
die postnatally
due to
dehydration

(Ehlermann
et al., 2003;
Huang et al.,
2005; Segre et
al., 1999)

Elevated

epidermolytic
ichtyosis;
epidermolytic
hyperkeratosis
; acanthosis
White Sponge
Nevus
(acanthosis);
benign
hyperplasia;
pachyonychia
congenita
ichthyosis
bullosa of
Siemens
hyperkeratosis
; ichthyosis

Mutations

(Komatsu et
al., 2007)
(Komatsu et
al., 2007)
(Komatsu et
al., 2007)
(Komatsu et
al., 2007)
(Komatsu et
al., 2007)
(Bolling et al.;
Lacz et al.,
2005; Muller
et al., 2006)
(Covaciu et al.,
2010; Muller
et al., 2006;
Porter et al.,
1998)
(Rugg et al.,
1999; Sun et
al., 2009)
(Gruber et al.,
2009; Haider
et al., 2006)

pachyonychia
congenita
1
Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
2
EGF FC: fold change between control and EGF at 100% confluent cell density.
Bolded entries are genes essential for the development of epidermal barrier in mice.
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Elevated
Elevated
Elevated
Elevated
Mutations

Mutations

Mutations

(Takizawa et
al., 2000)

Mutations

(Ness et al.,
1998; Pavez
Lorie et al.,
2009)
(Oh et al.,
2006)

Appendix B - List of 114 Genes Related to Skin Diseases Based on Literature
(Refer to Chapter 3, Figure 19) (cont.)
Transcript
Cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Skin
Diseases

Level
expressed in
skin disease

References

8015357

KRT9

keratin 9

4.24

-3.39

Mutations

(Corden and
McLean, 1996)

8036072

KRTDAP

21.19

-2.07

Elevated

(Tsuchida et
al., 2004)

7920191

LCE3A

2.01

3.00

psoriasis

SNPs

(Zhang, 2009)

7920185

LCE3D

52.44

1.81

psoriasis

SNPs

(Zhang, 2009)

8158167

LCN2

keratinocyte
differentiationassociated
protein
late cornified
envelope 3A
late cornified
envelope 3D
lipocalin 2

epidermolytic
palmoplantar
keratoderma
psoriasis

7.69

2.61

psoriasis

Elevated

7905563

LOR

loricrin

44.32

-19.49

Decrease

8153346

LYNX1

Ly6/neurotoxin 1

9.06

-1.32

psoriasis,
dermatitis
psoriasis

(Lee et al.,
2008)
(Hohl, 1993)

8119016

MAPK13

2.00

-1.14

psoriasis

Elevated

8000811

MAPK3

1.53

1.57

psoriasis

Elevated

(Johansen et
al., 2005)

8081386

NFKBIZ

1.51

1.23

atopic
dermatitis

Deficient mice
developed atopic
dermatitis

(Shiina et al.,
2004)

7986675

NIPA1

1.71

-1.16

Ichthyosis

Mutation

(Lefevre et al.,
2004)

8109563

NIPAL4

5.16

-1.21

congenital
ichtyosis

Mutation

(Dahlqvist et
al., 2007)

7995539

NOD2

3.05

-1.67

psoriasis

Mutation

(Young et al.,
2003a)

8105908

OCLN

mitogenactivated protein
kinase 13
mitogenactivated protein
kinase 3
nuclear factor of
kappa light
polypeptide gene
enhancer in Bcells inhibitor,
zeta
non imprinted in
PraderWilli/Angelman
syndrome 1
NIPA-like
domain
containing 4
nucleotidebinding
oligomerization
domain
containing 2
occludin

9.02

-2.30

psoriasis

Widely expressed

8075316

OSM

oncostatin M

1.55

-1.19

Elevated

7898413

PADI1

2.97

1.70

Decreased

7920228

PGLYRP
4

15.32

-2.08

psoriasis

SNPs

8171418

PIGA

peptidyl arginine
deiminase, type I
peptidoglycan
recognition
protein 4
phosphatidylino
sitol glycan
anchor
biosynthesis,
class A

psoriasis,
atopic
dermatitis
psoriasis

(Yoshida et al.,
2001)
(Boniface et
al., 2007)

1.56

-1.83

ichthyosis

Elevated

Knockout mice
died within a few
days after birth,
Harlequin
ichthyosis-like
features;
mutation
1
Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
2
EGF FC: fold change between control and EGF at 100% confluent cell density.
Bolded entries are genes essential for the development of epidermal barrier in mice.
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(Tsuji et al.,
2003)
(Johansen et
al., 2005)

(Chavanas et
al., 2006)
(Sun et al.,
2006)
(HaraChikuma et
al., 2004;
Tarutani et
al., 1997)

Appendix B - List of 114 Genes Related to Skin Diseases Based on Literature
(Refer to Chapter 3, Figure 19) (cont.)
Transcript
Cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Skin
Diseases

Level
expressed in
skin disease

References

8075468

PLA2G3

1.90

-1.45

PLA2G4
D

6.93

-1.38

(Sato et al.,
2009)
(Chiba et al.,
2004)

8041763

PRKCE

19.56

-8.40

hyperkeratosis
, acanthosis
psoriasis,
atopic
dermatitis
hyperplasia

Overexpressed

7987792

Overexpressed

8001007

PRSS8

2.23

1.34

ichthyosis

Decreased

7975545

PSEN1

phospholipase
A2, group III
phospholipase
A2, group IVD
(cytosolic)
protein kinase C,
epsilon
protease, serine,
8
presenilin 1

1.58

-1.44

8124865

PSORS1C
2

1.81

1.14

skin
tumorigenesis
psoriasis

SNPs

7922976

PTGS2

3.70

-2.37

dermatitis,
human
nonmelanoma

Elevated

(Ahn et al.,
2010; An et
al., 2002)

8150757

RB1CC1

2.60

-1.24

8025278

RETN

1.68

-1.54

acanthosis,
hyperkeratosis
psoriasis

Double knockout
with p53
Elevated

7920252

S100A7

27.47

1.98

Elevated

8150889

SDR16C5

12.84

-4.22

atopic
dermatitis,
psoriasis
psoriasis

(Wei et al.,
2009)
(Coimbra et
al.)
(Glaser et al.,
2009)

Increased

(Matsuzaka et
al., 2002)

8021603

SERPINB
13

4.13

-1.36

psoriasis

Elevated

(Abts et al.,
2001)

8023696

SERPINB
3

15.24

-1.51

atopic
dermatitis

Elevated

(Mitsuishi et
al., 2005)

8023688

SERPINB
4

14.47

-1.38

atopic
dermatitis

Elevated

(Yamane et al.,
2009)

7928171

SGPL1

1.62

-1.46

atopic
dermatitis in
dog

(Vogel et al.,
2009; Wood et
al., 2009)

8048717

SGPP2

Elevated;
knockout mice
died 15 weeks
after birth due to
non-lymphoid
lesions
Elevated

psoriasis
susceptibility 1
candidate 2
prostaglandinendoperoxide
synthase 2
(prostaglandin
G/H synthase
and
cyclooxygenase)
RB1-inducible
coiled-coil 1
resistin
S100 calcium
binding protein
A7
short chain
dehydrogenase/re
ductase family
16C, member 5
serpin peptidase
inhibitor, clade B
(ovalbumin),
member 13
serpin peptidase
inhibitor, clade B
(ovalbumin),
member 3
serpin peptidase
inhibitor, clade B
(ovalbumin),
member 4
sphingosine-1phosphate lyase
1

Elevated

sphingosine-110.21
-2.79
psoriasis
phosphate
phosphotase 2
8158224
SLC27A4
solute carrier
1.72
-1.19
ichthyosis
Knockout mice
family 27 (fatty
died shortly after
acid
birth;
transporter),
hyperkeratosis;
member 4
mutations
1
Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
2
EGF FC: fold change between control and EGF at 100% confluent cell density.
Bolded entries are genes essential for the development of epidermal barrier in mice.
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(Li et al.,
2005)
(Alef et al.,
2009)
(Xia et al.,
2001)
(Holm et al.,
2003)

(Mechtcheriak
ova et al.,
2007)
(Herrmann et
al., 2005;
Herrmann et
al., 2003; Klar
et al., 2009)

Appendix B - List of 114 Genes Related to Skin Diseases Based on Literature
(Refer to Chapter 3, Figure 19) (cont.)
Transcript
Cluster ID

Gene
Symbol

Gene
Description

Density
FC1

EGF
FC2

Skin
Diseases

Level
expressed in
skin disease

References

8153336

SLURP1

1.86

-1.36

Mal de
Meleda

Mutation

(Favre et al.,
2007)

8109001

SPINK5

21.52

-1.38

Netherton
syndrome

Mutation

(Geyer et al.,
2005)

7978222

TGM1

5.36

-1.38

lamellar
ichthyosis

Knockout mice
died 5 hrs after
birth due to
impaired skin
barrier function

(Huber et al.,
1995;
Kuramoto et
al., 2002;
Matsuki et al.,
1998)

8060432

TGM3

3.13

-1.86

Darier's
disease

Misregulated

(Candi et al.,
2002)

7988050

TGM5

5.01

-1.85

ichthyosis

Misregulated

8018966

TIMP2

2.75

1.27

eczema

Decreased

(Candi et al.,
2002)
(Miyoshi et al.,
2005)

8092169

TNFSF10

2.75

-2.40

atopic
dermatitis

Elevated

(Heishi et al.,
2002)

8107270

TSLP

2.01

-2.24

UGCG

2.72

-1.27

atopic
dermatitis
Gaucher
disease

Elevated

8157216

secreted
LY6/PLAUR
domain
containing 1
serine peptidase
inhibitor, Kazal
type 5
null mice died
because of
impaired
barrier skin
functiontransgl
utaminase 1 (K
polypeptide
epidermal type
I, proteinglutaminegammaglutamyltransfe
rase)
transglutaminase
3 (E polypeptide,
proteinglutaminegammaglutamyltransfera
se)
transglutaminase
5
TIMP
metallopeptidase
inhibitor 2
tumor necrosis
factor (ligand)
superfamily,
member 10
thymic stromal
lymphopoietin
UDP-glucose
ceramide
glucosyltransfer
ase

(Edwards,
2008)
(Beutler and
West, 2002;
Jennemann et
al., 2007)

8119898

VEGFA

1.97

-2.04

8019541

ZNF750

vascular
endothelial
growth factor A

acanthosis

Conditional
knockout mice
had extreme
TEWL leading
to death 4 days
after birth.
Knockout mice
died in utero due
to defect in blood
island formation,
elevated
Mutation

zinc finger
6.15
-1.42
psoriasis
protein 750
1
Density FC: fold change between the 50% and 100% confluent cell density untreated samples.
2
EGF FC: fold change between control and EGF at 100% confluent cell density.
Bolded entries are genes essential for the development of epidermal barrier in mice.
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(Carmeliet et
al., 1999;
Teige et al.,
2009; Xia et
al., 2003)
(Yang et al.,
2008)

Appendix C – Literature Support of the 245 Known Transcriptional Regulators
(Refer to Chapter 4, Tables 7 and 8)

1
2

Probe Set

Gene
Symbol

Gene title

MAX
FC1

MIN
FC2

Type of
transcriptional
regulators

Reference

221011_s_at

LBH

159.74

1.00

activator

(Briegel and
Joyner, 2001)

204420_at

FOSL1

limb bud and heart
development homolog
(mouse)
FOS-like antigen 1

77.30

2.19

TF

228964_at

PRDM1

34.29

2.16

repressor

202768_at

FOSB

33.03

-1.00

TF

228033_at

E2F7

PR domain containing 1,
with ZNF domain
FBJ murine osteosarcoma
viral oncogene homolog B
E2F transcription factor 7

30.66

1.14

repressor

206877_at

MXD1

29.95

1.00

repressor

202935_s_at

SOX9

27.98

3.00

TF

(Finzer et al.,
2000)
(Magnusdottir et
al., 2007)
(Ulery et al.,
2006)
(Endo-Munoz et
al., 2009)
(Grandori et al.,
2000)
(Pan et al.,
2008)

206127_at

ELK3

24.38

1.02

repressor or
activator

209189_at

FOS

24.33

-2.46

TF

209878_s_at

RELA

17.64

-4.63

TF/activator

(Ghosh and
Karin, 2002)

36711_at

MAFF

15.58

1.70

TF

(Motohashi et
al., 2004)

229404_at

TWIST2

13.90

-1.18

repressor

226319_s_at

LOC64481
1 ///
THOC4

12.26

-1.21

coactivator

(Lee et al.,
2003)
(Mertz et al.,
2007)

211834_s_at

TP63

11.58

-1.15

activator

224833_at

ETS1

11.13

1.40

TF

1555832_s_at

KLF6

v-ets erythroblastosis virus
E26 oncogene homolog 1
(avian)
Kruppel-like factor 6

9.60

1.45

activator

1552477_a_at

IRF6

9.09

-1.14

TF

238482_at

KLF7

9.08

1.27

TF/coactivator

1560224_at

AHCTF1

interferon regulatory factor
6
Kruppel-like factor 7
(ubiquitous)
AT hook containing
transcription factor 1

9.04

1.00

TF

MAX dimerization protein
1
SRY (sex determining
region Y)-box 9
(campomelic dysplasia,
autosomal sex-reversal)
ELK3, ETS-domain protein
(SRF accessory protein 2)
v-fos FBJ murine
osteosarcoma viral
oncogene homolog
v-rel reticuloendotheliosis
viral oncogene homolog A,
nuclear factor of kappa light
polypeptide gene enhancer
in B-cells 3, p65 (avian)
v-maf musculoaponeurotic
fibrosarcoma oncogene
homolog F (avian)
twist homolog 2
(Drosophila)
THO complex 4 /// similar
to THO complex subunit 4
(Tho4) (Ally of AML-1 and
LEF-1) (Transcriptional
coactivator Aly/REF)
(bZIP-enhancing factor
BEF)
tumor protein p63

EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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(Chen et al.,
2003; Wasylyk
et al., 2005)
(Durchdewald et
al., 2009)

(Senoo et al.,
2007; Yang et
al., 1998; Zhu et
al., 2007)
(Jung et al.,
2005)
Rubinstein et al,
2004
(Ben et al.,
2005)
(Matsumoto et
al., 1998)
(Okita et al.,
2004; Rasala et
al., 2006)

Appendix C - Literature Support of the 245 Known Transcriptional Regulators
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Probe Set

Gene
Symbol

Gene title

MAX
FC1

MIN
FC2

Type of
transcriptional
regulators

Reference

201169_s_at

BHLHB2

basic helix-loop-helix
domain containing, class B,
2

8.18

1.09

repressor

226711_at

FOXN2

forkhead box N2

7.86

1.72

TF

1554311_a_at

SUPT6H

suppressor of Ty 6 homolog
(S. cerevisiae)

7.82

2.62

chromatin
structure

206788_s_at

CBFB

7.74

-1.05

coactivator

205659_at

HDAC9

core-binding factor, beta
subunit
histone deacetylase 9

7.42

-1.01

corepressor

1554411_at

CTNNB1

7.20

1.28

coactivator

44783_s_at

HEY1

6.98

-1.07

repressor

40446_at

PHF1

catenin (cadherin-associated
protein), beta 1, 88kDa
hairy/enhancer-of-split
related with YRPW motif 1
PHD finger protein 1

6.64

-1.04

repressor

227261_at

KLF12

Kruppel-like factor 12

6.60

1.03

corepressor

209651_at

TGFB1I1

6.47

-1.10

coactivator

228634_s_at

CSDA

6.15

-1.59

repressor

210541_s_at

TRIM27

6.00

1.01

repressor

204790_at

SMAD7

transforming growth factor
beta 1 induced transcript 1
Cold shock domain protein
A
tripartite motif-containing
27
SMAD family member 7

6.00

1.11

TF/activator

208003_s_at

NFAT5

5.38

-1.15

TF

228625_at

CITED4

5.35

-1.32

coactivator

(Labalette et al.,
2004)

213032_at

NFIB

nuclear factor of activated
T-cells 5, tonicityresponsive
Cbp/p300-interacting
transactivator, with
Glu/Asp-rich carboxyterminal domain, 4
nuclear factor I/B

(Iizuka and
Horikawa, 2008;
Nakashima et
al., 2008;
Rossner et al.,
2008)
(Li et al.,
1992)Li et al,
1992
(Chiang et al.,
1996; Yoh et al.,
2007)
(Sakakura et al.,
2005)
(Zhang et al.,
2001)
(Zhu and Watt,
1999)
(Fischer et al.,
2005)
(Sarma et al.,
2008)
(Roth et al.,
2000)
(Inui et al.,
2007)
(Coles et al.,
1996)
(Bloor et al.,
2005)
(Liu et al.,
2003)
(Navarro et al.,
2008)

5.06

-1.08

TF/activator

200879_s_at

EPAS1

4.97

-2.57

activator

225289_at

STAT3

4.93

-2.02

TF

1552487_a_at

BNC1

endothelial PAS domain
protein 1
signal transducer and
activator of transcription 3
(acute-phase response
factor)
basonuclin 1

(Mukhopadhyay
et al., 2007)
(Conrad et al.,
1999)
(Brantley et al.,
2008; Snyder et
al., 2008)

4.84

1.40

TF

236429_at

ZNF83

zinc finger protein 83

4.67

1.40

TF

1555611_s_at

MBD1

methyl-CpG binding
4.65
-1.52
domain protein 1
216997_x_at
TLE4
transducin-like enhancer of
4.47
-1.77
split 4 (E(sp1) homolog,
Drosophila)
202875_s_at
PBX2
pre-B-cell leukemia
4.39
1.75
homeobox 2
1
EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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corepressor
corepressor

activator

(Matsuzaki et
al., 2004)
(Marine et al.,
1994)
(Fujita et al.,
2000)
(Brantjes et al.,
2001; Eberhard
et al., 2000)
(Okada et al.,
2003)
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206307_s_at

FOXD1

forkhead box D1

4.28

1.97

TF

215111_s_at

TSC22D1

TSC22 domain family,
member 1

4.23

1.32

repressor

214600_at

TEAD1

4.12

-1.06

activator

211603_s_at

ETV4

4.10

-1.05

activator

Zhu et al, 2005

203258_at

DRAP1

TEA domain family
member 1 (SV40
transcriptional enhancer
factor)
ets variant gene 4 (E1A
enhancer binding protein,
E1AF)
DR1-associated protein 1
(negative cofactor 2 alpha)

(Ernstsson et al.,
1996)
(Choi et al.,
2005; Iida et al.,
2007; Sommer
et al., 2006)
(Xiao et al.,
1991)

4.06

-1.42

repressor/corepres
sor

201417_at

SOX4

3.99

1.10

TF

206675_s_at

SKIL

SRY (sex determining
region Y)-box 4
SKI-like oncogene

3.93

1.21

repressor

228785_at

ZNF281

Zinc finger protein 281

3.89

1.96

repressor

221763_at

JMJD1C

3.70

1.37

coactivator

210971_s_at

ARNTL

3.66

-3.87

TF/coactivator?

1555639_a_at

RBM14

3.66

-1.01

coactivator

208735_s_at

CTDSP2

3.62

-1.34

activator

(Thompson et
al., 2006)

200919_at

PHC2

3.58

1.09

repressor

219729_at

PRRX2

jumonji domain containing
1C
aryl hydrocarbon receptor
nuclear translocator-like
RNA binding motif protein
14
CTD (carboxy-terminal
domain, RNA polymerase
II, polypeptide A) small
phosphatase 2
polyhomeotic homolog 2
(Drosophila)
paired related homeobox 2

(Castano et al.,
2000;
Mermelstein et
al., 1996)
(Farr et al.,
1993)
(Fitsialos et al.,
2007)
(Law et al.,
1999)
(Wolf et al.,
2007)
(Hogenesch et
al., 1998)
Yang et al, 2007

3.56

-1.18

TF

203313_s_at

TGIF1

TGFB-induced factor
homeobox 1

3.51

1.42

corepressor of
SMAD2

224760_at

SP1

Sp1 transcription factor

3.42

-1.06

TF

205375_at

MDFI

MyoD family inhibitor

3.42

-1.62

repressor

201368_at

ZFP36L2

3.41

1.17

TF

207109_at

POU2F3

zinc finger protein 36, C3H
type-like 2
POU class 2 homeobox 3

3.40

-4.89

repressor

226206_at

MAFK

3.39

1.71

repressor

225798_at

JAZF1

v-maf musculoaponeurotic
fibrosarcoma oncogene
homolog K (avian)
JAZF zinc finger 1

3.35

-1.02

repressor

206604_at

OVOL1

ovo-like 1(Drosophila)

3.31

-1.34

repressor

(Gunster et al.,
1997)
(Mitchell et al.,
2006)
(Hamid et al.,
2008; Wotton et
al., 2001;
Wotton et al.,
1999)
(Mora-Lopez et
al., 2008)
(Chen et al.,
1996; Ma et al.,
2003)
(Nie et al.,
1995)
(Shiina et al.,
2004)
(Dhakshinamoor
thy and Jaiswal,
2000)
(Nakajima et al.,
2004)
(Nair et al.,
2007)

EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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Probe Set

Gene
Symbol

Gene title

MAX
FC1

MIN
FC2

Type of
transcriptional
regulators

Reference

203874_s_at

SMARCA
1

3.27

1.05

chromatin
structure

(Banting et al.,
2005)

1554980_a_at

ATF3

3.20

1.00

201465_s_at

JUN

SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin,
subfamily a, member 1
activating transcription
factor 3
jun oncogene

3.14

1.14

corepressor,
repressor of Nrf2
TF

210086_at

HR

hairless homolog (mouse)

3.05

-1.96

TF

225265_at

RBMS1

3.04

1.23

activator/represso
r

1565254_s_at

ELL

3.02

1.04

TF

232231_at

RUNX2

2.98

1.02

activator

206173_x_at

GABPB2

2.98

1.03

TF

219199_at

AFF4

2.93

1.23

repressor

1558560_s_at

BLZF1

RNA binding motif, single
stranded interacting protein
1
elongation factor RNA
polymerase II
runt-related transcription
factor 2
GA binding protein
transcription factor, beta
subunit 2
AF4/FMR2 family, member
4
basic leucine zipper nuclear
factor 1 (JEM-1)

(Wang et al.,
2007)
(Bohmann et al.,
1987; Chen and
Chang, 2000)
(Ahmad et al.,
1998)
Normura et al,
2005

2.90

-1.12

coactivator

235791_x_at

CHD1

2.90

1.36

226952_at

EAF1

chromodomain helicase
DNA binding protein 1
ELL associated factor 1

2.86

-1.22

chromatin
structure
activator

210655_s_at

FOXO3

forkhead box O3

2.85

-1.55

activator

219657_s_at

KLF3

Kruppel-like factor 3
(basic)

2.83

-1.68

repressor

202171_at

VEZF1

vascular endothelial zinc
finger 1

2.82

1.22

TF

210365_at

RUNX1

2.82

-1.02

co-activator

201862_s_at

LRRFIP1

runt-related transcription
factor 1 (acute myeloid
leukemia 1; aml1 oncogene)
leucine rich repeat (in FLII)
interacting protein 1

2.81

1.21

repressor

210554_s_at

CTBP2

2.80

1.06

corepressor

202599_s_at

NRIP1

C-terminal binding protein
2
nuclear receptor interacting
protein 1

2.73

1.17

coactivator/repres
sor

201332_s_at

STAT6

signal transducer and
2.72
-1.91
activator of transcription 6,
interleukin-4 induced
201845_s_at
RYBP
RING1 and YY1 binding
2.71
1.13
protein
223780_s_at
MED13
mediator complex subunit
2.71
1.11
13
1
EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.

200

activator

corepressor/repres
sor
coactivator

(Kong et al.,
2005)
(Pratap et al.,
2008)
(Watanabe et
al., 1993)
(Niedzielski et
al., 2007)
(Duprez et al.,
1997; Tong et
al., 1999)
(Woodage et al.,
1997)
(Simone et al.,
2001)
(Brunet et al.,
1999)
(Perdomo et al.,
2005; Sue et al.,
2008)
(Aitsebaomo et
al., 2001;
Miyashita et al.,
2004)
(Wildey and
Howe, 2009)
(Rikiyama et al.,
2003; Suriano et
al., 2005)
(Zhao et al.,
2006)
(Rytinki and
Palvimo, 2008;
Zschiedrich et
al., 2008)
(Aoudjehane et
al., 2008)
(Garcia et al.,
1999)
(Rachez et al.,
1999)
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transcriptional
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227111_at

ZBTB34

2.70

1.13

repressor

(Qi et al., 2006)

204341_at

2.68

1.00

TF

(Beer et al.,
2002)

219850_s_at

TRIM16
///
TRIM16L
EHF

zinc finger and BTB
domain containing 34
tripartite motif-containing
16 /// tripartite motifcontaining 16-like
ets homologous factor

2.66

1.05

activator/represso
r

204512_at

HIVEP1

2.64

1.12

corepressor

235473_at

MED6

human immunodeficiency
virus type I enhancer
binding protein 1
Mediator complex subunit 6

(Kas et al.,
2000; Silverman
et al., 2002)
(Gaynor et al.,
1991)

2.63

-1.39

coactivator

243683_at

Mortality factor 4 like 2

2.62

-2.18

218284_at

MORF4L
2
SMAD3

SMAD family member 3

2.62

-1.12

activator/represso
r
activator

227718_at

PURB

purine-rich element binding
protein B

2.60

-1.06

repressor

203275_at

IRF2

interferon regulatory factor
2

2.56

-1.30

repressor

203394_s_at

HES1

2.49

-1.53

repressor

203739_at

ZNF217

hairy and enhancer of split
1, (Drosophila)
zinc finger protein 217

2.35

1.29

repressor

202147_s_at

IFRD1

interferon-related
developmental regulator 1

2.33

-1.53

corepressor/coacti
vator

223586_at

ARNTL2

aryl hydrocarbon receptor
nuclear translocator-like 2

2.30

1.20

TF, activator

224013_s_at

SOX7

2.24

-3.24

activator

217729_s_at

AES

2.20

-2.11

200049_at

MYST2

SRY (sex determining
region Y)-box 7
amino-terminal enhancer of
split
MYST histone
acetyltransferase 2

2.18

-2.68

repressor/corepres
sor
chromatin
structure

225539_at

ZNF295

zinc finger protein 295

2.16

-2.93

repressor

1559449_a_at

ZNF254

Zinc finger protein 254

1.98

-6.17

TF

223714_at

ZNF256

zinc finger protein 256

1.95

-3.16

repressor

202431_s_at

MYC

1.95

-1.03

TF

202191_s_at

GAS7

v-myc myelocytomatosis
viral oncogene homolog
(avian)
growth arrest-specific 7

1.93

-1.12

TF

1

EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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(Lee et al.,
1997)
(Tominaga et
al., 2003)
(Ashcroft et al.,
1999;
Descargues et
al., 2008;
Flanders et al.,
2002)
(Knapp et al.,
2006; Knapp et
al., 2007; Zhang
et al., 2008)
(Chae et al.,
2008; Han et al.,
2008)
(Sasai et al.,
1992)
(Cowger et al.,
2007)
(Batta and
Kundu, 2007;
Dieplinger et al.,
2007)
(Ikeda et al.,
2000;
Schoenhard et
al., 2002)
(Niimi et al.,
2004)
(Liu et al.,
2002a)
(Georgiakaki et
al., 2006; Iizuka
and Stillman,
1999)
(Wang et al.,
2005)
(Han et al.,
1999)
(Suzuki et al.,
2008)
(Murphy et al.,
2004)
(Ju et al., 1998)
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209292_at

ID4

1.93

-4.84

corepressor

(Pagliuca et al.,
1995)

1553613_s_at

FOXC1

Inhibitor of DNA binding 4,
dominant negative helixloop-helix protein
forkhead box C1

1.92

-1.70

TF

204908_s_at

BCL3

B-cell CLL/lymphoma 3

1.91

-1.08

activator

236128_at

ZNF91

zinc finger protein 91

1.88

-4.27

repressor

218486_at

KLF11

Kruppel-like factor 11

1.87

1.08

repressor

228483_s_at

TAF9B

1.76

-2.40

coactivator

238520_at

TRERF1

1.75

-5.95

coactivator

208763_s_at

TSC22D3

1.73

-4.91

TF

212436_at

TRIM33

TAF9B RNA polymerase
II, TATA box binding
protein (TBP)-associated
factor, 31kDa
Transcriptional regulating
factor 1
TSC22 domain family,
member 3
tripartite motif-containing
33

(Berry et al.,
2006; Berry et
al., 2005)
(Bours et al.,
1993)
(Nishimura et
al., 2001)
(Ellenrieder et
al., 2002)
(Lu and Levine,
1995)

1.73

1.14

repressor

1554415_at

TAF5L

219854_at

(Gizard et al.,
2006)
(Vogel et al.,
1996)
(He et al., 2006;
Venturini et al.,
1999)
(Kuninger et al.,
2006; Okumura
et al., 2006)

1.70

-1.07

coactivator

ZNF14

TAF5-like RNA
polymerase II, p300/CBPassociated factor (PCAF)associated factor, 65kDa
zinc finger protein 14

1.70

-2.86

coactivator

226574_at

PSPC1

paraspeckle component 1

1.67

-4.35

coactivator

219388_at

GRHL2

1.64

-5.31

TF

207980_s_at

CITED2

1.61

-2.67

coactivator

229500_at

SLC30A9

1.61

-1.27

coactivator

(Chen et al.,
2005)

226066_at

MITF

1.60

-4.61

TF/activator

213006_at

CEBPD

1.59

-3.36

activator/TF

213140_s_at

SS18L1

1.58

-2.91

activator

(de la Serna et
al., 2006)
(Clarkson et al.,
1995)
(Aizawa et al.,
2004)

225543_at

GTF3C4

grainyhead-like 2
(Drosophila)
Cbp/p300-interacting
transactivator, with
Glu/Asp-rich carboxyterminal domain, 2
solute carrier family 30
(zinc transporter), member
9
microphthalmia-associated
transcription factor
CCAAT/enhancer binding
protein (C/EBP), delta
synovial sarcoma
translocation gene on
chromosome 18-like 1
MRNA full length insert
cDNA clone EUROIMAGE
1674211

1.55

-2.61

TF

226652_at

USP3

1.53

-3.45

221827_at

RBCK1

1.50

-1.21

chromatin
structure
TF

1559881_s_at

ZNF12

1.49

-4.58

repressor

ubiquitin specific peptidase
3
RanBP-type and C3HC4type zinc finger containing
1
zinc finger protein 12

EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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(Kouzu-Fujita et
al., 2009)
(Kuwahara et
al., 2006)
(Peters et al.,
2002)
(Qu et al., 2007)

(Dumay-Odelot
et al., 2007;
Hsieh et al.,
1999)
(Nicassio et al.,
2007)
(Tatematsu et
al., 2005)
(Zhao et al.,
2006b)
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204069_at

MEIS1

Meis homeobox 1

1.49

-15.96

activator

218149_s_at

ZNF395

zinc finger protein 395

1.49

-5.23

repressor

225760_at

MYSM1

1.47

-1.98

coactivator

217547_x_at

ZNF675

myb-like, SWIRM and
MPN domains 1
zinc finger protein 675

1.46

-4.30

repressor

204702_s_at

NFE2L3

nuclear factor (erythroidderived 2)-like 3

1.43

-2.34

TF

227642_at

TFCP2L1

1.42

-1.56

repressor

218859_s_at

ESF1

1.40

-3.39

repressor

225655_at

UHRF1

1.40

-1.45

chromatin
structure

(Papait et al.,
2007)

208670_s_at

EID1

1.40

-1.08

repressor

223424_s_at

1.39

-4.67

activator

227680_at

ZSCAN2
1
ZNF326

Transcription factor CP2like 1
ESF1, nucleolar pre-rRNA
processing protein,
homolog (S. cerevisiae)
ubiquitin-like, containing
PHD and RING finger
domains, 1
EP300 interacting inhibitor
of differentiation 1
zinc finger and SCAN
domain containing 21
zinc finger protein 326

(Okada et al.,
2003)
(Sichtig et al.,
2007)
(Zhu et al.,
2007)
(Shin et al.,
2002)
(Nouhi et al.,
2007;
Sankaranarayan
an and Jaiswal,
2004)
(Rodda et al.,
2001)
(Oda et al.,
2004)

1.39

-2.73

activator

235201_at

FOXP2

forkhead box P2

1.37

-4.88

TF/repressor

209105_at

NCOA1

1.37

-2.48

coactivator

225026_at

CHD6

1.37

-2.79

200779_at

ATF4

1.36

-1.14

chromatin
structure
activator

203204_s_at

JMJD2A

1.36

-2.85

repressor

212420_at

ELF1

1.36

-2.75

activator

219551_at

EAF2

nuclear receptor coactivator
1
chromodomain helicase
DNA binding protein 6
activating transcription
factor 4 (tax-responsive
enhancer element B67)
jumonji domain containing
2A
E74-like factor 1 (ets
domain transcription factor)
ELL associated factor 2

(Park et al.,
2007)
(Chowdhury et
al., 1992)
(Lee et al.,
2000)
(Zhou et al.,
2008)
(Yuan and Xu,
2007)
(Thompson et
al., 2003)
(Liang and Hai,
1997)

1.35

-11.40

activator

244743_x_at

zinc finger protein 138 ///
similar to Zinc finger
protein 431

1.34

-3.39

repressor

222028_at

LOC7302
95 ///
LOC7312
65 ///
ZNF138
ZNF45

zinc finger protein 45

1.33

-2.68

TF

211778_s_at

OVOL2

ovo-like 2 (Drosophila)

1.31

-6.56

repressor

223506_at

ZC3H8

1.31

-2.72

repressor

231929_at

IKZF2

zinc finger CCCH-type
containing 8
IKAROS family zinc finger
2 (Helios)

1.29

-2.77

TF/activator

EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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(Zhang et al.,
2005a)
(Oettgen et al.,
1997)
(Jiang et al.,
2007; Xiao et
al., 2006)
(Tommerup and
Vissing, 1995)

(Shannon and
Stubbs, 1998)
(Wells et al.,
2009)
(Hwang et al.,
2002)
(Kelley et al.,
1998; Rebollo
and Schmitt,
2003)

Appendix C - Literature Support of the 245 Known Transcriptional Regulators
(Refer to Chapter 4, Tables 7 and 8)
Probe Set

Gene
Symbol

Gene title

MAX
FC1

MIN
FC2

Type of
transcriptional
regulators

Reference

207147_at

DLX2

distal-less homeobox 2

1.29

-6.52

TF?

1553348_a_at

NFX1

1.28

-3.19

TF/repressor

227884_at

TAF15

1.27

-4.55

coactivator

212462_at

MYST4

1.27

-3.08

coactivator

208859_s_at

ATRX ///
LOC7288
49

1.27

-2.97

chromatin
structure

225992_at

MLLT10

1.25

-3.30

TF

(Chaplin et al.,
1995)

202925_s_at

PLAGL2

nuclear transcription factor,
X-box binding 1
TAF15 RNA polymerase II,
TATA box binding protein
(TBP)-associated factor,
68kDa
MYST histone
acetyltransferase
(monocytic leukemia) 4
alpha thalassemia/mental
retardation syndrome Xlinked (RAD54 homolog, S.
cerevisiae) /// similar to
transcriptional regulator
ATRX isoform 1
myeloid/lymphoid or
mixed-lineage leukemia
(trithorax homolog,
Drosophila); translocated
to, 10
pleiomorphic adenoma
gene-like 2

(Ozcelik et al.,
1992)
(Song et al.,
1994)
(Lee et al.,
2004)

1.25

-2.87

activator

229394_s_at

GRLF1

1.23

-2.81

repressor

213203_at

SNAPC5

1.23

-3.15

TF

(Guo et al.,
2008; Ning et
al., 2008)
(LeClerc et al.,
1991)
(Henry et al.,
1998)

225840_at

TEF

1.23

-6.39

TF

238549_at

CBFA2T2

1.23

-2.11

corepressor

223218_s_at

NFKBIZ

1.22

-3.01

activator

(Matsuo et al.,
2007)

210253_at

HTATIP2

1.22

-3.23

coactivator

226352_at

JMY

1.21

-5.68

coactivator

222683_at

RNF20

1.21

-2.61

coactivator

202983_at

HLTF

(Wolf et al.,
2007)
(Shikama et al.,
1999)
(Kim et al.,
2005)
(Ding et al.,
1999)
(Sanchez-Diaz
et al., 2001)
(Cismasiu et al.,
2008)
(Van Dijk et al.,
1993)
(Lin et al.,
2004)
(Zhou et al.,
2000)

glucocorticoid receptor
DNA binding factor 1
small nuclear RNA
activating complex,
polypeptide 5, 19kDa
thyrotrophic embryonic
factor
core-binding factor, runt
domain, alpha subunit 2;
translocated to, 2
nuclear factor of kappa light
polypeptide gene enhancer
in B-cells inhibitor, zeta
HIV-1 Tat interactive
protein 2, 30kDa
junction-mediating and
regulatory protein
ring finger protein 20

helicase-like transcription
1.21
-3.83
factor
223135_s_at
BBX
bobby sox homolog
1.21
-2.95
(Drosophila)
222895_s_at
BCL11B
B-cell CLL/lymphoma 11B
1.21
-2.66
(zinc finger protein)
212148_at
PBX1
Pre-B-cell leukemia
1.21
-50.88
homeobox 1
217862_at
PIAS1
protein inhibitor of
1.20
-3.03
activated STAT, 1
203964_at
NMI
N-myc (and STAT)
1.19
-7.72
interactor
1
EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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activator
activator
repressor
activator
coactivator/corepr
essor
transcription
cofactor

(Merson et al.,
2006; Pelletier
et al., 2002)
(Gibbons et al.,
2008; Ritchie et
al., 2008)

(Gachon et al.,
2006; Inukai et
al., 2005)
(Martinez et al.,
2006)

Appendix C - Literature Support of the 245 Known Transcriptional Regulators
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Probe Set

Gene
Symbol

Gene title

MAX
FC1

MIN
FC2

Type of
transcriptional
regulators

Reference

206495_s_at

MIZF

MBD2-interacting zinc
finger

1.19

-2.05

repressor/activato
r

210555_s_at

NFATC3

1.19

-8.83

coactivator

200887_s_at

STAT1

1.19

-2.86

TF

201970_s_at

NASP

1.18

-7.93

242121_at

RNF12

nuclear factor of activated
T-cells, cytoplasmic,
calcineurin-dependent 3
signal transducer and
activator of transcription 1,
91kDa
nuclear autoantigenic sperm
protein (histone-binding)
Ring finger protein 12

(Mitra et al.,
2003; Sekimata
and Homma,
2004)
(Ho et al., 1995;
Masuda et al.,
1995)
(Scarabelli et
al., 2008)

1.18

-1.80

chromatin
structure
corepressor

218031_s_at

FOXN3

forkhead box N3

1.17

-4.09

repressor

226872_at

RFX2

1.17

-15.30

TF

212769_at

TLE3

1.16

-1.97

corepressor

(Brinkmeier et
al., 2003)

206724_at

CBX4

1.16

-4.66

corepressor

213293_s_at

TRIM22

1.16

-5.21

corepressor

221606_s_at

NSBP1

regulatory factor X, 2
(influences HLA class II
expression)
transducin-like enhancer of
split 3 (E(sp1) homolog,
Drosophila)
chromobox homolog 4 (Pc
class homolog, Drosophila)
tripartite motif-containing
22
nucleosomal binding
protein 1

1.16

-2.78

activator

203358_s_at

EZH2

enhancer of zeste homolog
2 (Drosophila)

1.16

-3.57

206542_s_at

SMARCA
2

1.15

-2.83

208718_at

DDX17

1.15

-2.71

218902_at

NOTCH1

1.14

1552685_a_at

GRHL1

226157_at

TFDP2

225935_at

CUX1 // --

SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin,
subfamily a, member 2
DEAD (Asp-Glu-Ala-Asp)
box polypeptide 17
Notch homolog 1,
translocation-associated
(Drosophila)
grainyhead-like 1
(Drosophila)
Transcription factor Dp-2
(E2F dimerization partner
2)
CDNA clone
IMAGE:4816860

chromatin
structure/represso
r?
coactvator

(Satijn et al.,
1997)
(Tissot and
Mechti, 1995)
(King and
Francomano,
2001)
(Hoffmann et
al., 2007)

201996_s_at

SPEN

222667_s_at

ASH1L

206858_s_at

HOXC6

spen homolog,
transcriptional regulator
(Drosophila)
ash1 (absent, small, or
homeotic)-like (Drosophila)
homeobox C6

(Muchardt and
Yaniv, 1993)

-2.74

coactivator/corepr
essor
TF

(Fuller-Pace and
Ali, 2008)
(Nguyen et al.,
2006)

1.14

-1.89

TF

1.13

-4.60

TF

1.13

-3.35

repressor

1.13

-3.08

repressor

(Henderson et
al., 2008)
(Zhang and
Chellappan,
1995)
(Stern et al.,
2008; Vanden
Heuvel et al.,
1996)
(Shi et al., 2001)

1.13

-2.75

1.13

-3.44

chromatin
structure
corepressor

EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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(Richardson et
al., 2006)
(Ostendorff et
al., 2000)
(Scott and Plon,
2005)
(Horvath et al.,
2004)

(Gregory et al.,
2007)
(Chariot et al.,
1996)
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Probe Set

Gene
Symbol

Gene title

MAX
FC1

MIN
FC2

Type of
transcriptional
regulators

Reference

204791_at

NR2C1

1.12

-2.63

repressor

202227_s_at

BRD8

nuclear receptor subfamily
2, group C, member 1
bromodomain containing 8

1.12

-2.71

coactivator

209911_x_at

histone cluster 1, H2bd

1.12

-1.72

207002_s_at

HIST1H2
BD
PLAGL1

1.12

-6.93

219878_s_at

KLF13

pleiomorphic adenoma
gene-like 1
Kruppel-like factor 13

chromatin
structure
TF

1.12

-1.91

activator

228038_at

SOX2

1.10

-11.43

activator

202963_at

RFX5

1.10

-3.54

activator

222016_s_at

ZNF323

SRY (sex determining
region Y)-box 2
regulatory factor X, 5
(influences HLA class II
expression)
zinc finger protein 323

(Tanabe et al.,
2007)
(Monden et al.,
1999)
(Zhu et al.,
2005)
(Varrault et al.,
2006)
(Song et al.,
1999)
(Sharov et al.,
2008)
Villard et al,
2000

1.10

-26.86

TF

(Pi et al., 2002)

203140_at

BCL6

1.10

-5.00

corepressor

201566_x_at

ID2 ///
ID2B

1.09

-11.54

repressor

(Yoshida et al.,
1996)
(Murphy et al.,
2004)

209538_at

ZNF32

B-cell CLL/lymphoma 6
(zinc finger protein 51)
inhibitor of DNA binding 2,
dominant negative helixloop-helix protein ///
inhibitor of DNA binding
2B, dominant negative
helix-loop-helix protein
zinc finger protein 32

1.07

-2.75

TF

222749_at

SUFU

suppressor of fused
homolog (Drosophila)

1.07

-3.10

corepressor

214004_s_at

VGLL4

vestigial like 4 (Drosophila)

1.05

-2.95

213707_s_at

DLX5

distal-less homeobox 5

1.05

-5.10

transcription
cofactor
activator

207558_s_at

PITX2

paired-like homeodomain 2

1.04

-3.54

TF

209989_at

ZNF268

zinc finger protein 268

1.04

-2.64

activator

226113_at

ZNF436

zinc finger protein 436

1.04

-2.88

repressor

239937_at

ZNF207

Zinc finger protein 207

1.03

-2.19

TF

203542_s_at

KLF9

Kruppel-like factor 9

1.02

-3.88

TF

223210_at

CHURC1

1.02

-2.63

activator

1559078_at

BCL11A

1.00

-2.82

repressor

209604_s_at

GATA3

churchill domain containing
1
B-cell CLL/lymphoma 11A
(zinc finger protein)
GATA binding protein 3

-1.00

-3.89

TF

1566324_a_at

MAF

v-maf musculoaponeurotic
-1.00
-4.05
fibrosarcoma oncogene
homolog (avian)
207826_s_at
ID3
inhibitor of DNA binding 3,
-1.01
-13.90
dominant negative helixloop-helix protein
1
EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.
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activator/represso
r
corepressor

(Mesa et al.,
1996)
(Dunaeva et al.,
2003; Stone et
al., 1999)
(Chen et al.,
2004)
(Samee et al.,
2008)
(Shang et al.,
2008)
(Shao et al.,
2006)
(Li et al., 2006)
(Pahl et al.,
1998)
(Imataka et al.,
1994; Imataka et
al., 1992)
(Sheng et al.,
2003)
(Senawong et
al., 2005)
(Joulin et al.,
1991; Labastie
et al., 1994)
(Hedge et al.,
1998; Kataoka
et al., 2004)
(Deed et al.,
1993)
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202815_s_at

HEXIM1

hexamethylene bisacetamide inducible 1

-1.02

-2.76

repressor

203221_at

TLE1

-1.02

-2.68

corepressor

220625_s_at

ELF5

-1.03

-29.70

activator

214058_at

MYCL1

-1.03

-4.90

TF

211126_s_at

CSRP2

-1.04

-2.94

coactivator

219041_s_at

REPIN1

transducin-like enhancer of
split 1 (E(sp1) homolog,
Drosophila)
E74-like factor 5 (ets
domain transcription factor)
v-myc myelocytomatosis
viral oncogene homolog 1,
lung carcinoma derived
(avian)
cysteine and glycine-rich
protein 2
replication initiator 1

(Yoshikawa et
al., 2008) Yik et
al, 2003
(Pickles et al.,
2002)

-1.05

-4.53

repressor

210993_s_at

SMAD1

SMAD family member 1

-1.05

-3.74

activator

203408_s_at

SATB1

SATB homeobox 1

-1.05

-3.42

209398_at

histone cluster 1, H1c

-1.06

-1.93

204999_s_at

HIST1H1
C
ATF5

chromatin
structure
repressor

-1.06

-2.65

TF/corepressor

229638_at

IRX3

activating transcription
factor 5
iroquois homeobox 3

-1.07

-10.58

repressor

210319_x_at

MSX2

msh homeobox 2

-1.08

-6.69

repressor

221531_at

WDR61

WD repeat domain 61

-1.08

-3.31

coactivator

216197_at

ATF7IP

activating transcription
factor 7 interacting protein

-1.09

-5.25

activator or
repressor

223213_s_at

ZHX1

zinc fingers and
homeoboxes 1

-1.10

-3.78

repressor

222146_s_at

TCF4

transcription factor 4

-1.10

-16.36

207469_s_at

PIR

-1.10

-11.73

224976_at

NFIA

pirin (iron-binding nuclear
protein)
nuclear factor I/A

-1.11

-4.52

activator/represso
r
transcription
cofactor
TF/activator

219517_at

ELL3

-1.15

-1.43

regulator

210239_at

IRX5

-1.15

-15.05

TF

222018_at

NACA ///
NACA3P
///
NACAP1

-1.16

-2.76

coactivator

227047_x_at

ZBTB4

-1.18

-2.62

repressor

223275_at

PRMT6

-1.18

-15.03

transcriptional
regulator/chromat
in structure

elongation factor RNA
polymerase II-like 3
iroquois homeobox 5
nascent polypeptideassociated complex alpha
subunit /// nascentpolypeptide-associated
complex alpha polypeptide
pseudogene 1 /// NACA
family member 3
pseudogene
zinc finger and BTB
domain containing 4
protein arginine
methyltransferase 6

EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.

207

(Choi and
Sinha, 2006)
(Atchley and
Fitch, 1995)

(Wei et al.,
2005)
(Kim et al.,
2006)
(He et al., 2001)
(Han et al.,
2008)
(Kim et al.,
2008)
(Pati et al.,
1999)
(Bilioni et al.,
2005)
(Takahashi et
al., 2001b)
Zhu et al, 2005
(Genes Dev)
(Chang et al.,
2005; Ichimura
et al., 2005)
(Kim et al.,
2007; Yamada
et al., 2003)
(Nguyen et al.,
2009)
(Pang et al,
2004)
(Qian et al.,
1995)
(Miller et al.,
2000)
(Kerschensteine
r et al., 2008)
(Akhouayri et
al., 2005)

(Filion et al.,
2006)
(Hyllus et al.,
2007; Miranda
et al., 2005)
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FC1
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Type of
transcriptional
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212346_s_at

MXD4

MAX dimerization protein
4

-1.19

-3.12

repressor

226895_at

NFIC

Nuclear factor I/C
(CCAAT-binding
transcription factor)

-1.23

-3.91

TF/activator

220225_at

IRX4

iroquois homeobox 4

-1.27

-3.37

TF

217991_x_at

SSBP3

single stranded DNA
-1.30
-2.72
binding protein 3
1
EGF Max FC: maximum fold change observed by EGF over the whole treatment time.
2
EGF Min FC: minimum fold change observed by EGF over the whole treatment time.

TF

(Hurlin et al.,
1995; Marcotte
et al., 2005)
(Qian et al.,
1995;
Wenzelides et
al., 1996)
(Garriock et al.,
2001)
(Wu, 2006)
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